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Abstract 
The aim of this thesis was to expand upon the knowledge of the mechanism of action 
and resistance of antifolate drugs in African trypanosomes with a specific focus on 
transport mechanisms. A media deficient in folate and thymidine was established 
which enabled the assessment of their modulation on antifolate in vitro potencies and 
also screen a small set of antifolate compounds.  The phenomenon of ‘thymineless-
death’ was found to account for methotrexate toxicity, as well as the primary 
mechanism of raltitrexed toxicity. This was confirmed by cell cycle studies 
demonstrating cell cycle arrest in S phase which could be rescued with thymidine.  
Transport kinetics of folate and methotrexate were characterised and found to be 
competitive substrates for uptake in T. brucei.  Transport of these substrates was 
inhibited by classical antifolates, but not by non-classical antifolates. Genome-wide 
RNAi library screens with methotrexate and raltitrexed identified the putative folate 
transporter genes to be involved in drug resistance. RNAi knockdown of the folate 
transport genes resulted in a substantial reduction in folate transport was seen.  RNAi 
knockdown also led to cross-resistance to classical antifolates, whereas these 
parasites became hypersensitive to non-classical antifolates. Methotrexate-resistant 
trypanosomes were generated in which transport of methotrexate and folate was 
substantially reduced. Amino acid changes were evident in the putative folate 
transporter genes but no change in transcription or copy number was evident. Cross 
resistance to classical antifolates was demonstrated in these resistant parasites and 
cells become hypersensitivity to non-classical antifolates (a similar phenotype to 
folate transporter RNAi knockdown). Proteomic studies were performed in drug-
resistant trypanosomes; however, no conclusive findings were evident due to 
ix 
 
limitations of these experiments.  In conclusion, these studies demonstrate good 
evidence of both transport-mediated drug action and drug resistance. 
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1.1 Kinetoplastids and the neglected tropical diseases (NTDs) 
 
The kinetoplastids are a group of flagellated, unicellular, protozoan organisms that 
contain a kinetoplast, and belong to the phylum Euglenozoa, order Kinetoplastida. 
The kinetoplast is a large network, inside the mitochondrion, consisting of a series of 
topologically interlocked DNA circles (mini or maxi-circles) containing copies of the 
mitochondrial genome (Shapiro and Englund, 1995). The Trypanosomatidae are 
distinguished by being uniflagellated and exclusively parasitic (Vickerman, 1976). 
They are divided into sub-genera Blastocrithidia, Endotrypanum, Crithidia, 
Herpetomonas, Leptomonas, Rhynchoidomomas, Phytomonas, Leishmania and the 
Trypanosoma (Stevens et al., 2001). Three distinct trypanosomatids cause human 
disease: African Trypanosomiasis (caused by Trypanosoma brucei), South American 
Trypanosomiasis (Chagas disease, caused by Trypanosoma cruzi) and Leishmaniasis 
(caused by Leishmania species).  
These trypanosomatid diseases have been classified as neglected tropical 
diseases (NTDs) of which they are 17 diseases in total, including viral, helminthic, 
bacterial and protozoan diseases (Yamey, 2002). NTDs mainly affect the poorest 
countries of the developing world; more than one billion people including half a 
billion children, but NTDs have traditionally been of limited interest to the 
pharmaceutical industry (2014). In recent years there has been renewed focus and 
interest in NTDs. There is now increased global awareness of their high disease 
burden and poverty-maintaining impact with recognition that these diseases can be 
prevented and treated.  Indeed the World Health Organization (WHO) has set 
assertive targets for the control and elimination of NTDs by 2020 (World Health 
Organization, 2012a).  
Table 1 DHFR 
Table 7 
Table 6 
Table 5 
Table 4 
Table 3 
Table 2 
Table 17 
Table 16 
Table 10 Table 11 
Table 12 
Table 8 
 
Table 9 
Table 14 Table 15 
Table 13 
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1.2 Chagas disease and Leishmaniasis 
Trypanosoma cruzi (T. cruzi), the causative agent of Chagas disease, is primarily 
transmitted by the faeces of the triatomine bug (Triatoma infestans) and is endemic 
to Central and South America. Globally there are an estimated ~8 million infected 
individuals (World Health Organization, 2012b). Wide-spread emigration of chronic 
carriers of T. cruzi to North America, Europe, and Australia is to be noted with 
respect to the risk of reactivation of latent disease (Gascon et al., 2010). There are 
only two established medicines available for the treatment of Chagas disease, 
nifurtimox and benznidazole.  These drugs are far from ideal with shortcomings such 
as lack of efficacy, side-effects and the danger of resistance emerging (Fairlamb et 
al., 2016; World Health Organization, 2012b). 
Subspecies of Leishmania are the causative agents for a group of diseases 
known as the leishmaniases (visceral, cutaneous and mucocutaneous leishmaniasis). 
Leishmania spp are transmitted through the bite of an infected female sandfly 
(Plebotominae spp). Globally the disease currently threatens 350 million people in 
88 countries (Scientific Working Group, 2004).  Treatment of leishmaniasis is 
limited to four front-line medicines: pentavalent antimonials (sodium stibogluconate 
and meglumine antimonate), amphotericin B (deoxycholate or liposomal 
formulations), paromomycin and miltefosine. Oral azoles (ketoconazole, 
itraconazole, and fluconazole) have also been used to varying success (Croft et al., 
2006). Again, current therapies are far from ideal and the need for new medicines is 
imperative. 
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1.3 Animal Trypanosomiases  
 
Animal trypanosomiases have a high social and economic impact on the countries 
they affect and there is a great need for the development of new veterinary 
trypanocides. Animal African Trypanosomiasis (AAT and also called Nagana) is 
caused by the trypanosome species T. congolense, T. vivax and, to a lesser extent, T. 
brucei brucei (Giordani et al., 2016). Nagana is present in sub-Saharan African 
countries and is transmitted by the teste fly. It mainly affects cattle and horses 
causing a fatal wasting disease, but, is also found in sheep and goats, having 
devastating consequences to livestock farming in affected countries.  Of note T. 
vivax can be transmitted by vectors other than the teste fly, in particular horseflies 
(Tabanus spp.) and stable flies (Stomoxys spp.) and transmission has been found in 
Central and South America along with other regions (Giordani et al., 2016). Surra, a 
wasting disease similar to Nagana, is caused by T. evansi and affects a large range of 
domestic and wild animals but is especially pathogenic in horses, camels and water 
buffalos (Giordani et al., 2016). Like T. vivax, T. evansi can be transmitted by 
vectors other than the teste fly. It has the widest geographic distribution of the 
trypanasomatids. Dourine, a disease caused by T. equiperdum, is found in horses and 
other equine animals (e.g. donkeys, mules).  It has no vectors and is transmitted 
through sexual intercourse (Claes et al., 2005). The trypanosome species T. simiae is 
pathogenic in pigs, causing a hyperacute and often fatal infection (Giordani et al., 
2016). Currently the most widely used compounds in the animal trypanosomiases are 
diminazene aceturate and isometamidium chloride; however, resistance to these 
compounds is well documented. Suramin is used to treat T. evansi but, again, 
resistance is commonly found (Giordani et al., 2016). 
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1.4 Human African Trypanosomiasis 
 
1.4.1 A brief introduction 
The unicellular flagellated protozoan parasite Trypanosoma brucei is the causative 
agent of human African trypanosomiasis (HAT), also known as African sleeping 
sickness. HAT threatens approximately 70 million people in 24 sub-Saharan-African 
countries (Franco et al., 2014).  There are two human pathogenic subspecies. T. 
brucei gambiense (T. b. gambiense) (98% of HAT cases) predominates in western 
and central Africa and is an anthroponotic disease primarily affecting humans with a 
small animal reservoir (an array of both domestic animals: pigs, sheep, dogs, and 
wild animals including reptilians and mammals) (Franco et al., 2014). The second 
human pathogenic subspecies, T. brucei rhodesiense (T. b. rhodesiense), 
predominates in southern-eastern Africa and causes a zoonotic disease primarily 
affecting animals (livestock and wild game) with humans inadvertently infected 
(Franco et al., 2014). The third subspecies of T. brucei, T. b. brucei is non-
pathogenic to humans and causes the disease Nagana (it is a less common cause of 
Nagana than T. congolense and T. vivax).  It is from this subspecies laboratory 
strains used in this thesis are derived. 
In 2011 reported new cases of HAT fell to below 7,000; however, the disease 
carries a sizeable risk of resurgence with socio-economic and environmental 
variables such as epidemiological population shifts, civil unrest and climate change 
(Franco et al., 2014; Simarro et al., 2012). HAT also has an impact in sustaining the 
cycle of poverty in neglected communities. As part of the WHO target portfolio 
complete elimination of gambiense HAT by 2020 has been set (World Health 
Organization, 2012a). To facilitate the elimination of the disease, new medicines are 
Figure 1.4 
 
 
 
 
 
Figure 1.1 Life cycle of African Trypanosomes 
 
Figure taken from Centre for Disease for Control and Prevention 
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required.  However, in the current timescale elimination of HAT is a target that is not 
anticipated. 
1.4.2 Life cycle of T. brucei  
HAT is primarily transmitted by the bite of a tsetse fly (Glossinidae spp.) and the 
life-cycle of the causative agent, T. brucei, is depicted in Figure 1.1. In the human 
host stages, parasites initially multiply at the bite site before entering the 
bloodstream via the lymphatic system where they proliferate as long and slender 
trypomastigotes (Vickerman, 1976) – named blood stream form (BSF) parasites. It is 
these long and slender forms that can bridge the blood vessel epithelium and move 
into extracellular spaces, including the central nervous system (CNS) (Langousis and 
Hill, 2014).  These cells rapidly proliferate by binary fission. During each wave of 
parasitaemia in the host, some parasites differentiate into non-proliferative short-
stumpy forms, triggered and regulated by the metabolite stumpy inducing factor 
(Reuner et al., 1997). In the first stage in the vector’s life cycle, these short-stumpy 
forms (taken up after the tsetse fly blood meal) differentiate into procyclic 
trypomastigotes in the fly’s midgut (Matthews and Gull, 1998). In the fly’s hindgut 
parasites differentiate into mesocyclic trypomastigotes before migration to the 
salivary gland where they differentiate into epimastigotes and then further into 
metacylic trypomastigotes (Van den Abbeele et al., 1999). The metacylic 
trypomastigotes are transferred from insect vector to human host by a bite of an 
infected tsetse fly into human skin, thus completing the life cycle of T. brucei.  The 
predominant mode of transmission of HAT is vector-borne by the tsetse fly, but 
other less common routes have been described including vertical transmission, blood 
transfusion, sexual contact and accidental laboratory transmission (Franco et al., 
Figure 2.1 
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2014). Indeed looking at transmission routes other than teste fly is crucial if 
elimination targets are to be achieved (Welburn et al., 2016).  
1.4.3 Immune evasion mechanisms 
T. brucei BSF parasites are covered by a dense surface coat composed of variant 
surface glycoproteins (VSGs), attached via a Glycosylphosphatidylinositol (GPI) 
anchor, that protects the parasites from lytic factors in human plasma and host 
immune invasion (Cross, 1975; Fenn and Matthews, 2007). One of the main escape 
mechanisms to evade the immune response is the ability of T. brucei to undergo 
antigenic variation.  Cells are covered by an estimated 5 million identical VSG 
dimers. However, the parasite can express a single antigenically distinct VSG from 
more than 2000 complete and partial (pseudogenes) VSG genes in a mono-allelic 
fashion (antigenic variation) thus enabling the parasite to deflect the immune 
response (Horn, 2014; Horn and Cross, 1997).  Moreover, host antibodies that bind 
to the parasites cell surface can be cleared by clathrin-mediated endocytosis in the 
flagellar pocket (Allen et al., 2003).  The flagellar pocket is an invagination of the 
membrane at the base of the parasites flagellum and is the sole site for exocytic and 
endocytic processes (Field and Carrington, 2009).  
VSG, its protein anchor GPI and the flagellar pocket have been proposed as 
vaccination candidates for HAT.  However due to the complex nature of the 
parasites’ immune evasion, endeavours in vaccine development for HAT have not 
been successful (La and Magez, 2011). Indeed, T. brucei infection has an inhibitory 
effect on B-cell response. In a mouse HAT model, infection was found to nullify 
both anti-trypanosome responses and immunological memory in general (Radwanska 
et al., 2008). There was loss of B cell responsiveness to new antigens and loss of 
memory responses to previously encountered antigens, including VSGs. Also, 
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infection abrogated a non-related vaccine induced memory response, with loss of 
DTPa (diphtheria, tetanus and pertussis) vaccine protection against a later B. 
pertussis challenge. 
1.4.4 Clinical Features and diagnosis of HAT 
HAT clinically evolves in two stages, an early haemolymphatic stage and a 
secondary meningoencephalitic stage that is defined by invasion of the CNS. First 
stage illness is characterised by non-specific symptoms including fever, arthralgia 
and lymphadenopathy. A trypanosomal chancre (a localised reaction to the bite of 
the tsetse fly) is rarely seen in T. b. gambiense but occurs in around 20% of patients 
with T. b. rhodesiense (Brun et al., 2010). If left untreated, first stage illness can 
cause anaemia and endocrine, kidney and cardiac dysfunction. Second stage illness 
(CNS stage) is associated with various progressive neuropsychiatric symptoms, 
disturbance of the sleep-wake cycle and progression to coma. T. b. rhodesiense HAT 
is typically an acute disease that leads to death within 6 months, in comparison 
T. b. gambiense HAT is typically a chronic disease with an average length of 3 years 
(Franco et al., 2014).  Indeed, if left untreated, both subspecies have a fatality rate up 
to 100% (Franco et al., 2014). Rarely have asymptomatic chronic carriers 
(serologically positive patients, negative for parasites on microscopy, who are 
asymptotic and survive with no treatment) been found in HAT. These silent carriers 
are a potential human reservoir for HAT transmission (Welburn et al., 2016).  
The non-specific clinical presentation of HAT means that a diagnosis 
requires laboratory evidence. The diagnosis of HAT follows a three-step pathway:  
screening, parasitic conformation and staging (Brun et al., 2010). Antibody detection 
using the Card-Agglutination Trypanosomiasis Test (CATT) is used for population 
screening. Patients with a positive CATT on whole blood or serum (serum is 
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preferential as it is more specific) undergo parasite detection by microscopy of 
lymph node aspirate and blood (after either capillary tube centrifugation or mini-
anion-exchange centrifugation of the blood sample) (Chappuis et al., 2005). 
Differentiation of the stage of the infection can only be done by analysis of the 
cerebral spinal fluid (CSF), obtained by lumbar puncture. The number of parasites 
present in the CSF is often very low, which can lead to false negative results (Bonnet 
et al., 2015). An increased white blood cell (WBC) count (indicative of meningeal 
inflammation) is also used as a marker of infection to increase diagnostic sensitivity. 
The WHO diagnostic criteria for second stage HAT requires the presence of 
trypanosomes in the CSF and/or WBC > 5 cells μl
-1 
(Brun et al., 2010). 
Current diagnostic methods for HAT can often be challenging both to 
perform and interpret; therefore, alternative new diagnostic platforms are being 
examined.  Lateral flow immunochromatographic devices (detection of antibodies 
targeted to specific antigens) are being progressed as rapid diagnostic tests (RDTs) 
for HAT.  Standard Diagnostics (SD BIOLINE HAT) and Coris Bioconcept (Sero-
K-SeT) have developed diagnostic instruments that use native VSG LiTat 1.3 and 
LiTat 1.5 to detect anti-trypanosome antibodies (Bonnet et al., 2015). In the field, 
both tests have sensitivity and specificity comparative to CATT (Bisser et al., 2016; 
Buscher et al., 2014). Moreover, DNA detection using loop-mediated isothermal 
amplification is highly specific and sensitive for HAT diagnosis (Kuboki et al., 
2003; Njiru et al., 2008). This test is currently used in the Democratic Republic of 
Congo and Angola (Bonnet et al., 2015). As well as initial diagnosis, methods to 
determine second stage illness are being developed. These include CSF PCR T. 
brucei detection and measuring CSF IgM and/or neopterin levels (a biomarker for 
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Figure 1.2 Chemical structures of HAT drugs in current use 
Table 1.1 Key characteristics of current HAT drugs 
Information for table taken from Fairlamb et al., 2016, Eperon et al., 2012 and   http://www.cdc.gov/parasites/sleepingsickness/health_professionals/ 
T.b.r =  Trypanosoma brucei rhodesiense   T.b.g = Trypanosoma brucei gambiense 
Drug Stage Species Mode of Action Resistance Mechanisms Significant 
Adverse Effects 
Treatment Regime 
Suramin First Stage T.b.r only. Unknown Laboratory-generated resistance - silencing 
of: 
invariant surface glycoprotein (ISG75), the 
AP1 adaptin complex, 
lysosomal proteases and major lysosomal 
transmembrane protein, 
also  N-acetylglucosamine  and  spermidine  
Skin reactions 
Fatal anaphylaxis 
1 gm IV on days 
1,3,5,14, and 21. 
Pentamidine First Stage Inactive in some 
T.b.r cases 
Unknown Melarsoprol/pentamidine cross resistance 
(MPXR): 
1. Laboratory and clinical resistance 
associated functional loss of P1 
adenine/adenosine transporter (TbAT1).  
2. Laboratory and clinical resistance 
associated with loss of AQP2 mediated 
transport and replacement with a chimeric 
AQP2/AQP3 gene 
Hypoglycaemia, 
diarrhoea and 
vomiting 
4 mg/kg/day IM or 
IV x 7-10 days 
Melarsoprol Second and 
First Stage 
All species Forms a cyclic 
complex with 
trypanothione (MelT). 
Inhibits trypanothione 
reductase along with 
other targets 
Encephalitic 
syndrome 
Tremor  
Peripheral 
Neuropathy 
2-3.6 mg/kg/day IV 
x 3 days. After 7 
days, 3.6 mg/kg/day 
x 3 days. Give a 3rd 
series of 3.6 
mg/kg/d after 7 
days. 
Eflornithine Second stage T.b.g only Inhibition of ornithine 
decarboxylase 
Laboratory-generated resistance due to loss 
of a non-essential 
amino acid transporter (TbAAT6).  
Inherent resistance in some  T.b.r field 
isolates 
Headaches 
Seizures 
Anaemia 
400 mg/kg/day IV 
in 4 doses x 14 days 
Niufurtimox Second stage as 
Eflornithine - 
Niufurtimox  
combination 
therapy (NECT) 
 
Eflornithine 
T.b.g only  
Progrug activated by 
nitroreductase (NTR) 
to form metabolites 
that kill parasites via 
unknown mechanism 
Laboratory: RNAi screen and laboratory-
generated resistant  line identified NTR to be 
associated with resistance 
Headaches 
Seizures 
Dizziness 
As NECT:  
IV eflornithine  200 
mg/kg every 12 h 
for 7 days, with oral 
nifurtimox 3 times 
daily for 10 days. 
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cellular immune response) (Lejon et al., 2002; Mugasa et al., 2012; Tiberti et al., 
2013).  
1.4.5 Current treatments for HAT 
There are five treatment options for HAT: pentamidine, suramin, melarsoprol, 
eflornithine (α-difluoromethylornithine or DFMO) monotherapy and nifurtimox-
eflornithine combination therapy (NECT). Drug structures are shown in Figure 1.2 
with a summary of their characteristics in Table 1.1. 
Suramin and pentamidine, both discovered in the early 20
th
 century, are still 
used today to treat the first stages of HAT. Suramin (1916) is active against both 
HAT species; however, it cannot be used against T. b. gambiense in West and 
Central Africa because of a risk of severe reactions in patients co-infected with 
Onchocerca volvulus (the causative agent of river blindness) (Brun et al., 2010). 
Suramin is given intravenously (IV) over a 3 week course and side effects include 
drug rash and nephrotoxicity, and in rare instances a severe hypersensitivity reaction. 
Its mechanism of action (MOA) is unknown. In the laboratory, resistance has been 
shown to be mediated by a number of mechanisms (Alsford et al., 2012) (Table 1.1), 
although resistance in the field has not been evident. Resistance to suramin, when 
used in animal trypanosomiasis (T. evansi), has been reported (Giordani et al., 2016). 
Pentamidine (1937), a diamidine drug, is used for early stage T. b gambiense but not 
for T. b. rhodesiense where it has reduced activity (Wang, 1995). Pentamidine is 
administered intramuscularly (IM) or by IV infusion for 7-10 days and is overall 
well tolerated. Its MOA is also unknown and resistance emerging from pentamidine 
only use has not been detected. However, melarsoprol/pentamidine cross resistance 
(MPXR) is a well-known phenomenon and will be described when discussing the 
drug melarsoprol.   
Figure 1.4 
Figure 152 
Figure 21 
Figure 20 
Figure 19 
Figure 18 
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Second stage treatment options are melarsoprol, DFMO and NECT. 
Melarsoprol (1949), a trivalent melaminophenyl arsenical, is active against both T. 
brucei subspecies and both disease stages (Jacobs et al., 2011a). However, due to its 
extreme toxicity it is reserved as second line for late stage T. b gambiense, and is 
used for late stage T. b. rhodesiense for which no other options currently exist. The 
most severe adverse effect of melarsoprol is encephalitic syndrome. It occurs in 5-
10% of treated patients, manifested by convulsions and coma, with a mortality rate 
of approximately 50% (Eperon et al., 2014).  A prodrug, melarsoprol is rapidly 
converted to melarsen oxide. It reacts covalently with vicinal dithiols, both in the 
parasite and the host, and its toxicity likely results from these interactions. It is 
trypanocidal as it is known to react with the parasite-specific dithiol trypanothione, 
to form a cyclic complex known as MelT (Fairlamb et al., 2016; Fairlamb et al., 
1989). Resistance to melarsoprol is a major concern with increasing numbers of 
treatment failures being reported in the field (Lutje et al., 2013; Robays et al., 2008). 
The functional loss of the P2 adenosine transporter (TbAT1) in drug uptake has been 
linked to MPXR both in the field and in the laboratory. Arsenicals (melarsoprol) and 
diamidines (pentamidine) are both imported into trypanosomes via TbAT1 (Carter 
and Fairlamb, 1993; Maser et al., 1999). TbAT1 gene deletion and loss-of-function 
single nucleotide polymorphisms have been described in drug resistance in the 
laboratory (Graf et al., 2016; Maser et al., 1999; Stewart et al., 2010) and in 
melarsoprol-resistant clinical isolates (Kazibwe et al., 2009; Matovu et al., 2001). 
Also the aquaporin AQP2, synonymous with the high-affinity pentamidine 
transporter, is important in MPXR (Baker et al., 2012).  Laboratory and clinical 
resistance was found to be consequential to a loss of AQP2 mediated transport and 
replacement with a chimeric AQP2/AQP3 gene (Graf et al., 2015; Graf et al., 2016; 
Figure 28 
Figure 25 
Figure 22 
Figure 27 
Figure 26 Figure 24 
Figure 23 
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Graf et al., 2013; Munday et al., 2014; Pyana et al., 2014). Also the ATP-binding 
cassette (ABC) transporter, MRPA, is known to account for melarsoprol resistance 
in T. brucei, likely through efflux of MelT (Maser et al., 2003; Shahi et al., 2002). 
 
DFMO, a fluorinated amino acid, is active against second stage T. b. 
gambiense HAT. In the 1980’s DFMO was first discovered to have antitrypanosomal 
activity both in vitro and in the field, leading to its approval and registration for 
clinical use in 1990 (Eperon et al., 2014). In 1995 production was discontinued by its 
suppliers; however, advocacy efforts by Médecins Sans Frontières in 2000 lead to 
DFMO monotherapy being used in field projects (Eperon et al., 2014). Four daily 2-
hour IV infusions for 14 days made the treatment regime logistically demanding. 
Side effects include headaches and seizures. DFMO is trypanostatic and is a 
selective irreversible inhibitor of ornithine decarboxylase (ODC), a key enzyme in 
polyamine synthesis.  The slower turnover of ODC in T. b. gambiense compared to 
human cells may account for greater sensitivity in the parasite.  Furthermore the 
innate resistance of T. b. rhodesiense to DFMO may be due to the swift turnover of 
ODC in this subspecies, as well as other mechanisms including decreased S-
adenosylmethionine metabolism (Bacchi et al., 1993; Iten et al., 1997).  TbAAT6 
was first identified in the transport of DFMO by Vincent et al (Vincent et al., 2010). 
DFMO uptake was reduced in drug-resistant parasites which were found to have a 
deleted copy of the TbAAT6 gene. Ectopic expression of TbAAT6 in drug resistant-
parasites, in which a copy of TbAAT6 was deleted, restored DFMO sensitivity to that 
of wild type (Vincent et al., 2010). Moreover, two RNA interference (RNAi) library 
screens have further verified TbAAT6 as the major determinant of DFMO resistance 
in the laboratory (Baker et al., 2010; Schumann-Burkard G. et al., 2011). DFMO 
drug resistance in T. b. gambiense is not evident in the field.   
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Nifurtimox, an oral 5-nitrofuran, has been used since the 1970s for the 
treatment of Chagas Disease. It is a prodrug activated by mitochondrial 
nitroreductase (NTR) to form highly reactive drug metabolites which are toxic to 
trypanosomes (Hall et al., 2011). NTR is a key determinant of drug resistance in the 
laboratory; shown both in an RNAi library screen (Baker et al., 2010) and in drug 
resistant T. brucei cell lines (Wyllie et al., 2016). Nifurtimox monotherapy showed 
limited efficacy in HAT and it was a trial of the drug combination of Nifurtimox and 
DFMO (NECT) in 2001 (Priotto et al., 2006) that demonstrated high efficacy and 
good safety profile of this combination therapy. NECT has greatly improved HAT 
treatment and is phasing-out the use of melarsoprol.  In NECT, DFMO is given 
200mg/kg twice daily for 7 days (reduced frequency compared to monotherapy) and 
nifurtimox is given orally three times daily for 10 days (the only oral treatment for 
HAT). Resistance to NECT has not yet been reported in the field, but, with clear 
modes of inhibition demonstrated in the laboratory (NTR a determinant of 
nifurtimox resistance (Wyllie et al., 2016; Baker et al., 2010) and TbAAT6 a 
determinant of DFMO resistance (Vincent et al., 2010; Baker et al., 2010; 
Schumann-Burkard G. et al., 2011)), there are fears of clinical resistance developing 
and this may have implication for future chemotherapies. Indeed, nifurtimox-
resistant T. brucei were found to be cross-resistant to other nitro drugs in vitro and, 
critically, cross-resistant to the clinical candidate fexinidazole (discussed in section 
1.4.7) was evident both in vitro and in vivo (Sokolova et al., 2010). Should this 
finding be reproduced in the field, resistance to nifurtimox as part of NECT could 
preclude the future use of nitro drugs in HAT, including fexinidazole. 
 
 
Figure 1.3 Chemical structures of HAT drugs in the pipeline 
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1.4.6 The drug discovery pipeline and continued endeavours  
Whilst NECT has been successfully employed in nearly all endemic countries, its 
practical limitations restrict its use to hospital settings. Also, concerns regarding 
resistance to NECT developing in the field are growing.  To enable the elimination 
of HAT, a WHO target by 2020, the development of new drugs is essential. Key 
characteristics  in the  target product profile (TPP) for HAT are that new medicines 
are oral, the administration period is of short duration, active against both T. brucei 
subspecies and both disease stages (penetrate CNS) and are cheaper compared to 
NECT (http://dndi.org). Two drugs are currently being assessed in HAT clinical 
trials: fexinidazole and SCYX-7158 (Figure 1.3). Fexinidazole is currently 
undergoing Phase ΙΙ/ΙΙΙ trials for HAT in the Democratic Republic of Congo and 
Central African Republic (Eperon et al., 2014). Fexinidazole, like nifurtimox, is a 
nitroaromatic compound. It is a prodrug that is quickly metabolised in vivo by two 
distinct pathways, flavin containing monooxygenease and cytochrome P450, into its 
two metabolites sulfone and sulfoxide. Despite modest in vitro activity the drug 
exhibited favourable in vivo activity in HAT mouse models (Tarral et al., 2014; 
Torreele et al., 2010).  Fexinidazole-resistant trypanosomes have been generated in 
vitro and demonstrate cross resistance to other nitroimidazoles, including nifurtimox 
(Sokolova et al., 2010). In addition, reduced levels of NTR expression were found in 
drug-resistant trypanosomes implicating a role of NTR in MOA and mechanisms of 
resistance of fexinidazole (Wyllie et al., 2016). Pharmacokinetic/pharmacodynamic 
properties of fexinidazole are not ideal, with limited solubility, anticipated high 
human dose and food affecting oral bioavailability and so other nitroimidazoles with 
improved properties were explored. The lead compound from this endeavour, DNDi-
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2035811 (Figure 1.3), is now a backup nitroimidazole (http://dndi.org) (Eperon et 
al., 2014). 
 
Another drug in clinical trials is SCYX-7158, an orally available 
benzoxaborole. This drug was highly efficacious in pre-clinical studies and is 
currently in phase Ι trials, as a single dose treatment for both HAT stages (Jacobs et 
al., 2011b). This oral drug would be an ideal candidate for HAT elimination,  if 
current clinical trials prove fruitful. Benzoxaborole compounds have been shown to 
kill bacteria and fungi through several mechanisms including inhibiting leucyl- 
tRNA synthetase (Rock et al., 2007); however, the mode of action in T. brucei 
remains unresolved. Benzoxaborole-resistant T. brucei cell lines have been generated 
in vitro and proteomic and genomic analysis of these lines provided an array of 
potential targets implicating a polypharmacological MOA (Jones et al., 2015).  
 
A continued effort is still required to deliver new development candidates for 
HAT. Academic institutions and pharmaceutical companies, either as joint projects 
or separate endeavours, continue to explore new target-based and phenotypic 
screening-based approaches. Moreover, in 2013 Novartis and GlaxoSmithKline 
made substantial investments in HAT drug discovery (Eperon et al., 2014). Essential 
metabolic pathways of the parasite, such as polyamine (Taylor et al., 2008) and 
trypanothione biosynthesis (Torrie et al., 2009), glycolysis (Lakhdar-Ghazal et al., 
2002) and N-myristoylation (Frearson et al., 2010) are being exploited to identify 
novel targets for the expansion of new treatments. Folate metabolism is one such 
pathway.  An aim of this thesis is to further dissect folate metabolism in T. brucei 
and in doing so to identify areas that can be exploited for drug discovery endeavours.   
 
 
 
 
Figure 1.4 Chemical structures of folic acid and antifolate drugs used in 
this thesis. 
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1.5 Folate metabolism in mammalian cells 
Folates are a family of B9 vitamins that serve as one-carbon donors in multiple 
essential biosynthetic pathways. They play an essential role in nucleic acid synthesis, 
methionine regeneration, and mitochondrial protein synthesis crucial in a wide 
variety of organisms (Ulrich et al., 2008). Folates consist of three chemical 
components, a pterin ring, p–aminobenzoic acid (pABA) and glutamic acid (Figure 
1.4 shows the chemical structure of folic acid). They can be found in oxidised form, 
folic acid, or as naturally occurring reduced forms. Indeed the primary circulating 
folate in humans is a reduced form, 5-methyl-tetrahydrofolate (5-methyl-THF) 
(Antony, 1992). Plants and most bacteria are able to synthesize folates de novo. 
However mammalians cells and trypanosomes must obtain folates from their 
environment. The mammalian folate pathway has been researched in great detail and 
much can be learned from these studies. 
 
1.5.1 Routes of folate uptake in mammalian cells  
Ingested dietary folates primarily exist in polyglutamate forms and cannot cross the 
cell membrane as long chain (>3) polyglutamate derivatives (Zeng et al., 2001).  In 
humans, hydrolysis from the ingested polyglutamate state to a monoglutamate form 
is accomplished by the enzyme glutamate carboxypeptidase II (GCPΙΙ) in the 
intestinal membrane (Chandler et al., 1986). Monoglutamate folates require specific 
uptake into cells as, under physiological pH, they are negatively charged owing to 
the ionization of the (dicarboxylic) glutamate moiety (Gonen and Assaraf, 2012). 
In human, three transport systems are currently known to regulate folate 
uptake, the proton-coupled folate transporter (PCFT), the reduced folate carrier 
 
 
 
Figure 1.5 Folate metabolism and compartmentalisation in mammalian 
cells.  
 
Fig 1.4 Taken from Gonen and Assaraf (2012). 
 
 
Key: 
RFC = reduced folate carrier 
PCFT = proton-coupled folate transporter 
cFPGS = cytosolic folypoly-γ-glutamate synthase 
mFPGS = mitochondrial folypoly-γ-glutamate synthase 
MFT = mitochondrial folate transporter 
GGH = γ-glutamyl hydrolase 
ABCC1-5= ATP-binding cassette (ABC) transporters C1-5 
ABCG2 = ATP-binding cassette (ABC) transporters G2/breast cancer resistant 
protein 
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(RFC) and folate receptors (FRs) (Gonen and Assaraf, 2012) (Figure 1.5). PCFTs are 
principally expressed in the upper regions of the small intestine (proximal jejunum 
and duodenum). The PCFT is a unidirectional symporter of folate with H+ and the 
high concentrations of H+ in the acidic environment of the small intestine facilitates 
folate uptake (Qiu et al., 2006). At pH 5.5, PCFT has high affinity for folic acid, 
reduced folates (including 5-methyl-THF), and for classical antifolates such as 
methotrexate (MTX) and pemetrexed (PMX) (Km largely in 0.5-3 μM range) (Wang 
et al., 2004; Zhao et al., 2008). Some transport activity has also been observed at 
physiological pH. Structurally, PCFT has 12 transmembrane domains with the N and 
C termini located in the cytoplasm (Zhao et al., 2010). In humans, PFCT is also 
expressed in a variety of other tissues including kidney, liver, splenic tissue and 
other tissues of the gastrointestinal tract (Qiu et al., 2006). 
A second transport system, RFC, facilitates folate uptake predominantly in 
the lower intestine. RFC is a classic transmembrane facilitative carrier, and, like 
PFCT, has 12 transmembrane domains with the N and C termini located within the 
cytoplasm (Matherly and Hou, 2008). Deficient of an ATP-binding domain, it is a 
bidirectional anion antitransporter that facilitates the exchange of extracellular 
folates with intracellular organic phosphates (Goldman, 1971).  It functions at 
physiological pH and also has high affinity for reduced folates (Km 1-4 μM), has 
moderate affinity for MTX (range 2.3  to 26 M)  but has a low affinity for folic acid 
(Km 200-400 μM)  (Sirotnak, 1985; Sirotnak and Tolner, 1999). RFC can be 
expressed in virtually all tissues and cell lines and, in humans, it is also found in 
tissues including bone marrow, lung and coronary tissue (Visentin et al., 2014). 
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Of note, the pH values in different regions of the small intestine correlate 
with the optimal conditions for folate transport via PCFT and RFC. Intraluminal pH 
is rapidly changed from highly acid in the stomach to about pH 6 in the duodenum 
(Fallingborg, 1999), correlating with PCFT having an optimal pH of 5.5 and being 
primarily expressed in the proximal jejunum and duodenum. The pH gradually 
increases in the small intestine from pH 6 to about pH 7.4 in the terminal ileum 
(Fallingborg, 1999), correlating with RFC having optimal pH of 7.4 and being 
primarily expressed in terminal ileum. 
A third route of folate uptake is via the family of high-affinity folate 
receptors (FRs). FRs are cysteine-rich glycoproteins that mediate folate uptake 
through endocytosis (Rijnboutt et al., 1996). In humans FRs are encoded by three 
closely located gene loci within chromosome 11q13.3-q13.5 region consisting of 
three isoforms, FRα, FRβ and FRγ.  FRα and FRβ are GPI-anchored cell surface 
glycoproteins whereas FRγ is a secreted protein (Antony, 1996). Frα and FRβ 
display very high affinity for folic acid (Kd~: 0.1-1 nM) and reduced folates (Kd: 1-
10 nM) and a relatively lower affinity for MTX (Kd >100 nM) (Antony, 1996; 
Rijnboutt et al., 1996). FRs are the main route of uptake of 5-methyl-THF, the most 
predominate circulatory form of folate. FRα is found on the membrane of epithelial 
tissues (in particular the uterus, placenta, choroid plexus, retina and kidney) and FRβ 
found in hematopoietic tissues (e.g. thymus and spleen) (Zhao et al., 2011). 
 
1.5.2 Intracellular folate metabolism in mammalian cells  
Following cellular uptake via the influx routes described above, folate metabolism 
can be compartmentalised into three main intracellular compartments, the cytosol, 
 
 
Figure 1.6 Folate metabolism and one-carbon transfer reactions in mammalian 
cells  
 
Metabolic Reactions 
 
1 = DNA synthesis 
2 = Purine Synthesis 
3 = Protein Synthesis 
4 = AdoMet and methylation reactions 
 
 
Enzyme Key: 
 
DHFR  dihydrofolate reductase  
GCS   glycine cleavage system 
SHMT  serine hydroxymethyl transferase 
MTHFD  methylene tetrahydrofolate dehydrogenase  
MTHFC  methenyl tetrahydrofolate cyclohydrolase  
FMT  methionyl-tRNA formyltransferase 
MTHFR  methylene tetrahydrofolate reductase 
MS  methionine synthase 
TS   thymidylate synthase 
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the mitochondria and the lysosome (Figure 1.5). Polyglutamylation of intracellular 
folates occurs in the cytosol and mitochondria, whereas hydrolysis occurs in the 
lysosome (Gonen and Assaraf, 2012) (Figure 1.5).  Polyglutamylation is regulated 
by the enzyme folylpoly-γ-glutamate synthase (FPGS). FPGS catalyses the 
sequential addition of glutamic acid to the γ-carboxyl group of reduced folates and 
classical antifolate drugs (Gonen and Assaraf, 2012). It plays a crucial role in 
intracellular folate regulation. Polyglutamylated folates cannot cross lipid bilayers 
and are no longer substrates for influx transporters (e.g. RFC) and efflux 
transporters, which enables intracellular retention (Zeng et al., 2001).  Also, 
polyglutamylated folates are better substrate than monoglutamates for various 
intracellular folate dependent enzymes (Gonen and Assaraf, 2012). FPGS enables the 
accumulation of polyglutamates in the mitochondria, the site of key intracellular 
folate functions and the principal reservoir of intracellular folates (Lin et al., 1993). 
Counteracting the process of polyglutamylation is hydrolysis to monoglutamate 
folate forms, by the glycoprotein enzyme γ-glutamyl hydrolase located in the 
lysosome (Galivan et al., 2000; Gonen and Assaraf, 2012). This allows folates to be 
exported out of the cell by efflux mechanisms to be described later. 
THF is the biologically active form of folate and its derivatives are utilised 
for a variety of one-carbon transfer reactions essential for cellular proliferation and 
maintenance both in the cytosol and mitochondria. Indeed, THF cofactors that 
originate in the cytosol can be transported into the mitochondrion by the 
mitochondrial folate transporter (MFT) (Lawrence et al., 2011). Various forms of 
THF have been identified intracellularly (e.g. 5-methyl-, 5,10-methylene- and 10-
formyl-THF) (Figure 1.6). THF itself is a cofactor for the production of glycine from 
serine by serine hydroxymethyl transferase (SHMT) both in the cytosol and 
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mitochondrion (Stover and Schirch, 1990). Moreover it is also a cofactor in the 
mitochondrial glycine cleavage system (GCS) for the catabolism of glycine.  The 
GCS is a multienzyme system comprised of four proteins: T-protein, P-protein, H-
protein and L-protein. GCS–P protein (a pyridoxal phosphate-dependent glycine 
decarboxylase) catalyses the decarboxylation of glycine and the reductive 
methylamination of the lipoamide which is then covalently attached to GCS-H 
protein (a hydrogen carrier protein) and then shuttled to GCS-T protein and GCS-L 
protein. GCS-T protein (a tetrahydrofolate-requiring aminomethyltransferase) 
catalyses the transfer of methylene to THF and subsequent release of ammonia. 
GCS-L protein (a lipoamide dehydrogenase) is used in the oxidation of the 
dihydrolipoyl residue of H-protein.  
5,10-Methylene-THF is exploited in the cytosol for the reductive methylation 
activity of thymidylate synthase (TS) that converts deoxyuridine monophosphate 
(dUMP) tothymidine monophosphate (dTMP) for DNA synthesis. The by-product of 
this reaction is dihydrofolate (DHF) which is reduced to THF by dihydrofolate 
reductase (DHFR) an abundant key cytosolic enzyme that maintains cellular THF. 
DHFR also sequentially reduces folic acid to DHF. 5,10-Methylene-THF is 
converted into 10-formyl-THF by the C1-THF synthase complex (which includes 
methylene-THF dehydrogenase (MTHFD) and methenyl-THF cyclohydrolase 
(MTHFC) (Hum et al., 1988). 10-Formyl-THF is used for cytosolic de novo purine 
synthesis as well as for the formation of methionyl-tRNA by methionyl-tRNA 
formyltransferase (FMT).  Methionyl-tRNA is used for the initiation of 
mitochondrial protein synthesis. Methylene-THF reductase (MTHFR) catalyses the 
conversion of 5,10-methylene-THF  to 5-methyl-THF . 5-Methyl-THF serves as a 
mitochondrial one carbon donor for methionine synthase (MS). MS converts 
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homocysteine to methionine, a precursor for the production of S-adenosylmethionine 
(AdoMet) which is utilised in the methylation of DNA and histones.     
 
1.5.4 Folate efflux in mammalian cells 
Efflux of folates is principally mediated by ATP-binding cassette (ABC) 
transporters.  These are high capacity, low-affinity transmembrane transporters that 
couple ATP hydrolysis to transport substrates across the cell membrane. Multidrug 
resistant proteins (MRP/ABCC) compromise 13 members of the ABCC sub-family 
that are distinct by the conserved structure of the ATP-binding domain or nucleotide 
binding domains ((Zhou et al., 2008).  Folates are amongst the various substrates of 
ABCC1-5, and these efflux pumps have been demonstrated to export THF, THF 
substrates and antifolate drugs out of the cell (Assaraf, 2006). Moreover, a low-
capacity high-affinity ABC transporter capable of folate and antifolate drug export is 
the breast cancer resistant protein (BRCP/ABCG2) (Chen et al., 2003; Ifergan et al., 
2004). ABC transporters are expressed in various tissues including the duodenum 
small intestine, biliary and liver tissue. Moreover, organic anion transporters 
(OAT1B1 and OATB3) present in the basolateral membrane of hepatocytes may also 
have a role in folate transport (Visentin et al., 2014). Folate export from the 
lysosome is thought to be mediated by PCFT and driven by the large pH gradient 
between endosome-lysosome and the cytosol (Zhao et al., 2007).  
 
1.6 Folate metabolism in the Trypanosomatids 
Trypanosomes, like mammalian cells, are auxotrophic for folates (Sienkiewicz et al., 
2008; Vickers and Beverley, 2011). Research into parasite folate metabolism mainly 
 
 
 
 
Figure 1.7 Folate and pteridine transport pathways in Leishmania 
 
Figure modified and adapted from Vickers and Beverley (2011). 
 
 
Key: 
 
BT1   biopterin transporter 1 
DHFR   dihydrofolate reductase 
FT(s)   folate transporters 
GCS    glycine cleavage system 
PCD    pterin-4 alpha-carbinolamine dehydratase 
PTR1   pteridine reductase 1 
SHMT   serine hydroxymethyl transferase 
TS    thymidylate synthase 
qDPR    quinoid dihydropteridine reductase 
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examines the roles of specific folate-dependent enzymes (and transporters) in 
metabolism and virulence, and extrapolates targets for current and new antifolate 
drugs. Of the three distinct trypanosomatids, T. brucei, T. cruzi and Leishmania 
species, the majority of the underpinning knowledge in folate metabolism is derived 
from studies in Leishmania.  
 
1.6.1 Folate metabolism in Leishmania 
Leishmania transports folates via a novel superfamily of transporters known as 
Folate Biopterin Transporters (FBT). This class of transporter family was identified 
first in Leishmania (Kundig et al., 1999; Richard et al., 2002) and later found in the 
other kinetoplastids (Ouameur et al., 2008). Leishmania has 14 FBTs and the 
function of four members, BT1, FT1, FT5 and AdoMetT1 has been described. FT1 
and FT5 specifically transport folates. FT1 is the predominant folate transporter in 
Leishmania and has a high affinity/high capacity for folate, (Richard et al., 2004), 
while FT5 is a high affinity/low capacity transporter (Richard et al., 2002). In 
contrast, BT1 is a biopterin transporter that mediates the uptake of folate but 
primarily mediates the uptake of the pteridine biopterin (Kundig et al., 1999) (Figure 
1.7).  AdomeT1, the fourth characterised member of the FBT family in Leishmania, 
is a high affinity transporter of  AdoMet (Dridi et al., 2010a).  
Intracellular oxidised folates are reduced sequentially to THF by the actions 
of pteridine reductase 1 (PTR1) and DHFR-TS (Vickers and Beverley, 2011) (Figure 
1.7) with studies showing that DHFR-TS is responsible for the preponderance of 
THF production (Nare et al., 1997). PTR1 has a dual action in folate and pteridine 
metabolism. It reduces folic acid to DHF, and DHF to THF, and can also 
sequentially reduce biopterin to dihydrobiopterin and then to tetrahydrobiopterin 
 
 
 
Figure 1.8 Folate metabolism in T. brucei and Leishmania 
 
Enzyme Key: 
DHFR  dihydrofolate reductase  
FMT  methionyl-tRNA formyltransferase 
FPGH   folylpoly-γ-glutamate hydrolase  
FPGS   folylpoly-γ-glutamate synthase 
FTHFL 10-formyl tetrahydrofolate ligase 
GCS   glycine cleavage system 
SHMT  serine hydroxymethyl transferase 
MetE   vitamin B12-independent methionine synthase  
MetH   vitamin B12-dependent methionine synthase  
MTHFC  methenyl tetrahydrofolate cyclohydrolase  
MTHFD  methylene tetrahydrofolate dehydrogenase  
MTHFR  methylene tetrahydrofolate reductase 
PTR-1  pteridine reductase - 1  
TS   thymidylate synthase 
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(Bello et al., 1994). However, both in vitro (Bello et al., 1994) and in vivo 
(Cunningham et al., 2001) studies have shown PTR1 not to be essential in 
Leishmania, with the activity of other bypass enzymes in folate metabolism likely to 
account for this. In trypanosomatids, DHFR-TS is a homodimer constituting DHFR 
fused to TS using a linker peptide to form the bifunctional enzyme DHFR-TS. This 
is in contrast to humans where DHFR and TS are separate enzymes.  In Leishmania 
DHFR has little activity in reducing unconjugated folate and has greater activity in 
reducing DHF (Nare et al., 1997) with PTR1 able to reduce folate to DHF (Bello et 
al., 1994).  Unlike PTR1, DHFR-TS is essential both in vitro (Cruz and Beverley, 
1990) and in vivo (Nare et al., 1997). Indeed DHFR-TS has been explored as a drug 
target in Leishmania (Gilbert, 2002). 
The reduction of THF to 5,10-methylene-THF by mitochondrial GCS activity 
enables intracellular glycine catabolism. Leishmania and the other trypanosomatids 
possess close orthologues of the GCS P-protein, GCS T-protein and GCS H-protein 
(Vickers and Beverley, 2011). GCVP (which encoded GCS P-protein) null mutants 
lacked GCS activity in vitro; however parasites were viable, but their growth was 
reduced with serine depletion (Scott et al., 2008). In GCVP-null mice attenuation of 
Leishmania infection was found.  Leishmania possesses the enzyme SHMT which, 
like GCS, reduces THF to 5,10-methylene-THF, but does so by converting serine to 
glycine (Figure 1.8). The fact that GCVP null mice had attenuated infectivity 
suggests that the parasites cannot scavenge sufficient serine in vivo to facilitate 
SHMT to fully recompense for loss of GCS activity. In Leishmania SHMT has two 
orthologues, located in the cytosol and the mitochondria respectively (Gagnon et al., 
2006).  SHMT inactivation, through knockdown of the two orthologues, 
demonstrated that it was not essential for parasite growth in vitro in a rich media 
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(Roy and Ouellette, 2015). When the media was serine deplete, parasite growth was 
substantially reduced with SHMT inactivation. 
Unlike mammalian cells, trypanosomatids lack de novo purine synthesis 
(Bellofatto, 2007) and so the prime function of 10-formyl-THF is the formylation of 
methionyl-tRNA by FMT. In Leishmania 10-formyl-THF can be generated by 
enzymes of the C1-THF synthase complex, either by the sequential reduction of 
5,10-methylene-THF by MTHFD and MTHFC, or directly from THF by the activity 
of 10-formyl-THF ligase (FTHFL) (Figure 1.8). FTHFL was shown to be non-
essential in vitro and in vivo, likely due to the bypass actions of MTHFD and 
MTHFC (Murta et al., 2009). However, MTHFC was shown to be essential in vitro 
and the phenotype could be rescued by FTHFL overexpression (Murta et al., 2009).  
5-Methyl-THF can be formed intracellularly from 5,10-methylene-THF by the action 
of methylenetetrahydrofolate reductase (MTHFR). MTHFR is not essential both in 
vitro and in vivo (Vickers et al., 2006), indeed the parasite can source extracellular 5-
methyl-THF using FBT uptake as previously described. Polyglutamylation of 
intracellular folates is carried out by the enzyme FPGS. Studies in Leishmania found 
that overexpression of FPGS increased long chain glutamates (Glu5) while in 
parasites where one FPGS allele was interrupted glutamates were predominantly 
short chained (Glu3, Glu4). Also, long term accumulation of folates was substantially 
increased with FPGS overexpression (El Fadili et al., 2002).   
 
1.6.2 Folate metabolism in T. brucei 
Comparatively, very little is known about folate metabolism in T. brucei and most of 
our understanding of folate metabolism in trypanosomatids is based on Leishmania. 
However, comparative genomics indicates that T. brucei lacks a number of genes in 
25 
 
folate-dependent pathways that are found in L. major (Berriman et al., 2005). 
Indeed, folate metabolising enzymes such as SHMT, MTHFR and FTHFL, which 
have been studied in Leishmania, are not found in T. brucei (Figure 1.8).  The lack 
of SHMT suggests T. brucei is entirely dependent on the GCS for generating 5,10-
methylene-THF; moreover, the lack of MTHTR suggests that T. brucei is more 
reliant on uptake of host 5-methyl-THF via putative transporters. These differences 
between T. brucei and Leishmania suggest that folate metabolism in T. brucei may 
be more vulnerable to disruption and advocates greater potential for antifolate drug 
therapeutics in T. brucei. 
When comparing folate uptake, T. brucei has 7 FBT homologues compared to the 
14 FBT homologues found in Leishmania (Ouameur et al., 2008). Folate uptake and 
the function of FBTs have not been characterised in T. brucei. Two enzymes in 
folate metabolism which have been studied to a degree in T. brucei are PTR1 and the 
bifunctional DHFR-TS enzyme. In T. brucei PTR1 is essential for cell survival 
(Sienkiewicz et al., 2010), in contrast to Leishmania where it is not essential.  
TbPTR1 knockdown by RNAi resulted in loss of viability in vitro and loss of 
virulence in vivo.  TbPTR1 is reported to display low activity in reducing folate and 
DHF (Ong et al., 2011) and so its essentiality may be based more on its function to 
reduce pterins. T. brucei, unlike Leishmania, lack quinoid dihydropteridine reductase 
(qDPR) genes and are solely dependent on PTR1 for H4B production, thus 
explaining why PTR1 is essential in T. brucei. TbPTR1 has been explored as a drug 
target. An in silico fragment screen was used to identify hits against PTR1 
(Mpamhanga et al., 2009) and co-crystal structures were obtained from compounds 
containing a core benzimidazole scaffold to give a potent inhibitor (Spinks et al., 
2011). Although potent inhibitors of the enzyme were identified this did not correlate 
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with in vitro potency and further work is required to understand lack of cellular 
activity (Gilbert, 2013). 
 
The bifunctional enzyme DHFR-TS is also essential for T. brucei survival in vitro 
and in vivo (Sienkiewicz et al., 2008). Nutritional recue was achieved in vitro with 
the addition of thymidine, highlighting thymidine scavenging as a bypass in dTMP 
production via the action of thymidine kinase (TK). Also, DHFR-TS
-/-
 cells could 
not be rescued with an enzymatically active TS on a plasmid, demonstrating that 
both DHFR and TS are required for thymidylate synthesis. There was a lack of 
infectivity in vivo in DHFR-TS
-/-
 mice. Sensitivity to classical antifolate drugs 
(including MTX) was substantially reduced in DHFR-TS
-/-
 parasites, validating the 
enzyme as a drug target. TbDHFR-TS has recently been recombinantly produced, 
which was challenging as the TS activity of recombinant TbDHFR-TS was highly 
unstable (Gibson et al., 2016). TbDHFR-TS was unable to reduce folic acid, which 
is in agreement with  Leishmania  DHFR-TS, highlighting that in the 
trypanosomatids DHFR  primarily functions to reduced DHF to THF.  
 
 
1.6.3 Folate metabolism in T. cruzi 
Of the trypanosomatids, least is known about folate metabolism in T. cruzi. There 
are three homologues of the FBT family that are annotated in the genome, but their 
function has yet to be characterised (Ouameur et al., 2008).  Of note, as well as 
having PTR1 T. cruzi also has a second pteridine reductase, PTR2. PTR2 can reduce 
dihydrobiopterin and DHF, similar to the function of PTR1; however, it cannot 
reduce oxidised pteridines or folates (Robello et al., 1997; Senkovich et al., 2003). 
Crystal structures of an inhibitor (MTX) and a substrate (DHF)-complex with PTR2 
have also been elucidated (Schormann et al., 2005). DHRF-TS has been studied in T. 
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cruzi.  Single gene knockout T .cruzi parasites (TcDHFR-TS
+/-
) have been generated 
(Xu et al., 2009; Branadan et al., 2011), however attempts to create a double null 
mutant (TcDHFR-TS
+/-
) did not succeed (Branadan et al., 2011). Also, thymidine 
supplementation to culture media did not aid in obtaining double null parasites, 
suggesting that DHFR-TS may be essential in vitro. Impaired parasite growth was 
observed in DHFR-TS
+/-
 in vitro and also these mutants displayed reduced virulence 
in mice (Branadan et al., 2011).  There have been few endeavours in regards to 
DHFR-TS targeted drug discovery in T. cruzi.  TcDHFR enzyme activity and whole 
cell activity (amastigote) has been assessed in a few chemical series with moderate 
results (Chowdhury et al., 1999; Chowdhury et al., 2002; Gilbert, 2002; 
Khabnadideh et al., 2005). 2-4 Diaminopyrimidine based compounds were also 
tested in mice; however, a lack of in vivo activity was found (Pez et al., 2003). The 
crystal structure of TcDHFR-TS has been reported and docking sites and binding 
affinities of novel and known DHFR-TS inhibitors have been characterised 
(Schormann et al., 2008; Senkovich et al., 2009) gaining insight into the DHFR and 
TS active sites that can be exploited for the development of antifolate-based 
compounds for T. cruzi.  
 
1.7 Antifolate drugs 
 
Antifolate drugs, also known as folate antagonists, or antifols, are drugs that inhibit 
the intracellular actions of folic acid derivatives.  Folate dependent processes such as 
purine and thymidylate biosynthesis are blocked, resulting in cell death. 
‘Thymineless-death’ describes the phenomenon of cell death via inhibition of dTMP 
and DNA synthesis leading to cell cycle arrest in S phase (Khodursky et al., 2015). 
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Indeed antifolate drugs are known be cytotoxic during the S phase of the cell cycle 
(Di Gennaro E. et al., 2009; Taylor and Tattersall, 1981). 
 
In the 1940s aminopterin was discovered to be an effective treatment in 
childhood acute leukaemia. It was replaced by MTX which was found to be less 
toxic and, decades after this, more rationally designed new generation antifolates 
have been developed. Today, antifolates are commonly used as adjuvant drugs with 
chemotherapy in the treatment of human malignant diseases (e.g.  MTX, PMX, 
raltitrexed (RTX)) (Gonen and Assaraf, 2012; Wilson et al., 2014). Also, antifolates 
are used for non-malignant diseases. They are used clinically in the treatment of 
inflammatory diseases including rheumatoid arthritis and psoriasis (MTX); and are 
used in infectious diseases such as protozoal infections (pyrimethamine (PYR) used 
as an antimalarial agent and against toxoplasmosis), bacterial infections 
(trimethoprim (TMP) is a broad-spectrum antimicrobial) and fungal infections 
(trimetrexate (TMX) is used against Pneumocystis pneumonia) (Walling, 2006; 
Wright and Anderson, 2011). 
 
Antifolates can generally be divided into two main categories, classical 
antifolates and non-classical antifolates. Classical antifolates, such as MTX and 
RTX, bear close structural resemblance to naturally occurring folates and contain a 
terminal glutamate residue and undergo intracellular polyglutamylation in 
mammalian cells. They also use the same mechanism as folates for cell entry via 
specific transporters (e.g. RFC, PCFT, FRs in mammalian cells) (Gonen and 
Assaraf, 2012). Non-classical antifolates, such as PYR and nolatrexed (NTX) are 
devoid of a glutamate moiety and are not polyglutamylated (Gonen and Assaraf, 
2012). Non-classical antifolates are often termed lipophilic. However, in themselves 
they are not that lipophilic. Indeed, the clinically used non-classical antifolates that 
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have been tested in this thesis (Figure 1.4) have LogP values < 2. But these drugs are 
relatively lipophilic compared to classical antifolates that contain glutamate, a very 
hydrophilic moiety, and have LogP values < 0 (LogP values from 
http://chemspider.com). A further subdivision of antifolates can be made in regards 
to whether they are primarily selective for DHFR or TS. MTX is a potent 
competitive and reversible inhibitor of DHFR whereas newer antifolates such as 
RTX and NTX have been designed to directly inhibit TS. Structurally, compounds 
with a primary amine at position 4 favour DHFR inhibition and a carbonyl 
substituent in this position selects for TS inhibition (Phan et al., 2001).  This change 
in selectivity is explained by the carbonyl oxygen providing extra hydrogen bonding. 
Moreover, TS-targeted classical antifolates have a terminal glutamyl moiety which 
results in polyglutamylation of the drug and better binding to TS (Synold et al., 
1996). In this thesis a selection of both classical and non-classical antifolate drugs 
were used and within these groups compounds were either DHFR or TS selective 
(Figure 1.4).  As well as primarily targeting DHFR and TS some antifolates also 
inhibit two key enzymes in de novo purine biosynthesis, β-glycinamide 
ribonucleotide transformylase (GART) and 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase (AICART). For the antifolates used in this thesis, 
PMX, primarily targeting TS, is also known to inhibit DHFR, GART and AICART 
(Wilson et al., 2014). 
 
Antifolates are known to have a greater toxic effect in rapidly dividing cells, 
since their requirement for purines and thymidylate for DNA synthesis is high. 
Therefore, they are effective in killing malignant cells, but also have adverse effects 
on cells which divide rapidly such a bone marrow, skin, and hair. Indeed the folic 
acid derivative leucovorin (5-formyl-THF) is used as a folic acid supplement to 
30 
 
reduce the toxic side effects in patients receiving MTX treatment (Shiroky et al., 
1993; Treon and Chabner, 1996).  Resistance to antifolate drugs has emerged 
clinically, both in the treatment of malignant diseases (Gonen and Assaraf, 2012) and 
non-malignant diseases (inflammatory and infectious diseases) (Brolund et al., 2010; 
Gregson and Plowe, 2005; van der Heijden et al., 2007).  Mechanisms of resistance 
include: decreased influx (via specific transporters for classical antifolates), impaired 
polyglutamylation (via FPGS), increased hydrolysis (via γ-glutamyl hydrolase), 
overexpression and mutations of enzyme targets (e.g. DHFR and TS), expanded 
intracellular folate pool and increased efflux (Assaraf, 2007; Gonen and Assaraf, 
2012). 
  In light of this, new generation antifolates are being designed to overcome 
these drug resistance mechanisms. In T. brucei the bifunctional enzyme DHFR-TS 
was found to be a target of antifolate drugs and MTX was shown to have nanomolar 
whole cell potency (Sienkiewicz et al., 2008).  This has heightened the possible role 
of antifolate drugs as chemotherapeutic agents for HAT. Some antifolate drugs are 
available in oral preparations and also some have good CNS penetration, which 
confers well with the TPP for new compounds for HAT. However, there are many 
questions regarding the MOA of antifolates in T. brucei yet to be addressed (i.e. 
transport of drug, cell cycle effect and cidal/static effect). Understanding drug 
resistance mechanisms will help identify any problems if the drugs are used in the 
field, as well as giving insight into designing new and refining existing antifolates. 
 
It should be noted that when testing antifolate drugs against T. brucei or 
investigating folate metabolic pathways in vitro, the utilisation of folate and 
thymidine depleted medium is essential. Standard culture for BSF T. brucei, based 
on HMI9, is very nutrient rich compared to the parasites natural in vivo environment. 
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This can hinder drug discovery endeavours as nutrient rich media could mask drugs 
that are potential pharmacologically active in vivo. Minimal media for in vitro 
culture have been used to create more physiologically relevant conditions (Baltz et 
al., 1985; Creek et al., 2013; Sienkiewicz et al., 2008). Indeed DHFR-TS inhibitors 
were shown to be most potent when tested in a folate deficient media ‘FDM’ 
(Sienkiewicz et al., 2008). High folate levels in vitro have been found to hinder 
antifolate drug potency in other systems (Nare et al., 1997; Peters et al., 1999). 
However, when testing antifolate drug potency in T. brucei media should be 
deficient of not only folate but also thymidine.  Antifolates reduced the intracellular 
THF pool, which in turn circumvents dTMP and DNA synthesis resulting in 
‘thymineless-death’, but, T. brucei can also salvage extra-cellular thymidine by-
passing de novo dTMP synthesis (Sienkiewicz et al., 2008). In mammalian cells it is 
well-established that salvage nucleotide synthesis can hinder the inhibitory effects of 
antifolates (Jackman et al., 1991; Kinsella et al., 1997; Sobrero and Bertino, 1986). 
The standard media for T. brucei cell culture (HMI9) contains folate concentrations 
that are 150-2,000 times the plasma concentration in humans (Wahlin et al., 2002) 
and thymidine concentration 23-90 times that of humans (Howell et al., 1981). 
Consequently, this non-physiological high folate concentration could reduce the anti-
trypanosomal potency of antifolate drugs through mechanisms such as competition 
for drug uptake, hindering cellular retention by competition for polyglutamylation by 
FPGS or through competition for the active site of target enzymes (e.g. DHFR-TS).   
 
1.8 Aims and Objectives 
 
The aim of this thesis is to expand upon the knowledge of the mechanism of action 
and resistance of antifolate drugs in T. brucei brucei, the model organism for HAT. 
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Mechanism of Action 
 To establish a folate and thymidine depleted media that will enable studies to 
examine antifolate drug potencies under physiological conditions.  
 To identify the nature of killing (cidal/static) and confirm mechanism of 
action (‘thymineless-death’) of antifolates. 
  To screen a small library of DHFR-TS/PTR1 inhibitors of the Drug 
Discovery Unit (DDU).  
 To describe the transport kinetics of folate and MTX in T. brucei. To 
determine whether antifolates and folate derivatives compete with folate 
uptake into cells.   
Mechanism of Resistance 
 To identify mechanism of resistance by a RIT-Seq study with selected 
classical antifolate drugs and to confirm hits from these screens by RNAi 
knockdown and phenotypic studies. 
 To establish a MTX resistant cell line and identify key parameters involved 
in the mode of resistance by phenotypic studies, DNA and proteomic (stable 
isotope labelling with amino acids in cell culture (SILAC)) analysis. 
  
33 
 
 
 
 
Chapter 2:     
Material and 
Methods 
 
 
  
34 
 
2.1 Materials and chemicals  
DHFR-TS inhibitors were obtained as follows: NTX, PMX and RTX from Sequoia 
Research Products; MTX, TMP, PYR and WR99210 from Sigma Aldrich; metoprine 
(MTP) from Toronto Research Chemicals; and TMX from Tocris Bioscience.  
Melarsoprol was purchased from Rhone-Poulenc. Solid stocks of compounds 1, 2 
and 4 - 16 from the “antifolate set” (see Fig 3.4) were sourced from the chemistry 
team of the Dundee Drug Discovery (DDU). Stocks were dissolved in DMSO and 
Dr Stephen Paterson confirmed purity and identity of the compounds by liquid 
chromatography - mass spectrometry and, when required, nuclear magnetic 
resonance. All compounds were of 90% purity or higher. Folic acid, p-
aminobenzoyl-L-glutamic acid (pABA-Glu) and biopterin were obtianed from 
Schircks Laboratories. 
3
H-Folic acid (64 Ci mmol
−1
) and 
3
H-MTX (38.2 Ci mmol
−1
) 
were purchased from Hartmann Analytical. Stable isotope-labelled amino acids were 
purchased from CK Gas Products.  
 
2.2 Trypanosomatid cell cultures and culture media 
Media and reagents used for culturing trypanosomes were filter sterilised using a 
Steriflip filtration unit (0.22 μm PES membrane, Millipore). 
2.2.1 HMI9-T Media 
HMI9-T was prepared based on HMI9 medium (Hirumi and Hirumi, 1989). 
However 56 μM 1-thioglycerol was substituted for 200 μM 2-mercaptoethanol  as 
the reducing agent (Greig et al., 2009). Liquid IMDM (Thermo Fisher) was 
supplemented with 10% dialysed FCS (Gibco, Life Technologies), 10 % Serum 
Plus
TM 
(SAFC biosciences), 2 μM  GIBCO ® GlutaMAX™ (Thermo Fisher), 110 μg 
Table 2.1: Composition of HMI9-T, RPMI-BM and TBM  
COMPONENTS HMI9-T (mM) RPMI-BM (mM) TBM (mM) 
 
    Amino acids 
Hydroxy L-proline 0 0.153 0 
Glycine 0.400 0.133 0.400 
L-Alanine 0.281 0 0.281 
L-Arginine  0.398 1.75 0.398 
L-Asparagine  0.167 0.379 0.167 
L-Aspartic acid 0.226 0.150 0.226 
L-Cystine 2HCl 0.381 0.285 0.381 
L-Glutamic Acid 0.510 0.136 0.510 
L-Glutamine 4.00 2.05 2.00
 a
 
L-Histidine 0.200 0.297 0.200 
L-Isoleucine 0.802 0.782 0.802 
L-Leucine 0.802 0.782 0.802 
L-Lysine hydrochloride 0.798 0.670 0.798 
L-Methionine 0.201 0.202 0.201 
L-Phenylalanine 0.400 0.291 0.400 
L-Proline 0.348 1.82 0.348 
L-Serine 0.400 0.286 0.400 
L-Threonine 0.798 0.568 0.798 
L-Tryptophan 0.0784 0.745 0.0784 
L-Tyrosine disodium salt 0.462 0.248 0.462 
L-Valine 0.803 0.571 0.803 
     Vitamins 
Biotin 0.0000533 0.000820 0.0000533 
Choline chloride 0.0286 0.0214 0.0286 
D-Calcium pantothenate 0.00839 0.000524 0.00839 
Folic Acid 0.00807
b 
0.0000309
c 
0
d 
i-Inositol 0.0400 0.194 0.0400 
Niacinamide 0.0328 0.00820 0.0328 
Pyridoxal / pyridoxine 0.0196
e 
0.00485
f 
0.0196
e 
Para-Aminobenzoic Acid 0 0.00730 0 
Riboflavin 0.00106 0.000532 0.00106 
Thiamine hydrochloride 0.0119 0.00297 0.0119 
Vitamin B12 0.0000096 0.0000037 0.0000096 
      Salts 
Calcium ions  1.49
g 
0.424
h 
1.49
g 
Nitrate ions 0.000752
i 
0.8480
j 
0.000752
i 
Magnesium Sulphate (MgSO4) 0.814 0.407 0.814 
Potassium Chloride (KCl) 4.40 5.33 4.40 
Sodium Bicarbonate (NaHCO3) 36.00 23.81 36.00 
Sodium Chloride (NaCl) 77.59 103.45 77.59 
Sodium Phosphate 0.906 5.64 0.906 
Sodium Selenite (Na2SeO3.5H20) 0.0000658 0 0.0000658 
    Other components 
D-Glucose (Dextrose) 25.00 11.2 (25.1) 
k 
25.00 
HEPES 25.03 25 25.03 
Phenol Red 0.0399 0.0133 0.0399 
Sodium Pyruvate (total) 1.0 (2.0)
 k
 0 (2.0)
 k
 1.0 (2.0)
 k
 
Glutathione (reduced) 0 0.00326 0 
     Additional supplements    
D-Glucose 0 14.0  0 
HEPES 0 25 0 
Bathocuproine sulphonate 0.05 0.05 0.05 
Cysteine 1.5 1.5 1.5 
Thioglygerol 0.2 0 0 
Hypoxanthine 1.0 1.0 1.0 
Mercaptoethanol 0 0.2 0.2 
Pyruvate  1.0 (see above) 2.0 (see above) 1.0 (see above) 
Thymidine  0.16 0
l
 0
d
 
Foetal bovine serum (% )                               10  10 10 
Serum Plus (%)                                              10  0.5 0 
Key: 
a) As GIBCO ® GlutaMAX™, L-alanyl-L- glutamine,  a dipeptide substitute 
for L-glutamine 
b) From Iscove’s Modified Dulbecco’s Media and 10% Serum Plus, excluding 
any contribution from FBS 
c) From 0.5% Serum Plus and folate free RPMI medium, excluding any 
contribution from FBS 
d) Excluding any contribution from FBS 
e)  As pyridoxal hydrochloride 
f)  As pyridoxine hydrochloride 
g)  As CaCl2 
h)  As Ca(NO3)2 
i)  As KNO3 
j)  As Ca(NO3)2 
k)  Values in parentheses include additional supplements 
l)   Excluding any contribution from 0.5% Serum Plum Plus, folate free RPMI 
medium and FBS. 
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ml
-1
 pyruvic acid, 39 μg ml
-1
 thymidine, 2.8 μg ml
-1
 bathocuproine disulfonic acid, 
182 μg ml
-1
 L-cysteine and 13.6 μg ml
-1
 hypoxanthine, and reduced with 56 μM 1-
thioglycerol.  
2.2.2 Folate and Thymidine Depleted Media 
Folate (as folic acid) and thymidine depleted media is not commercially available 
and in-house nutrient depleted media was prepared by hand. Initially a folate and 
thymidine deficient media, based upon ‘FDM’, was prepared as previously described 
(Sienkiewicz et al., 2008) and named RPMI-based media (RPMI-BM). This media 
was made using a folate-free RPMI 1640 medium (Thermo Fisher), supplemented 
with 50 x MEM  amino acid solution (Thermo Fisher), and addition of 0.5% Serum 
Plus
TM 
(SAFC biosciences).  A second nutrient depleted media was prepared based 
on HMI9-T (Greig et al., 2009), lacking Serum Plus
TM
, folate and thymidine, and 
using 2-mercaptoethanol instead of thioglycerol as the reducing agent. This was 
named T. brucei base media (TBM) (Gibson et al., 2016). A comparison of media 
types is shown in Table 2.1. In TBM residual folate is only provided by the 10% 
foetal calf serum (FCS, GE Healthcare) component.   
2.2.3 SILAC Media 
SILAC media was prepared essentially as described (Urbaniak et al., 2013) but 
without the addition of excess folate. SILAC IMDM depleted of L-arginine and L-
lysine (Thermo Fisher) was supplemented with 10% dialysed FCS (Gibco, Life 
Technologies) and 110 μg ml
-1
 pyruvic acid, 39 μg ml
-1
 thymidine, 2.8 μg ml
-1
 
bathocuproine disulfonic acid, 182 μg ml
-1
 L-cysteine and 13.6 μg ml
-1
 hypoxanthine 
and reduced with 200 μM 2-mercaptoethanol. 
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2.2.4 Culture Conditions 
For routine culture, blood stream-form (BSF) T. brucei ‘single marker’ S427 (Wirtz 
et al., 1999) and 2T1 strains (Alsford et al., 2005) were cultured in TBM and HMI9-
T medium. S427 cells were supplemented with 2.5 μg ml
-1
 neomycin (G418) to 
maintain expression of T7 RNA polymerase and a tetracycline repressor protein 
(TetR) and 2T1 cells supplemented with 1 μg ml
-1
 phleomycin (TetR) and 1 μg ml
-1
 
puromycin (PAC resistance cassette). Trypanosomes were incubated at 37 
o
C in the 
presence of 5% CO2. Cultures were routinely passaged into fresh media every 48 or 
72 h and cell density kept below 5 x 10
6
 cells ml
-1
.  
2.2.5 Cell counting 
Cells were counted using a CASY cell counter model DT according to 
manufacturers’ instruction. For cell densities below 5 x 10
5
 cells ml
-1 
(below 
comfortable limit of detection) trypanosomes were manually counted using a 
Haemocytometer (Neubauer).  
 
2.3 General Molecular Biology 
2.3.1 Isolation of genomic DNA  
Mid-log cells (a total of ∼ 4 x 107) were pelleted by centrifugation (800g, 10 min, 25 
o
C) and resuspended in 250 μl of gDNA lysis buffer (10mM Tris-HCl, pH 8,  100nM 
NaCl, 25nM EDTA, 0.1 mg ml
-1
 proteinase K, 0.5% (w/v) SDS) and incubated at 56 
o
C overnight. Four volumes of 95% EtOH were added to the lysate and the tube 
inverted several times to mix. DNA was spooled and precipitated in 90% EtOH 
followed by a further precipitation in 70% EtOH. After ensuring the remaining EtOH 
was drained off, isolated gDNA was resuspended overnight at RT in 100 μl elution 
Table 2.2 Primers used in this study 
Primer Name 
 
Primer Sequence Primer Purpose 
LIB2f 5′-TAGCCCCTCGAGGGCCAGT Sequencing RNAi library fragments 
LIB2r 5′-GGAATTCGATATCAAGCTTGGC Sequencing RNAi library fragments 
TbFT1-3 stem loop fwd 5’-GATCGGGCCCGGTACCGCTTGTGAGTTGGGTTTGGT Generate FT1-3 RNAi construct 
TbFT1-3 stem loop rev 5’-GATCTCTAGAGGATCCCGATCACAAGTGGAAGAGC Generate FT1-3 RNAi construct 
Stem loop seq fwd 5’-AATAGTGGACTCTTGTTCCA Sequencing stem loop construct 
Stem loop seq rev 5’-AAAGGGGGATGTGCTGCAAG Sequencing stem loop construct 
FT Fw 5’-ATGACCACGTCACCGAAC Southern Blot 
FT Rx 5’-CTAATTGGCTGTGGGTTC Southern Blot 
TR Fw 5’-ATGTCCAAGGCCTTCG Southern Blot 
TR Rev 5’-TCACAGGTTAGAGTCCG Southern Blot 
TbTERT fwd 5′-GAGCGTGTGACTTCCGAAGG RT qPCR 
TbTERT rev 5’-AGGAACTGTCACGGAGTTTGC RT qPCR 
TbFT1-3 qPCR fwd 5′-GAATTGCTGACAACATCATT RT qPCR 
TbFT1-3 qPCR rev 5′-TCACTGCGTAACCAAATGTA RT qPCR 
TbFT1 fwd 5’-GATGCCTTGATGATACTGC Sequencing MTX line 
TbFT 1 rev 5’-CGCTTCTACATGTACTTAC Sequencing MTX line 
TbFT 2 fwd 5’-GCGTAACATTATACAATAC Sequencing MTX line 
TbFT 2 rev 5’-GAATATAGTCCACCTGCTC Sequencing MTX line 
TbFT 3 fwd 5’-GAGGTAACCCTTCCATTTTG Sequencing MTX line 
TbFT 3 rev 5’-ACATACACACACACACAC Sequencing MTX line 
TbFT Univ fwd 1 5’-CTTCCACTTGTGATCGCGAAG Sequencing MTX line 
TbFT Univ rev 1 5’-GACGCGGCGAATCAAGCG Sequencing MTX line 
TbFT Univ  fwd 2 5’-CACCCTCGCTATTGTGTACG Sequencing MTX line 
TbFT Univ rev 2 5’-GACATTGTCGATTGCGCCAG Sequencing MTX line 
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buffer (Qiagen) and confirmed to be pure by spectrophotometry (260:280 ratio >1.8) 
using a NanoDrop (Thermo Scientific) .  
 
2.3.2 Agarose-gel electrophoresis. 
DNA was analysed using agarose gels (0.8% (w/v), VWR) containing 20 μg 
ethidium bromide   per 100 ml and made in TAE buffer (40 nM Tris, 20 mM acetic 
acid, and 1 mM EDTA). Electrophoresis was carried out at 100 V in TAE buffer 
until the desired separation was attained. The separation of a DNA marker (1 kbp 
plus DNA ladder, Promega) enabled DNA bands to be compared and estimated 
using UV transillumination for visualisation.  
 
2.3.3 Quantitative RT-PCR 
T. brucei RNA was isolated from ∼ 1 x 107 parasites using an RNeasy purification 
kit (Qiagen) as per manufacturer’s instructions and cDNA was then synthesised from 
these samples using a high capacity RNA-to-cDNA kit (Applied Biosystems). 
Primers were designed by Dr Natasha Sienkiewicz using Premier Biosoft’s Beacon 
Designer 6 to amplify a 117 bp region that is common to all three FT genes, but 
different from the region that is targeted by RNAi (primer sequence Table 2.2).  
qRT-PCR reactions included 1 μl (40 ng) cDNA, 1 μl (500 nM) each of the forward 
and reverse primers, 10 μl Brilliant III Ultra-Fast QPCR Master Mix (Agilent 
Technologies),  0.3 μl (30 nM) of reference dye and the remaining volume nuclease 
free PCR grade-treated water. Cycling conditions were: 95 °C for 3 min followed by 
40 cycles of 95 °C for 20 s; 60 °C for 20 s, and analysis was conducted using an 
Agilent Mx3005P machine. The reference gene TERT (Tb927.11.10190, telomerase 
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reverse transcriptase) allowed normalization of the data by providing a baseline of 
transcription levels (primer sequence Table 2.2).  Relative quantification of cDNA 
was determined using the ∆∆Ct method and a student’s unpaired t-test was used to 
dtermine significance. Statistical analyses were performed using Microsoft Excel 
2010. 
 
2.3.4 Synthesis of Southern blot probes 
PCR DIG synthesis kit (Roche) was used to make DIG labelled probes for Southern 
blotting. Primers designed against FT1-3 (Table 2.2) were used to amplify the target 
region of DNA from plasmid DNA, as described in the manufacturers’ protocol. To 
test label incorporation, DIG labelled product was ran on an agarose gel and 
exhibited a decrease in electrophoretic mobility compared to the unlabelled control. 
 
2.3.5 Southern blot 
Samples of gDNA (5 μg) were digested with EcoR1 overnight at 37 
o
C. The digested 
products were separated on a 0.8 % agarose gel (containing 20 μg ethidium bromide  
in 200 ml) for 3 h at 80 V in TAE buffer. The gel was washed in 0.25 M HCl for 10 
min to de-purinate the DNA prior to equilibrating in 0.4 M NaOH for 2 min. The 
DNA was transferred onto a positively charged nylon membrane (Roche) by 
capillary mechanism for ∼ 90 min using 0.4 M NaOH as the transfer buffer. The 
membrane was pre-incubated with DIG Easy Hyb solution for 2 h at 42 
o
C followed 
by overnight incubation with fresh DIG Easy Hyb solution containing 2 μl of the 
denatured DIG labelled probe. The probe was denatured by heating at 100 
o
C for 10 
min before rapidly cooling on ice. Following overnight incubation, the membrane 
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was washed twice in low-stringency conditions (25
o
C, 5 min, 2 x saline sodium 
citrate (SSC) with 0.01% (w/v) sodium dodecyl (SDS)) followed by two high-
stringency washes (68 
o
C, 15 min, 0.5 x SCC with 0.01% SDS) to remove any 
excess probe (20 x SSC (Ambion) compromises 3M sodium chloride and 0.3 M 
sodium citrate, pH 7.0). The blot was prepared for development using DIG block and 
wash buffer set (Roche) as per manufactures’ instructions and detected using Anti-
DIG AP-Conjugate Antibody (Roche) with the chemiluminescent substrate, CSPD 
(Roche).  Films were exposed (Hyperfilm
TM
, Amersham) from 1 min to 5 min and 
developed with a KODAK film developer. 
 
2.4 EC50 and resazurin assay 
EC50 values (drug concentration that gives half-maximal response) of antifolates 
against BSF trypanosomes were determined in 96-well microtitre plates. Serial 
doubling dilutions of drugs (5-50 mM stocks prepared in DMSO) were prepared in 
100 l of TBM and parasites, routinely cultured in HMI9-T, were added in 100 l 
TBM with a final cell density of 2.5 × 10
3
 cells ml
−1 
in 96-well plates. A final 
volume of 0.5% DMSO was in all wells, including controls. After a 72 h incubation 
cell density was determined using a resazurin-based assay (Jones et al., 2010; Raz et 
al., 1997) with fluorescence measured using a Biotec Instruments FLX 800 
fluorescent plate reader (excitation of 528 nm and emission of 590 nm). Resazurin 
(20 l of a 500 M stock, giving 45.5 M final concentration) was added at 68 h for 
4 hours of incubation prior to fluorescence being measured at 72 h   Data was 
corrected for background fluorescence. EC50 values were calculated using GraFit v 
5.0.13 with a 3-parameter fit (see below) from triplicate readings.  
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In this equation Range is the fitted uninhibited value, x is the inhibitor concentration 
and s is the Hill slope of the curve. 
 
2.5 Static-Cidal Assay  
2.5.1 Limit of detection 
The static-cidal assay was adapted from a previously published method (De Rycker 
et al., 2012). Briefly, 200 µl of T. brucei cells grown in TBM were dispensed in 
triplicate into a 96-well plate at the following densities: 0, 5×10
3
, 1×10
4
, 2×10
4
, 
5×10
4
, 1×10
5
 and 2×10
5
 cells ml
−1
. Resazurin (Sigma) was then added at a 45.5 µM 
final concentration and the plates were incubated for 4 h and florescence measured 
as previously described in section 2.4. Using linear regression, cell number versus 
fluorescence signal was plotted. The limit of detection was determined as the cell 
density with a signal higher than the mean, plus three times the standard deviation 
(SD) of the mean, of the blank wells (no cells).  
 
2.5.2 Growth assays 
Three replicate 96-well plates of serial doubling dilutions of each compound were 
prepared and trypanosomes were seeded into each plate at a final concentration of 4 
× 10
5
 ml
−1
 (200 µl final volume in TBM). All wells, including controls (no drug), 
contained a final volume of 0.5% DMSO. Immediately resazurin (45.5 µM final 
concentration) was added to plate 1, and all plates (plates 1-3) were then incubated. 
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After 4 h, florescence of the time zero plate (plate 1) was measured. At 20 h and 44 h 
plates 2 and 3 respectively were processed in the same manner.  A growth curve was 
taken from triplicate readings of florescence signal and calculated as a percentage 
against the no drug control. The Minimum Cidal Concentration (MCC) was 
determined as the lowest drug concentration that causes a reduction in fluorescence 
signal at 48 h relative to time zero (De Rycker et al., 2012). 
 
2.6 Cell-Cycle Analysis 
T. brucei cultures in TBM were seeded at 3 × 10
5
 cells ml
−1
 and treated with varying 
concentrations of MTX and RTX and supplemented with either excess 160 µM or 1 
µM thymidine (the physiological level found in mouse plasma (Clarke et al., 
2000b)). After 20 h cells were harvested by centrifugation (10 min, 800 g, 25 
o
C), 
washed in FACS buffer (1 x PBS pH 7.0, 5 mM EDTA and 1% FCS) and 
supernatant removed. Cells were fixed in 1% formaldehyde in FACS buffer, in a 
drop-wise fashion while gently vortexing to reduce cell clumping, incubated at RT 
for 10 min and stopped by centrifugation. Cells were then permeabilized with 0.01% 
Triton X-100 in FACS buffer, incubated at RT for 30 min and stopped by 
centrifugation. Cells were resuspended in 400 μl staining solution (FACS buffer, 10 
μg ml
−1
 propidium iodide, 100 μg ml
−1
 RNase A), stained for 45 min at 37 
o
C in the 
dark before being analysed by flow cytometry.  Samples were analysed and data 
acquired on a FACS Canto (Becton Dickinson, BD) using BD FACSDiva Software. 
Pulse-width analysis was used to ensure the exclusion of doublets and clumps 
(Garcia-Martinez et al., 2009). Triplicate or duplicate samples were used in each 
analysis. Data was visualized using FlowJo software (Tree Star). Evaluation of cell 
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cycle distribution using the Watson-Pragmatic model (Watson et al., 1987) or the 
Dean-Jett-Fox model (Dean and Jett, 1974; Fox, 1980) could not be attained for drug 
treated cells.  These models assume that data is distributed in normal cell cycle 
phases; however, cell cycle was greatly disturbed in treated cells to an extent that 
distribution could not fit these algorithms.    
 
2.7 Transport Experiments 
2.7.1 Transport Assay 
Prior to transport being measured, trypanosomes routinely grown in HMI9-T media 
were split to  5 × 10
3
 cells ml
-1 
in TBM and then cultured in TBM for 72 h. Cells 
were pelleted by centrifugation (800 g, 10 min, 4 
o
C), washed twice and resuspended 
in ice-cold transport buffer (33 mM HEPES, 14 mM glucose, 4.6 mM KCl, 0.07 mM 
MgSO4,  0.3 mM MgCl2, 23 mM NaHCO3,  98 mM NaCl,  0.55 mM CaCl2, 5.8 mM 
NaH2PO4, pH 7.3) (Ali et al., 2013a) at a density of 2.5 x 10
8
 cells ml
-1
. Transport 
was carried based on a method previously described (Ong et al., 2013). Uptake was 
determined by mixing 100 μl of trypanosomes with 100 μl of transport buffer that 
contains the radiolabelled ligand (0.5μCi) and, when required, potential inhibitors of 
transport. This mixture is layered over 100 μl of dibutyl phthalate (Sigma Aldrich) 
and uptake was stopped by centrifugation (16,000g, 1 min) of the mixture through 
the dibutyl phthalate layer. Microcentrifuge tubes were then immediately flash 
frozen in liquid nitrogen. The bottom of the tubes (containing the cell pellet) were 
cut straight into scintillation vials and then solubilized in 150 μl of 1 M NaOH 
overnight.  Scintillation fluid (2 ml) was added the following day and radioactivity 
was measured using a liquid scintillation counter (Beckman LS 6500). 
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2.7.2 Rate and Km  app analysis 
Uptake of [
3
H]-folic acid (0.04 μM) was measured in the presence of varying 
concentrations of unlabelled folate, in the same way, uptake of [
3
H]-MTX (0.07 μM) 
was measured in the presence of varying concentrations of unlabelled MTX. Linear 
uptake of both folate and MTX was assessed over 150 s with five 30 s time points 
(30, 60, 90, 120 and 150 s). Data was then fitted using a robust non-linear fitting to 
the linear equation y = mx + c. In a similar manner, non-specific binding of 
radiolabeled ligand (folate or MTX respectfully) to trypanosomes at 4 
o
C (on ice) 
was determined. Uptake of folate or MTX in pmol 10
8
 cells
-1
 was calculated using 
their [
3
H] specific activities, cell number and dilution factor of unlabelled substrate.  
As these transport experiments reflect the activity of multiple transporters (FT1-3) 
the Km app (apparent Km app of multiple, distinct transport activities) of folate and 
methotrexate transport was calculated. To calculate Km app, data was fitted by non-
linear regression to the Michaelis–Menten equation and a weighted mean from three 
independent experiments was calculated. 
 
2.7.3 Folate and MTX inhibition studies 
Linear rate of uptake was determined as described but with the addition of 100 μM 
of competing inhibitor and standard assay mixture modified to contain 
approximately [S] = Km app (folate at 2.0 μM and MTX at 13 μM) and corrected for 
additional DMSO (0.4%). To measure IC50 (inhibitor concentrations giving 50% 
inhibition) uptake of the substrate was determined over a range of inhibitor 
concentrations across 7-8 point serial doubling dilutions. Data was expressed as 0-
100% of the no drug control.  Using GraFit 5.0, data was fitted by non-linear 
regression to a two-parameter IC50 equation: 
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In this equation, x is the inhibitor concentration and s is the Hill slope of the 
curve. 
To determine the mode of inhibition of both MTX to folate uptake, and vice 
versa, the linear rate of uptake was measured as described but with three different 
inhibitor concentrations and four different substrate concentrations. The resulting 
data was plotted as a Lineweaver-Burke transformation and the graphs inspected to 
confirm competitive inhibition mode (intersection on y-axis). An F-test confirmed 
the mode of inhibition as linear competitive. The entire data set was globally fitted to 
the competitive-mode equation 1.  
     Equation 1 
 
 
If folate and MTX are competitive substrates for the same transporter then: 
  
for folate Equation 2 
 
for MTX:    Equation 3                                                 
[M] and [F] refer to the concentrations of MTX and folate respectively  
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Dividing equation 3 by equation 2 constitutes: 
Equation 4                                                 
  
The IC50 for MTX occurs when:                                                                                                             E Equation 5   
 
 
By substituting equation 5 into equation 4 and rearranging:  
     Equation 6 
 
 
In the same way, the IC50 for folate can be calculated:     
  
       
           Equation 7     
  
 
2.7.4 Folate uptake in high and low folate conditions. 
The transport assay was performed as previously described in section 2.7.1, except  
cells were either cultured for 72 h in TBM (low folate conditions) or TBM 
supplemented with  9 μM folate  (high folate conditions) prior to assay.  Folate 
uptake was assessed at either 2 μM (Km app ) or 20 μM (saturating concentrations) of 
folate. Uptake was measured over 10 min at 8 time points (30, 60, 90, 120, 150, 300, 
450 and 600 s), with linearity of uptake fitted using a robust non-linear fitting to the 
linear equation y = mx + c for the first 5 time points. 
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2.8 RNAi library 
2.8.1 Cell culture and extraction of genomic DNA 
The RNAi library screen was performed in TBM and carried out based on the 
protocol previously described (Glover et al., 2015). On day 0, a frozen RNAi library 
stock was thawed in media, maintained under blasticidin (1 μg ml
-1
) and phleomycin 
(1 μg ml
-1
) control, expanded to a cell density of 2.5 × 10
7
 cells in 150 ml media and 
then induced with tetracycline (1 μg ml
-1
). Following induction for 24 h, 15 nM 
MTX or 10 nM RTX were added. Starting drug concentration is normally 
approximately 2 × EC50 (Glover et al., 2015). EC50 data is usually generated from 
cells routinely passaged in HMI9-T and then diluted in TBM at the start of the assay 
(EC50 MTX = 12 nM and RTX 38 nM). However, in RNAi library screening, cells 
will be maintained in TBM for up to 48 h before drug being added. To have a better 
impression of EC50 in this scenario, parasites were cultured in TBM for 48 h prior to 
EC50 being measured (EC50 MTX = 5.7 nM and RTX 2.5 nM). Starting drug 
concentrations of 15 nM MTX and 10 nM RTX were derived to reflect these 
differences in EC50. Throughout the screen, cultures were split and supplemented 
with fresh drug as required. After 4 days, concentrations of MTX and RTX were 
increased to 30 nM to select a resistant population. 2 days after recovery of the 
resistant population (day 11) gDNA was extracted using the Qiagen DNeasy Blood 
& Tissue Kit, as per manufactures instructions.  
 
2.8.2 PCR amplification of fragments and mapping 
RNAi target fragments were amplified by PCR using LIB2f and LIB2r primers and 
protocol from Glover et al (Glover et al., 2015).  For low through-put identification 
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of fragments, PCR products were separated on an agarose gel and individual bands 
were excised using a QIA quick Gel Extraction Kit (Qiagen), as per manufactures 
instructions, and sequenced by the DNA sequencing service at the University of 
Dundee using the Lib2f and Lib2r primers (Table 2.2). Sequencing results were 
BLAST searched against the T. brucei 927 reference genome using v9.0, 
(http://tritrypdb.org) to identify hits. For high through-put identification of fragments 
the PCR products were PCR purified (QIAquick PCR Purification Kit, Qiagen), 
made to 10 μg DNA, and sent to BGI (Beijing Genomics Institute) to be fragmented 
and sequenced using an Illumina HiSeq platform. Using Bowtie 2 (Langmead and 
Salzberg, 2012) and the parameters very-sensitive-local–phred33, reads were 
mapped to the T. brucei 927 reference genome.  The generated alignment files were 
then manipulated with SAMtools (Li et al., 2009) and a custom script used to 
identify reads containing identifying barcodes (GCCTCGCGA). Using the Artemis 
genome browser (Carver et al., 2012) total and barcode only reads were mapped to 
the T. brucei 927 reference genome. Dr Richard Wall assisted with computational 
alignment work. 
 
2.9 Generation of RNAi knockdown cell line. 
2.9.1 Polymerase Chain reaction (PCR) 
PCR was carried out using template T. brucei genomic DNA (100 ng), Platinum Taq 
polymerases (Invitrogen) as per manufacturer’s standard protocol, and primers 
designed using RNAit (Redmond et al., 2003) to generate a 536 kb PCR fragment, 
conferring specific knockdown to Tb927.8.3620, Tb927.8.3630 and Tb927.8.3650 
genes (FT1, 2 and 3 respectively).  The PCR product was confirmed by agarose-gel 
48 
 
electrophoresis and purified using the QIAquick PCR Purification Kit (Qiagen), 
eluting in 30 μl of elution buffer.  
 
2.9.2 pRPa
SLi
 vector and PCR insert preparation and ligation  
For cloning in a sense orientation both the pRPa
SLi
 vector (Alsford and Horn, 2008) 
and PCR product were digested with the sense fragment cloning restriction enzymes 
Acc65I (25 U, NEB) and BamH1 (25 U, NEB) for 90 min at 37 
o
C, then both PCR 
purified. Digested vector and digested PCR product were ligated with T4 DNA 
Ligase (400 U, NEB) for 120 min at room temperature with the following cocktail (1 
μl of insert, 7 μl vector, 1 μl T4 DNA Ligase, 1 μl T4 DNA Ligase Reaction Buffer).  
 
2.9.3 Transformation of competent cells 
The total ligation reaction (10 μl) was added into 25 μl of One-Shot TOP-10 cells 
(Invitrogen) and incubated on ice for 30 min. Cells were then subjected to heat shock 
for 45 s at 42 
o
C in a water bath, followed by a further incubation on ice for 2 min. 
250 μl of SOC media (Invitrogen) was added and the resulting culture was incubated 
at 37 
o
C for 1 h with agitation at 200 rpm. Cells were plated out on Luria Bertani 
(LB) agar plates supplemented with ampicillin (50 g ml
-1
) and incubated at 37 
o
C 
overnight, resultant colonies were picked and grown overnight at 37 
o
C with 
agitation  at 200 rpm in 10 ml of LB media with ampicillin. Cells were pelleted by 
centrifugation (3000g, 10 min at 4 
o
C) and purified using the Qiagen Miniprep kit as 
per manufacturer’s instructions.  
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2.9.4 Confirming the organisation of stem loop cassette  
DNA prepared from individual colonies was digested with the restriction enzymes 
Acc65I and Bam H1 and analysed by agarose-gel electrophoresis to determine 
whether the integration of this insert into the pRPa
SLi
 vector had occurred.  Positive 
colonies were sequenced, using the respective primers (Table 2.2), by the DNA 
sequencing service at the University of Dundee. 
Steps 2.9.2 and 2.9.4 were repeated with the anti-sense cloning restriction 
enzymes XbaI (NEB) and Bsp120I (NEB) for full construction of the stem loop 
plasmid.  
 
2.9.5 Transfection into BSF T. brucei  
The final plasmid was linearized with AscI (50 U, NEB) overnight at RT and EtOH 
precipitated and suspended in sterile water (1 μg ml
-1
). Twenty four hours prior to 
transfection 2T1 strains, in HMI9-T, were split and kept of puromycin selection to 
reduce selection of puromycin resistant clones. Parasites, at  2 x 10
7
 cells, were 
electroporated using programme X-001 of the Nucleofector II electroporator 
(Amaxa, Cologne, Germany) (Burkard et al., 2007) following the addition of 5 μg of 
linearized DNA suspended in 100 μl cytomix (van den Hoff et al., 1992). 
Subsequent to electroporation, cells were transferred into a flask of 25 ml HMI9-T 
media and after 6 h transformants were cloned by limiting dilution and maintained 
under phleomycin (1 μg ml
-1
) and hygromycin (2.5 μg ml
-1
) selection. Puromycin 
sensitivity (1 μg ml
-1
) was tested for full integration of the construct (double 
homologous recombination) and RNAi was induced with 1 μg ml
-1 
tetracycline (tet).   
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2.10 MTX-resistant cell lines 
2.10.1 Generation of MTX-resistant cell lines  
These cell lines were kindly generated by Dr Natasha Sienkiewicz and described as 
follows. MTX resistant T. brucei cell lines were generated using S427 cells 
continuously grown in TBM for 4 weeks prior to resistance generation. Lines were 
generated in two independent flasks. Starting at a sublethal concentration of 0.05 μM 
MTX, trypanosomes were sub-cultured in the presence of increasing concentrations 
of drug. After 72 days when cells were able to survive and grow at 800 nM, cells 
were cloned by limiting dilution in the absence of drug. EC50 determinations to 
confirm resistance was carried out by myself and the clone from each independent 
cell lines that displayed the highest rate of resistance was selected for further studies 
(named MTX R1 and MTX R2). Cell lines were maintained in TBM without MTX. 
EC50 were carried out four months later to determine whether resistance had been 
maintained in the absence of MTX.  
 
2.10.2 Sequencing of DNA 
To attain full and unique coverage of Tb927.8.3620, Tb927.8.3630 and Tb927. 
8.3650 (FT1-3) primers were designed (Table 2.2). PCR was carried out using 
Platinum Taq polymerases (Invitrogen) as per manufacturer’s standard protocol. The 
template concentrations ranged from 200-2 ng of gDNA from the parental cell line 
(WT), MTX R1 and MTX R2, and PCR conditions optimised for each target of 
interest. PCR products were PCR purified (Qiagen Kit) and sequenced in-house 
(Dundee Sequencing Unit) and CLC Main Workbench 6 used for analysis.  
Sequences were aligned using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/) (Li 
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et al., 2015). Topological models of FT1-3 were visualised using the web-based 
Protter software (http://wlab.ethz.ch/protter/start/) (Omasits et al., 2014).  
 
2.10.3 Transport Studies in MTX-resistant cell lines 
Uptake of [
3
H]-folic acid (0.04 μM) and of [
3
H]-MTX (0.07 μM) was determined as 
2.3.2 but at a set concentration of unlabelled substrate (5 μM folate and 20 μM MTX 
respectively) instead of at varying concentrations. One transport experiment was 
undertaken each for folic acid and MTX.  Linear rate of uptake was determined in 
triplicate and the weighted mean of the experimental triplicate was calculated.  
Weighted mean was used, where each value is “weighted” according to the 
probability of it being correct. This method takes into account the uncertainty in any 
given experimental calculation and does not introduce bias (Young, 1962). p values 
were calculated using a Student’s unpaired t-test.   
 
2.11 Proteomic Profiling 
2.11.1 Cell labelling 
SILAC-labelling was carried out in prepared SILAC media (section 2.2.4). WT, 
MTX R1 and MTX R2 cells were harvested at log-phase and washed twice in PBS to 
remove exogenous L-Arginine and L-Lysine from the TBM. Cells were resuspended 
in PBS and seeded at a density of 3 × 10
4
 ml
−1
 in the SILAC media. L-Arginine and 
L-Lysine (light, medium and heavy labels) amino acids were added at a 
concentration of 120 nM and 240 nM respectively (30% of the original HMI11 
concentration) to the prepared SILAC media. WT cells were labelled with light L-
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Arginine and L-Lysine (HMI11-R0K0), MTX R1 with medium L-Arginine U - 
13
C6 
and L-Lysine 4,4,5,5 - 
2
H4 (HMI11-R6K4) and MTX R2 with heavy L-Arginine U - 
13
C10  and L-Lysine 4,4,5,5 - 
2
H6  (HMI11-R10K8).  
Following 5 days passage (cells split on d 2) and growth to approx. 16-18 cell 
divisions,  cells were  harvested at  ~ 1-2×10 
6
 cells ml
−1
  by centrifugation (800g, 10 
min, RT). Cells were washed twice in ice-cold PBS and finally resuspended in PBS 
containing 1X Complete Mini Protease Inhibitor Cocktail (Roche). WT cells 
(HMI11-R0K0) were equally mixed (1:1) with either MTX R1 (HMI11-R6K4) or 
MTX R2 (HMI11-R10K8) to a total concentration of 1.4 x 10
8
 cells. Cells were 
suspended in 140 μl of Laemmli buffer containing 1 mM dithiothreitol (BioRad). 
Samples were boiled for 10 min and stored at -80
o
C until further processing. In 
addition, the remaining unmixed MTX R1 cells (HMI11-R6K4) and MTX R2 cells 
(HMI11-R10K8) were harvested as described previously to be used as controls 
separated for label incorporation.  
 
2.11.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). 
Aliquots of WT (R0K0) v Res 1 (R6K4) and WT (R0K0) v Res 2 (R10K8) were made 
up to 2.0 x 10
7 
cells and medium and heavy isotope controls were aliquoted to 2.0 x 
10
6 
cells. Proteins  were separated on  a NuPAGE bis-tris 4–12% gradient 
polyacrylamide gel (Invitrogen) at 200 V with NuPAGE MES SDS running buffer 
(0/1% SDS, 1mM EDTA, 50mM MES, 50nM Tris Base,  pH 7.3) for 20 min.  The 
gel was washed in H20 three times (10 min per wash), with agitation, before staining 
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with Instant-Blue (Expedeon) at RT for 1-2 h. The stain was removed and a further 
three 10 min H20 washes were undertaken to de-stain the gel. 
 
2.11.3 Mass spectrometry 
All in-gel digestion and mass spectrometry was carried by the FingerPrints 
proteomics service at the University of Dundee 
(http://proteomics.lifesci.dundee.ac.uk). The protocol was provided by Douglas 
Lamont and the key steps from this are described. Reduction and alkalisation of 
cysteine residues was performed by adding dithiothreitol then 2-iodoacetamide 
respectively to the gel preparation. The protein was trypsinized, lyophilised and 
resuspended in 5% formic acid. Samples were fractionised by C18 reverse phase into 
6 fractions prior to LC-MS/MS analysis.   Analysis of peptides was performed on an 
Ultimate 3000 RSLCnano system (Thermo Scientific) coupled to a LTQ OrbiTrap 
Velos Pro (Thermo Scientific). Samples were loaded in 0.1% formic acid (buffer A) 
and separated using a binary gradient consisting of buffer A and buffer B (80% 
acetonitrile, 0.08% formic acid).  Peptides were initially trapped on an Acclaim 
PepMap 100 (C18, 100 μM x 2 cm) and then separated on an Easy-Spray PepMap 
RSLC C18 column (75 μM x 50 cm) (Thermo Scientific). Samples were transferred 
to ms via an Easy-Spray source with temperature set at 50
o
C and a source voltage of 
1.9kV.    
 
2.11.4 Data Analysis 
Mass spectra was analysed by the FingerPrints proteomics service using MaxQuant 
version 1.5.2.8 which incorporates the Andromeda search engine (Cox and Mann, 
2008; Cox et al., 2011). Proteins were identified by searching the T. brucei 927 
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annotated protein from TriTrypDB (v9.0, http://tritrypdb.org). Search parameters 
specified a MS tolerance of  as 4.5 ppm with the MS/MS tolerance set at 0.6 Da. 
SILAC ratios of H/L based on R0K0 and either R6K4 or R10K8 were calculated then 
normalised to adjust for loading difference based on identification of peptides using 
1% False Discovery Rate. SILAC ratios were calculated using uniquely mapped 
peptides that were a minimum of 7 amino acids in length. Data was visualized by 
myself, using Perseus 1.3.0.4 (http://perseus-framework.org). Differential expression 
was determined using a significance B test (Cox and Mann, 2008).  
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Chapter 3                 
Dissecting the mechanism of action 
and transport of antifolate drugs in 
Trypanosoma brucei 
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Fig 3.1 Cumulative growth of BSF T. brucei in different media.  
(A) Cultured in RMPI-BM and HMI9-T. Open circle, HMI9-T; closed circles, 
RMPI-BM plus thymidine; open squares, RMPI-BM. 
(B) Cultured in TBM. Open circle, TBM plus thymidine and folate: closed circle, 
TBM plus thymidine; open square, TBM plus folate; closed square, TBM only. 
Media was supplemented with 160 µM thymidine and 9 µM folate, as required.  
Cumulative growth over 14 days. Doubling times were determined by linear 
regression and analysed using GraFit. 
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3.1 Growth of BSF T. brucei in different media 
In 1989, Hirumi & Hirumi published the HMI9 medium, based on IMDM, where 
continuous in vitro culture could be maintained by the inclusion of reducing and 
chelating agents (2-mercaptoethanol and bathocuproine sulfonate) (Hirumi and 
Hirumi, 1989). Today, HMI9 is now most widely utilised for BSF T. brucei cell 
culture, with variants such as HMI9-T (thioglycerol instead of 2-mercaptoethanol as 
a reducing agent) and HMI911 (lacks Serum Plus
TM
) adopted as well (Creek et al., 
2013; Greig et al., 2009). Indeed in our research group and in the DDU HMI9-T 
medium is used for standard in vitro culture. However, HMI9-T medium contains 
high concentrations of folate, as folic acid (7.9 μM from IMDM), and thymidine 
(160 μM added to IMDM) (Sienkiewicz et al., 2008). Additionally folate 
concentrations are ~ 9 μM when including the contributions of Serum Plus
TM
 (0.62 
μM when supplied by SAFC Biosciences (Sienkiewicz et al., 2008)) and FCS (~3 
nM when supplied by GE Healthcare (personal communication)). In order to 
characterise the properties of drugs acting on folate metabolism, an objective of this 
thesis, folate and thymidine depleted medium was made and cumulative growth 
analysed.  
 
BSF T. brucei S427 cells failed to grow when cultured in RPMI-BM (made 
as per section 2.2.3) and died after 72 h (Figure 3.1 A). However, cells grew in 
RPMI-BM supplemented with thymidine (160 µM), demonstrating that thymidine 
serves as a nutritional rescue in these cells.  Cell growth in a media deficient in both 
thymidine and folate was required for inhibitor studies and as a consequence TBM 
was prepared, as per section 2.2.3. Cells grew in TBM, indeed cells grew to a similar 
rate regardless of supplementation with thymidine and/or folate (Figure 3.1 B). Cells 
grew slightly slower when cultured in TBM (doubling time 8.2 h) and RPMI-BM 
Table 3.1. Effect of folate and thymidine on sensitivity of T. brucei to DHFR-TS 
inhibitors in vitro.  Cells were cultured in TBM with the addition of thymidine (160 
µM) and/or folate (9µM). Results are the weighted means ± standard error of 3 
independent experiments  
Inhibitor No addition + Thymidine + Folate + Thymidine  
 + Folate 
EC50 µM Hill 
Slope  
EC50 µM Hill 
Slope  
EC50 µM Hill 
Slope  
EC50 µM Hill 
Slope  
         
Methotrexate          
(MTX) 
0.012 ± 
0.001 
4.8 0.12 ± 
0.03 
1.2 1.31 ± 
0.13 
1.3 8.16 ± 
2.78 
1.4 
Raltitrexed                                       
(RTX) 
0.038 ±
0.001 
4.7 > 250 - 64.8 ± 4.3 4.8 > 250 - 
Pemetrexed          
(PMX) 
0.020 ± 
0.001 
5.2 > 250 - 12.9 ± 1.1 3.2 >250 - 
Trimetrexate                        
(TMX) 
0.32 ±
0.02 
5.2 2.82 ± 
0.36 
1.4 1.23 ± 
0.06 
4.8 4.09 ± 
0.35 
1.9 
Pyrimethamine           
(PYR) 
2.26 ± 
0.32 
0.9 2.01 ± 
0.34 
0.8 6.32 ± 
0.71 
1.1 6.87 ± 
0.33 
1.0 
Trimethoprim                                    
(TMP) 
48.8 ± 3.7 1.4 59.8 ± 8.6 0.8 170 ± 28 0.7 145 ± 22 0.6 
Nolatrexed                         
(NTX) 
33.8 ± 3.7 2.9 32.7 ± 4.7 1.8 21.8 ± 2.0 2.0 39.6 ± 
7.2 
1.8 
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plus thymidine (doubling time 8.5 h) compared to when cultured in standard HMI9-
T medium (doubling time 7.3 h). TBM was carried forward for further in vitro 
studies in this thesis.  
 
3.2 In vitro effects of known DHFR and TS inhibitors on T. brucei 
To assess the specificity of a range of known DHFR and TS inhibitors, EC50 values 
for growth inhibition against T. brucei were compared in TBM where 
supplementation of folate could potentially reduce drug potency by competing with a 
drug for its target and thymidine could serve as a by-pass mechanism for inhibition 
of DHFR or TS (Table 3.1 and structures shown in Figure 1.4).  
Antifolates had highest potency against BSF T. brucei when tested in a 
medium depleted in folate and thymidine (TBM), apart from NTX where there was 
no real change detected. In TBM, MTX, RTX, and PMX showed nanomolar 
potencies and have high Hill slope (s) values, ~5, indicative of an ‘all or nothing’ 
type of concentration effect.  TMX also possessed high nanomolar potency in TBM 
with a similar Hill slope. With the exception of NTX, supplementation with folate 
and thymidine to TBM reduced the parasites’ susceptibility to the antifolate drugs. 
For MTX, PYR and TMP the addition of folate alone had a more substantial effect in 
reducing susceptibility than addition of thymidine alone. For MTX, supplementing 
with folate or thymidine substantially decreased the Hill slope to a similar extent. 
MTX is known to inhibit both DHFR-TS and PTR1 in T. brucei (Shanks et al., 2010; 
Spinks et al., 2011; Gibson et al., 2016). The monoglutamate form of MTX has been 
shown to have picomolar Ki values against TbDHFR enzyme (Ki 95 pM) (Gibson et 
al., 2016), micromolar Ki values against TbTS (463 μM) (Gibson et al., 2016) 
(polyglutamylation of MTX likely increasing TS affinity) and nanomolar values 
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Fig 3.2 Cell cycle analyses of MTX and RTX treated cells. 
(A) and (B) Cells cultured in TBM plus 1 µM thymidine.  (A) Cell count of 
untreated cell compared to 20 hrs treatment with MTX or RTX. (B) The histogram 
from the FACs analysis is presented as; light purple, untreated cells; blue, 50 µM 
MTX; green, 100 µM MTX; red, 50 µM RTX; black, 100 µM RTX.  The Y-axis on 
the overlay histogram is "% of Max". 
 (C) and (D) Cells cultures in TBM plus either 1 µM thymidine or excess 160 µM 
thymidine. (C) Cell count of untreated cells compared to 20 hrs treatment with MTX 
or RTX in 1 µM or excess 160 µM thymidine.  The histogram from the FACs 
analysis is presented as; light purple, untreated cells; dark purple; untreated cells plus 
excess thymidine; blue, 50 µM MTX; green, 50 µM MTX plus excess thymidine; 
red, 50 µM RTX; black, 50 µM RTX plus excess thymidine.  The Y-axis on the 
overlay histogram is "% of Max". 
Fig 3.2 Cell cycle analyses of TX and RTX treated cells. 
(A) and (B) Cells cultured in TB  plus 1 µ  thy idine.  (A) Cell count of 
untreated cell co pared to 20 hrs treat ent with TX or RTX. (B) The histogra  
fro  the FACs analysis is presented as; light purple, untreated cells; blue, 50 µ  
TX; green, 100 µ  TX; red, 50 µ  RTX; black, 100 µ  RTX.  The Y-axis on 
the overlay histogra  is "  of ax". The  x-axis is  DNA  content  measured  using 
 (C) and (D) Cells cultures in TBM plus either 1 µM thymidine or excess 160 µM 
thymidine. (C) Cell count of untreated cells compared to 20 hrs treatment with MTX 
or RTX in 1 µM or excess 160 µM thymi ine.  The histogram from th  FAC  
analy is is presented as; light purple, untreated cells; dark pur le; untreated cells plus
excess thymidine; blue, 50 µM MTX; green, 50 µM MTX plus excess thymidine;
red, 50 µM RTX; black, 50 µM RTX plus excess thymidine.  The Y-axis on the 
overlay histogram is "% of Max".     The  x-axis is  DNA  content  measured  using 
 Propidium Iodine (PI) staining and pulse area (A).
 Propidium Iodine (PI) staining and pulse area (A).
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against TbPTR1 (Ki app 11.1 nM) (Spinks et al., 2011). Indeed in vitro low 
concentrations of MTX may inhibit DHFR and higher concentrations PTR1. A steep 
Hill slope is characteristic of DHFR (or TS) inhibition (unpublished from 
Sienkiewicz et al., 2008) and a shallow Hill slope of PTR1 inhibition (Spinks et al., 
2011). Therefore abolishing the effect of thymidine and/or folate starvation would 
reveal the second mode of action, lowering the Hill slope. Thymidine addition did 
lower the Hill slope of TMX which is consistent with the above hypothesis. For RTX 
and PMX growth inhibition was completely abolished with thymidine 
supplementation and folate addition resulted in a substantial reduction in 
susceptibility while the Hill slope remained high, indicative of inhibition primarily 
through TS. For TMX, supplementation with either folate or with thymidine had a 
comparable effect on reducing drug potency and with supplementation of thymidine 
alone the Hill slope was reduced.  Melarsoprol was used as a control and there was 
no change in EC50 (2 nM) and Hill slope value (~3) across all media types (results 
not shown). MTX (targeting DHFR) and RTX (targeting TS) were taken forward as 
lead compounds from these cell-based potency tests.  
 
3.3 Cell Cycle Analysis 
With results of in vitro potency suggesting ‘thymineless-death’ to be a mechanism of 
MTX toxicity (susceptibility to MTX reduced with thymidine addition) and more-so 
RTX toxicity (RTX potency abolished with thymidine addition) (Table 3.1) cell 
cycle analysis was undertaken to confirm this mode of action. Untreated cells 
showed a normal distribution of G1, S (DNA synthesis) and G2/M phase; however 
with both MTX and RTX treatment this distribution was substantially disrupted 
(Figure 3.2 A).  With both 50 nM and 100 nM MTX treatment cells were arrested in 
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S phase and, with the higher MTX concentration, cells were distributed earlier in S 
phase. With 50 nM RTX treatment cells were distributed in S phase into G2/M 
phase, and with 100 nM RTX cells were distributed more prominently in S phase. 
With both MTX and RTX treatment parasites were unable to complete DNA 
synthesis from 2N (G1) to 4N (G2/M) with arrest within S phase. Moreover total cell 
density was reduced with 20 h drug treatment compared to the untreated control, 
MTX; 50 nM ~ 7 fold and 100 nM ~ 9 fold, RTX; 50 nM  and 100 nM both ~ 6 fold. 
(Figure 3.2 B).   
 
Figure 3.2 C demonstrates that excess thymidine supplementation can reverse 
the cell-cycle effects of both MTX and RTX.  Untreated cells showed a normal 
distribution of G1, S and G2/M phase with 1μM thymidine (physiological levels in 
mice (Clarke et al., 2000b) or excess 160 μM thymidine. In MTX and RTX treated 
parasites with excess thymidine supplementation, cell cycle distribution changes 
from that of arrest in S phase to that of a more normal cell cycle distribution with 
cells distributed in G1, S and G2/M phase. Returning to ‘normal’ distribution with 
thymidine supplementation is most prominently seen in RTX treated cells. Figure 3.2 
D illustrates that with the addition of excess thymidine the total cell density of MTX 
or RTX treated cells returned to that of the untreated controls (MTX = 2.6 × 10 
5
 
cells ml
-1
, MTX plus excess thymidine = 1.6 × 10 
6
 cells ml
-1
, RTX = 3.3 × 10 
5
 cells 
ml
-1
, RTX plus excess thymidine = 1.6 × 10 
6
 cells ml
-1
). 
 
3.4 Static-cidal assay for MTX and RTX  
In T. brucei drug discovery, compounds with trypanocidal activity are more 
desirable than compounds with trypanostatic activity and therefore an objective was 
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Fig 3.3 Static-cidal assay for drugs tested in TBM. 
(A) Detection limit of static-cidal assay. Solid line, linear regression of cell count 
against fluorescence signal; dashed line, mean value of blanks; dotted line, assay 
detection limit (2 x 104 cells ml−1). 
(B, C, D) Growth curves and MCC are shown for melarsoprol (B), MTX (C) and 
RTX (D). Growth is calculated as a percentage against the no drug control. Error 
bars represent standard deviation.  
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to determine the static/cidal nature of MTX and RTX, the lead compounds from in 
vitro potency testing.  
In a standard EC50 analysis over 72 h, the initial parasite cell density is below 
the limit of detection of the assay, which means one cannot discriminate between 
drugs with a cidal effect from drugs with a static effect. Indeed, the limit of detection 
of the resazurin assay was measured to be 2.0 x 10
4
 cell ml
-1
 (Figure 3.3 A) and the 
starting density of 2.5 × 10
3
 cells ml
−1  
(as described in section 2.4 ) used for standard 
EC50 assays is below this limit of detection.  To determine the cidal nature of MTX 
and RTX, parasite starting density was increased to 4.0 × 10
5 
cell ml
-1
 as previously 
described (De Rycker et al., 2012).  
A decline in parasite density after drug exposure (reduction in fluorescent 
signal) is indicative of trypanocidal activity.  Cidal activity is observed in the 
melarsoprol control after 48 h with a Minimum Cidal Concentration (MCC) of 12.2 
nM (Figure 3.3 B). For all concentrations of MTX and RTX the signal at 48 h was 
not equal to or less than the starting signal (t= zero), compared to melarsoprol where 
some concentrations at 48 h were less than t = zero (Figure 3.3 C + D).  Melarsoprol 
would therefore be described as rapidly cidal at 48 h whereas MTX and RTX were 
not fully cidal at 48 h, albeit due to the limitations of the assay MTX and RTX 
showed static activity.  
3.5 MTX and RTX potency in folate and thymidine ranges found in 
mouse plasma 
With MTX and RTX showing nanomolar potencies in TBM further in vitro potency 
studies were carried out in view of potential future in vivo testing.  Previous studies 
have demonstrated that plasma folate levels in mice can vary from ~71 nM to ~350 
Table 3.2 Modulation of folate and thymidine levels to mimic physiological 
ranges found in mouse plasma: Effect on MTX and RTX treatment in vitro. 
Results are the weighted means ± standard error of triplicate readings. MTX, 
methotrexate; RTX, raltitrexed. 
 
 
 
 
 
Drug + Folate 
(nM) 
+ Thymidine 
(nM) 
EC50 
(nM) 
Hill slope 
 
 
MTX 
 
~30 
 
1,000 
 
16.1 ± 0.6 
 
5.2 
 
MTX 
 
~30 
 
- 
 
17.7 ± 0.7 
 
3.9 
 
MTX 
 
~80 
 
1,000 
 
29.2 ± 1.5 
 
5.6 
 
MTX 
 
~80 
 
- 
 
30.5 ± 1.3 
 
5.7 
 
MTX 
 
~300 
 
1,000 
 
118 ± 10 
 
8.3 
 
MTX 
 
~300 
 
- 
 
82.3 ± 5.0 
 
4.7 
     
 
RTX 
 
~30 
 
1,000 
 
122 ± 6 
 
3.8 
 
RTX 
 
~30 
 
- 
 
175 ± 8  
 
4.4 
 
RTX 
 
~80 
 
1,000 
 
315 ± 15 
 
5.2 
 
RTX 
 
~80 
 
- 
 
421 ± 23 
 
4.5 
 
RTX 
 
~300 
 
1,000 
 
1830 ± 104 
 
4.6 
 
RTX 
 
~300 
 
- 
 
1760 ± 124 
 
6.7 
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nM dependent on whether mice are fed a folate-depleted or folate-replete diet (Wang 
et al., 2010) with thymidine levels ~ 1 μM (Clarke et al., 2000b).  MTX and RTX 
potency was tested in trypanosomes with the addition of 1 µM thymidine and either 
30, 80 or 300 nM folate comparable to the ranges detected in mice, with 30 nM 
folate being the lower limit of detection.   
Modulation of folate concentration, rather than thymidine, affected the 
potency of both MTX and RTX as depicted in Table 3.2.  Increasing folate levels 
only (without thymidine addition) from 30 to 300 nM shifts MTX potency 5 fold, 
and RTX potency 14 fold. The addition of 1 µM thymidine does not substantially 
change the EC50 values of both MTX and RTX at the respective folate 
concentrations. This is compared to results in section 3.1 where the addition of 
excess thymidine (160 μM) to TBM reduced MTX susceptibility by 10 fold and 
abolished the effect of RTX.  Hill slopes are not substantially changed with the 
addition of mice physiological levels of thymidine or folate, with MTX and RTX 
retaining their ‘all or nothing’ concentration effect.  
 
3.6 “Antifolate set” drug screen in various media 
Known DHFR-TS inhibitors (MTX, RTX and PEM) displayed nanomolar potencies 
against T. brucei when tested in TBM, a media which is deficient in both folate and 
thymidine (result in section 3.2). In T. brucei drug screening programmes, standard 
HMI9-T media is routinely used (Brand et al., 2012; Oduor et al., 2011; Pena et al., 
2015); however, this media would not accurately assess the potency of drugs acting 
on folate metabolism due to the excessive amount of folate and thymidine present in 
the media.  An objective of this thesis was to assess whether TBM would be a good 
media candidate for in vitro T. brucei screening of chemicals with potential 
Figure 3.4 Chemical structures of “antifolate set” 
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Table 3.3 Screen of “antifolate set” across media types.    
Cells were cultured in TBM with the addition of thymidine (160 µM) or folate (9 µM), or in HMI9T. PTR1 and DHFR enzyme activity 
measured by biologists of the DDU using a cystochrome c-coupled assay as per previously described (Shanks et al., 2010).  
a
 = Ki as of 
(Vanichtanankul et al., 2011) 
b 
= Ki as of (Spinks et al., 2011). NT = not tested. Results of in vivo potency testing are the weighted means ± 
standard error of 3 (n = 3) or 2 (n =2) independent experiments. 
Compound Enzyme Activity 
EC50 (nM) 
 
TBM 
(n=3) 
TBM + Thymidine 
(n=2) 
TBM + Folate 
(n=2) 
HMI9T 
(n=2) 
 PTR1 DHFR EC50 (nM) Hill Slope (s) EC50 (nM) Hill Slope (s) EC50 (nM) Hill Slope (s) EC50 (nM) Hill Slope (s) 
1 - - 18500 + 4700 1.7 27100 + 2600 2.7 45300 + 22300 1.6 23600 + 5020 1.9 
2 - - 31800 + 8440 1.0 22200 + 1780 2.4 >25000 - >25000 - 
3 - 
a
1.1 4210 + 379 8.0 5590 + 2630 23.6 4150 + 601 7.5 6220 + 501 3.4 
4 
b
98 
b
>50 3360 +  209 3.5 3290 +  251 3.3 3170 + 284 4.0 6260 + 255 6.1 
5 
b
800 
b
>50 6720 + 382 6.4 6570 + 550 5.6 6830 + 1030 9.9 7350 + 180 3.0 
6 4 60 6.67 + 1.71 0.47 7.52 + 1.89 0.44 28.1 + 5.08 0.61 47.5 + 6.05 0.92 
7 6 NT 130 + 15.0 1.2 141 + 18.5 1.3 167 + 13.2 3.0 187 + 17.7 1.7 
8 2 40 58.6 + 12.8 0.45 134 + 32.4 0.60 210 + 61.1 0.36 177 + 34.8 0.61 
9 3 3500 203 + 13.7 1.4 132 + 16.7 1.1 231 + 21.5 1.3 323 + 21.4 3.3 
10 60 600 131 +  13.7 0.74 59.6 + 9.97 0.55 62.1 +  8.62 0.51 149 + 9.05 0.79 
11 20 40 91.2 + 5.75 1.1 71.1 + 9.23 0.85 112 +  8.71 1.3 133 + 17.6 1.7 
12 5.3 250 240 + 33.8 0.60 392 + 119 0.68 240 + 78.4 0.43 625 + 56.4 0.89 
13 3.6 83 478 + 76.4 0.76 643 + 119 0.68 838 + 161 0.80 666 + 60.8 0.74 
14 11 1020 569 +  90.2 0.61 568+ 19.9 0.58 980 + 137 0.73 866 + 137 0.87 
15 11 1010 387 + 76.6 0.67 384 + 109 0.49 951 + 144 0.86 1080 + 177 0.76 
16 6.6 52 278 + 46.0 0.68 199 + 102 0.37 662 + 133 0.91 507 + 105 0.67 
17 7.4 0.8 13.8 + 0.80 3.0 104 + 45.9 0.98 1220 +  102 1.46 7070 + 987 0.87 
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antifolate properties. In addition, it would be beneficial to elucidate whether testing 
drug potency in TBM with thymidine or folate supplementation could give an insight 
into the mode of action of inhibitors, specifically if they are targeting DHFR-TS.  
A compound set was established containing inhibitors known to possess 
potency against the T. brucei DHFR enzyme: MTX (compound 17) with DHFR 
activity in T. brucei (Gibson et al., 2016) and WR99210 (compound 3) with 
established DHFR enzyme activity in Plasmodium falciparum  (Winstanley et al., 
1995) and evidence to suggest DHFR activity in T. brucei (Vanichtanankul et al., 
2011). The set also included compounds known to inhibit DHFR to a lesser extent 
than their primary enzyme target. It was known from an in-house DDU drug 
discovery programme  against T. brucei PTR1 that there were a number of 
compounds that, as well as primarily targeting the PTR1 enzyme, also inhibited 
DHFR to varying degrees, as an off-target effect (Shanks et al., 2010; Spinks et al., 
2011). Compounds (4 to 16) were selected from this programme for this cell based 
drug screen and these compounds covered a variety of different chemical series 
(Figure 3.4). Compound selection was limited by availability, however compounds 
from four different chemical classes were included; 2-aminobenzimidazoles, 6 and 5 
substituted 2,4- diaminoquinazolines, and tetrahydropyridopyrimidines. This set also 
included 2 compounds (compounds 1 and 2) containing a pABA-Glu moiety, mainly 
to assess the pABA-Glu moiety in antifolate drug discovery. This compound set 
(total of seventeen compounds) was known as the “antifolate set”.  
The “antifolate set” were tested in TBM, TBM supplemented with thymidine 
and folate respectively, and standard HMI9-T media (Table 3.3). Compounds 1 and 
2 (pABA-Glu containing) displayed weak potency (high micromolar) across all 
media types (Table 3.3). For the remaining compounds (3-17) there was a marked 
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increase in potency when tested in TBM compared to HMI9-T media. Compound 3 
(WR99210) and compounds 4 and 5 (2-aminobenzimidazoles) displayed micromolar 
potencies across all media types but had a high Hill slope (> 3) suggesting inhibition 
of DHFR-TS (see section 3.2). WR99210 had previously been shown to have an in 
vitro EC50 of 0.09 + 0.02 μM in T. brucei (Vanichtanankul et al., 2011), however 
this could not be replicated in this drug screen where EC50 were ~ 4 - 6 μM across 
media types.  
 The addition of folate had a greater effect in increasing EC50 than the 
addition of thymidine for compounds 6-9. In particular compounds 6 and 9 have low 
nanomolar enzyme activity against both PTR1 and DHFR and the addition of folate 
reduced whole cell susceptibility by ~ 4 fold for these compounds.  There was no 
substantial change in EC50 in compounds 10 and 11 with thymidine or folate 
supplementation. Compound 11 has nanomolar enzyme activity against both PTR1 
and DHFR. In the tetrahydropyridopyrimidines group (compounds 12-16) 
supplementation with folate and thymidine did not change whole cell EC50 to any 
great extent.  Of note a shallow Hill slope (<1) is a characteristic of PTR1 inhibition 
(compounds 4-16) and this is evident in whole cell potencies with the exception of 
compounds 7, 9 and 11 were Hill slopes are >1, this could suggest other off-target 
effects for these three compounds (e.g. DHFR-TS).   The MTX control behaved as 
expectedly with folate supplementation having a more substantial effect in increasing 
EC50 than thymidine supplementation (88 fold and 8 fold respectively) which 
highlights selectivity of DHFR inhibition over TS inhibition. 
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Figure 3.5 Folate transport  
(A) Linearity of folate uptake at 23 oC.  Time point at 30 s for 10 µM and 8 µM not 
plotted due to loss of pellet during experiment. (B) Intercepts (from panel (A) at time 
zero) as a function of folate concentration (C) Effect of temperature on folate uptake. 
Uptake of 10 µM folate at 23 oC (open circles) or 4 oC (closed circles). Time points 
were done in triplicate and the mean and SEM are shown. (D) Uptake of folate fitted 
by Michaelis-Menten equation using rates obtained from the slopes of data in panel 
(A)  
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Figure 3.6 MTX transport  
(A) Linearity of MTX uptake at 23 oC.   Time point at 30 s for 20 µM not plotted due 
to loss of pellet during experiment. (B) Intercepts (from panel (A) at time zero) as a 
function of MTX concentration C. Effect of temperature on MTX uptake. Uptake of 
20 µM MTX at 23 oC (open circles) or 4 oC (closed circles). Time points were done 
in triplicate and the mean and SEM are shown. (D) Uptake of MTX fitted by 
Michaelis-Menten equation using rates obtained from the slopes of data in panel (A)  
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3.7 Transport Studies 
A core objective to this thesis was to determine how folate and antifolate drugs are 
transported into cells. This will expand the current knowledge around the mode of 
action of these drugs. 
 
3.7.1 Folate Uptake and Km app analysis 
To address the transport kinetics of folate (folic acid) uptake in BSF T. brucei the 
linearity of folate uptake over time was first determined. The linearity of the assay 
was based on  previous studies which  demonstrated that folate uptake was rapid and 
linear over 2-3 minutes in Leishmania parasites (Ellenberger and Beverley, 1987). 
Indeed in T. brucei the rate of folate uptake was found to be linear over 150 seconds 
up to 10 µM at 23 
o
C (Figure 3.5 A). A plot of the y-axis intercepts (time zero) of the 
varying concentrations of folate is linear (Figure 3.5 B), which demonstrates non-
specific binding of folate.  The rate of uptake of folate is temperature-dependent with 
a 10-fold higher rate at 23 
o
C (0.24 + 0.03 pmol s
-1 
[10
8
 cells]
-1
) compared to 4 
o
C 
(0.02 + 0.01 pmol s
-1 
[10
8
 cells]
-1
) (Figure 3.5 C).  It was found that the uptake of 
folate in BSF T. brucei  obeys simple Michaelis-Menten kinetics with a Km app of 
2.07 + 0.63 µM and Vmax of 0.19 + 0.02 pmol s
-1 
[10
8
 cells]
-1
 (Figure 3.5 D). 
3.7.2 MTX Uptake and Km app analysis 
In the same way as folate uptake was established, MTX uptake was found to be 
linear and directly proportional over 150 s up to 20 µM (Figure 3.6 A) at 23 
o
C with 
evidence of non-specific binding (Figure 3.6 B). The rate of uptake of 20 µM MTX 
at 23 
o
C was determined to be 0.40 + 0.06 pmol s
-1 
[10
8
 cells]
-1
 compared to 0.03 + 
0.01 pmol s
-1 
[10
8
 cells]
-1 
at 4 
o
C, indicative of temperature-dependent uptake (Figure 
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Figure 3.7 Effect of anti-foles and folate metabolites on uptake of folate or 
MTX. 
Uptake of folate (A) and MTX (B) is measured in the presence of 100 µM of each 
inhibitor. Black bar, DMSO control; grey bars, ‘non-folate-like’ structures; white 
bars, ‘folate-like’ structures.  Assay mixture corrected for additional DMSO (0.4 %.) 
and modified to contain approx. [S] ≅ Km  app (folate at 2  µM   and  MTX at 13 µM). 
 
Uptake  was  determined  over  a  150s  incubation  peroid.
3.7.   antifolates  and     t  of folate or 
.
Table 3.4 Uptake of folate and MTX is measured in the presence of varying 
concentrations of inhibitor. The standard assay mixture is modified to contain 
approx. [S] = Km and corrected for additional DMSO (0.4 %.). IC50 is calculated 
using a two-parameter fit. ND, not determined. Results are IC50 value ± standard 
error.  
 
 
Substrate 
 
IC50 against 
folate (µM) 
 
Hill Slope 
 
IC50 against 
MTX (µM) 
 
Hill Slope 
     
Methotrexate 3.4 + 0.4 1.2 -  
Folic Acid -  1.9 + 0.4 1.0 
5 –Methyl 
THF 
6.3 + 1.0 0.9 8.0 + 0.8 0.9 
pABA-Glu 30.8 + 3.7 0.8 33.5 + 4.6 1.0 
Pemetrexed 3.2 + 0.3 0.8 ND  
Raltitrexed 1.8 + 0.4 0.8 ND  
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3.6 C). MTX uptake also obeys simple Michaelis-Menten kinetics (Figure 3.6 D) 
with a Km app of 16.5 + 3.0 µM and Vmax of 0.68 + 0.11 pmol s
-1 
[10
8
 cells]
-1
. 
 
3.7.3 Inhibitor Studies 
After establishing the kinetics parameters of folate and MTX uptake, uptake was 
measured in the presence of other folate derivatives (metabolites and antifolates) to 
establish if they had any effect on substrate uptake.  Folate uptake was found to be 
inhibited by the classical antifolates MTX, RTX and PTX and the folate metabolite 
5-methyl-THF (principal form found in human plasma) (Figure 3.7 A). Conversely, 
uptake of folate does not appear to be inhibited by the non-classical antifolates TMX, 
NTX, TMP, PYR nor biopterin.  pABA-Glu had a substantial effect in inhibiting 
folate uptake (~21% residual folate uptake).   
Furthermore, MTX uptake was found to be inhibited by classical antifolates 
(RTX, PMX) and folic acid, but not inhibited by non-classical antifolates (TMX, 
NTX, TMP, PYR) or biopterin (Figure 3.7 B).  pABA-Glu also had a substantial 
effect in inhibiting MTX uptake (~11% residual uptake). 
 
3.7.4 Potency of Inhibition 
‘Folate-like molecules’, at a set concentration (100 µM), where shown to inhibit 
folate and MTX uptake. The potency of inhibition was further characterised by 
measuring the compounds IC50 against substrate uptake. The IC50’s for MTX and 
folate against folate and MTX uptake were 3.4 µM and 1.9 µM respectively. RTX 
and PMX had comparative potencies to MTX in inhibiting folate uptake (Table 3.4). 
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Figure 3.8 Mode of inhibition of folate transport by MTX and vice versa 
(A) Ki determination of MTX with respect to folate. Folate concentrations were 
varied in the presence of fixed concentrations of MTX. MTX was added at 0 μM 
(open circles); 0.5 µM (closed circles) and 1 µM (open squares). (B) Folate was 
added at 0µM (open circles); 0.5 µM (closed circles) and 1 µM (open squares) and 
MTX was the variable concentration to determine Ki of folate with respect to MTX.  
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5-methyl-THF inhibited both FA and MTX uptake to the same extent but at a lower 
potency than the classical antifolates. pABA-Glu was the weakest inhibitor of both 
folate (30.8 µM) and MTX (33.5 µM) uptake. For all substrates Hill slopes were, 
within experimental error, 1. This is indicative of simple binding of one ligand to 
one transporter. Indeed IC50 curves appear to go down towards zero and therefore it 
is unlikely that other transporters are involved. 
 
3.7.5 Mode of Inhibition 
To determine the mode of inhibition of MTX to folate uptake the rate of uptake of 
folate was measured whilst varying folate concentrations in combination with a set 
range of MTX concentrations resulting in a double reciprocal plot, or Lineweaver –
Burk plot, of the data (Figure 3.8 A).  In a similar way, the mode of folate inhibition 
of MTX uptake was also determined (Figure 3.8 B). Plotting 1/v against 1/[S] gives 
an intercept of 1/Vmax on the y axis, 1/[S] = -1/Km app on the x axis and the slope 
factor is Km app/Vmax. Presenting the data in this way, the mode of inhibition was 
confirmed to be competitive. With changes in [I], competitive inhibition affects Km 
app (x intercept and slope factor) only and not Vmax (y intercept) since infinitely high 
concentrations of [S] displace [I].   
In addition, an F-test in GraFit confirmed that data fitted best to competitive 
inhibition. Using the competitive-mode equation (Section 2.7.3) the inhibition 
constant (Ki) of MTX competing with folate uptake was calculated to be 0.48 µM. 
and folate competing with MTX uptake was 0.94 µM. If two substrates compete for 
the same target (folate transporter) then an IC50 can be determined using equations 6 
and 7 of section 2.7.3. By applying experimental derived values to these equations an 
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Figure 3.9 Folate uptake in low and high folate conditions. 
Folate transport was measured in ‘low folate’ conditions (TBM) at 20 µM (open 
circles) and 2 µM (open squares); and in ‘high folate’ conditions (TBM plus 9 µM 
folate) at 20 µM (closed circles) and 2 µM (closed squares). Data points are the 
mean of two biological replicates with error bars indicative of SEM. (A) Folate 
uptake over 10 mins. (B) Linearity of folate uptake over 150 s.  
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IC50 of MTX against folate uptake was found to be 2.2 µM and the reverse for folate 
against methotrexate uptake was 2.9 µM. These values are comparable to the actual 
EC50 values found, 3.4 µM for MTX against folate uptake and 1.9 µM for folate 
against MTX uptake (Table 3.4), giving good evidence of a competitive substrate 
model for folate and MTX transport. 
Ki (Kd) values cannot be calculated for RTX, PMX and pABA-Glu as Vmax 
for these competing substrates is required in order to do so (see section 2.7.3, 
equations 6 and 7). If these compounds were competitive inhibitors (and do not 
undergo transport) and not competitive substrates then Ki = 0.5IC50 as experiments 
were performed at [S] = Km. However, based on the structural similarity of these 
compounds to folate and MTX and the fact that they inhibit DHFR-TS (therefore get 
into the cell) it is likely that these compounds are competitive substrates in the same 
way that folate and MTX were found to be. 
 
3.7.6 Folate transport in high and low folate conditions 
To establish whether high extracellular folate conditions affects folate transport into 
cells, folate transport was measured at 2 µM (Km app), and 20 µM (saturating 
concentrations, indicative of Vmax) in TBM and TBM supplemented with excess 
folate (9 µM). Over 10 mins, folate transport at 2 µM and 20 µM does not appear to 
be affected by folate conditions (Figure 3.9 A).  Looking more closely at linear 
transport over 150 s, transport at 2 µM and 20 µM also does not appear to be 
affected, to any great extent, by low or high folate growth conditions (0.15 and 0.14 
for 2 µM compared to 0.34  and 0.30 for 20 µM respectively, measured in pmol s
-1 
[10
8
 cells]
-1
) (Figure 3.9 B).  
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Of note, this experiment also confirms steady state Michaelis-Menten 
kinetics for folate transport, as when [S] = Km app, then v = Vmax/2. Indeed the rate, 
measure at pmol s
-1 
[10
8
 cells]
-1
, at 2 µM (Km app) is half that of the rate at 20 µM 
(indicative of Vmax) for both high and low folate conditions respectively, 0.15 
compared to 0.34 and 0.14 compared to 0.30 (low and high folate respectively).  
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Chapter 4 
 
Dissecting the mechanism(s) of 
resistance of antifolate drugs in 
Trypanosoma brucei 
 
  
• PCR
• NGS RNAi targets
• Map to genome
Extract
genomic DNA
CCCTGCAGGAATTCGATATCAAGCTTGGCCTGTGAGGCCTCGCGA – RNAi insert – TCG
Induced RNAi 
library (10x 
genome)
RIT-seq
Drug
selection
A
B
Figure 4.1 RIT-seq schematic 
Figure 4.1 Adapted from Glover et al 2015. 
(A) T. brucei dsRNA expression and RNAi is induced by tetracycline (tet). 
Knockdown has the potential to confer a selective advantage under drug pressure. 
With drug exposure to a heterogeneous population (multi-coloured) gene 
knockdowns display a growth defect (red), whereas the surviving population does 
not (blue). (B) RIT-seq comprises amplification of RNAi target fragments. In red, 
signature barcode used to identify sequence; in blue, sequencing primer TbrR1SF1; 
underlined, RNAi cassette component of the TbrF1 primer. 
Day
0 1 2 3 4 5 6 7 8 9 10 11 12
C
um
ul
at
iv
e
 g
ro
w
th
, c
e
lls
 m
l-1
106
108
1010
1012
1014
1016
1018
R
N
A
i t
ar
ge
ts
R
al
tit
re
xe
d
kbp
Tb927.8.3620
Tb927.8.3630
Tb927.8.3650
Tb927.8.3620
Tb927.8.3630
Tb927.8.3650
R
N
A
i t
ar
ge
ts
M
et
ho
tr
ex
at
e
1.5
1.0
0.5
A
B
Figure 4.2 Selection of drug resistance by RNAi and low-throughput RIT-seq 
(A) Growth phenotype of RNAi library cells treated with MTX or RTX. Closed 
squares, untreated control; closed circles, MTX treated and open circles RTX treated. 
(B) Low throughput RIT-seq. PCR products representing RNAi target fragments, 
derived from the RNAi screen, were separated on an agarose gel. Highlighted FT 
family ID’s in both screens. 
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4.1 RIT-seq Analysis 
4.1.1 Selection of drug resistance by RNAi 
A T. brucei RNAi library screen was used to investigate the putative mechanism of 
resistaFigurence of two inhibitors of the bifunctional T. brucei DHFR-TS enzyme 
using MTX, which targets DHFR, and RTX which targets TS. Parasites were 
exposed to a sub-lethal dose of each drug to select a resistant phenotype. With 
tetracycline induction, each cell produces dsRNA from the integrated RNAi target 
fragment. Knockdown has the potential to facilitate parasite survival under drug 
treatment (Figure 4.1 A) and from the surviving population RIT-seq is used to 
generate a read-out (Figure 4.1 B).  Figure 4.2 A demonstrates the growth phenotype 
of RNAi library cells treated with MTX or RTX. After 4 days, concentrations of 
MTX and RTX were increased from 15 nM and 10 nM, respectively, to 30 nM for 
both drugs and resistant populations were isolated for RIT-seq analysis. 
 
4.1.2 Low-throughput RIT-seq  
Low-throughput RIT-seq identified DNA fragments that were subsequently 
sequenced in-house and mapped to the T. brucei 927 reference genome 
(http://tritrypdb.org).  PCR fragments seen in both the MTX and RTX screens are 
shown in Figure 4.2 B and the genes identified by sequencing are shown in Table S1 
and Table S2. In both screens two PCR fragments strongly mapped to putative folate 
transporter genes FT1-3: Tb927.8.3620, Tb927.8.3630 and Tb927.8.3650 (Figure 4.2 
B, Table S1 and S2). The putative folate transporter orphan gene Tb11.v5.0766 was 
also implicated.  For some PCR fragments, no or poor sequence data was generated 
through ‘mis-priming’ on gDNA in such T. brucei RNAi library screens 
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Figure 4.3 High-throughput RIT-seq 
(A, C) Hits from the MTX and RTX antifolate RNAi screens are displayed in 
genome-wide RIT-seq maps. Hits are loci identified by fragments that map with > 
1000 reads per kilobase per million (RPKM). ‘High confidence’ hits, indicated in 
green, are characterised by multiple RIT-seq fragments. Other ‘low confidence’ loci 
with mapped reads are highlighted in grey.  
(B, D) The Artemis screen-shots of ‘high confidence’ hits identified for MTX and 
RTX. Hits in green and flanking protein coding sequences indicated as black bars. 
Red peaks, forward reads with RNAi-construct barcodes; blue peaks, reverse reads 
with RNAi-construct barcodes; grey peaks, all other reads. 
Table 4.1: Extended hit list for MTX RIT-seq analysis 
(>1000 RPKM 'barcoded reads' and >200 RPKM 'all mapped reads' cut-offs)
RPKM Total reads RPKM Total reads
Tb927.8.3620 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 387390 310399 159467 1000562
Tb927.8.3650 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 190118 146668 71770 450315
Tb927.8.3630 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 106956 82928 83978 526914
Tb11.v5.0766 folate transporter, putative 85370 41033 91104 350379
Tb927.11.14360 mitochondrial carrier protein (MCP2) 16568 7047 15474 52150
Tb927.11.14350 mitochondrial carrier protein (MCP22) 5637 2323 2664 9163
Tb927.8.3640 JAB1/Mov34/MPN/PAD-1 ubiquitin protease, putative 5491 2571 3133 11459
Tb927.8.1040 protein phosphatase inhibitor, putative 2096 361 934 1343
Tb927.9.5960 succinate dehydrogenase, putative 1671 375 724 1356
Tb927.11.14370 hypothetical protein, conserved 1388 1694 438 4072
Tb927.8.5840 hypothetical protein, conserved 1182 278 431 846
Table 4.2: Extended hit list for RTX RIT-seq analysis 
(>1000 RPKM 'barcoded reads' and >200 RPKM 'all mapped reads' cut-offs)
RPKM Total reads RPKM Total reads
Tb927.8.3620 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 425569 352755 176660 1245838
Tb927.8.3650 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 139362 113541 58099 409726
Tb927.8.3630 folate transporter, expression site-associated gene 10 (ESAG10) protein, putative 125517 99759 91451 644928
Tb11.v5.0766 folate transporter, putative 78888 39418 87613 378723
Tb927.7.1600 C-1-tetrahydrofolate synthase, cytoplasmic, putative 57287 20709 21075 70202
Tb927.7.1610 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative 12920 11529 4807 34755
Tb927.11.14350 mitochondrial carrier protein (MCP22) 6967 2917 3117 12050
Tb927.11.14360 mitochondrial carrier protein (MCP2) 3962 1686 8384 31759
Tb927.11.12460 hypothetical protein, conserved 3598 4672 931 10650
Tb927.10.7520 folylpolyglutamate synthase, putative (FPGS) 1242 855 816 4556
Primary 'hit' >1 fragment per gene
Secondary 'hit' ≤ 1 fragment per gene
Adjacent to 'hit'
Gene ID Gene description Barcoded reads only All mapped reads
Adjacent to 'hit'
Barcoded reads only All mapped readsGene ID Gene description
Primary 'hit' >1 fragment per gene
Secondary 'hit' ≤ 1 fragment per gene
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(Tb927.10.1740 and Tb927.10.1750, personal communication David Horn). 
Moreover, a fragment mapping to Tb927.10.2430 (putative- receptor-type adenylate 
cyclase GRESAG 4) was identified but not validated by high-throughput RIT-seq 
(see below).   
 
4.1.3 High-throughput RIT-seq  
High-throughput RIT-seq, with sequencing generated by the Beijing Genomics 
Institute, confirmed and extended the preliminary analysis above. Genome coverage 
was adequate for both drug screens. For the MTX screen, 2.4 million paired reads 
were generated of which 70% mapped to the reference genome (Table 4.1) and for 
the RTX screen, 2.6 million paired read were generated of which 71% mapped to the 
reference genome (Table 4.2). Of note, further analysis of the MTX and RTX 
screens against a reference genome including the T. brucei 427 telomeric and 
metacyclic VSG expression site regions mapped 95% of the reads for both drugs. 
The vast majority of the other reads map to expression site associated genes 
(ESAG10) genes in the VSG expression sites, which share 90-94% gene identity to 
the chromosome 8 tandem folate transport genes FT1-3.  
Hits implicated from high-throughput RIT-seq are depicted in Figure 4.3.  
The putative folate transporters, FT1-3, and a redundant orphan folate transporter 
gene, Tb11.v5.0766, are the predominant ‘hits’ in both the MTX and RTX screens 
accounting for 91% and 89% of all mapped reads respectively (Fig 4.3 B and D 
Table 4.1, Table 4.2). Other ‘hits’ include a mitochondrial carrier protein (MCP2, 
Tb927.11.14360), found in both MTX and RTX screens (Fig 4.3 B and D) and  C-1-
THF synthase (Tb927.7.1600) specific to the RTX screen (Fig 1 D). Another 
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Figure 4.4 Evidence of RNAi knockdown of FT1-3 
(A) Cumulative growth of WT cells and FT1-3 RNAi line + or - tet induction. 
Doubling times were determined by linear regression and analysed using GraFit. 
Closed squares, WT 2T1 cells; closed circles, RNAi knockdown - tet; open circles, 
RNAi knockdown + tet.  
(B) qRT-PCR shows down regulation of FT RNA in RNAi line.  Data is mean + 
SEM of four experimental replicates.  p values shown. 
(C) Representative drug sensitivity (EC50) plots for MTX. Closed circles, day 3 
RNAi knockdown- tet; open circles, day 3 RNAi knockdown + tet; closed squares, 
day 6 RNAi knockdown - tet and open squares; day 6 RNAi knockdown + tet. 
 
Table 4.3 Potency shifts of DHFR-TS Inhibitors in FT RNAi knockdown. 
EC50 values (nM) of antifolates against un-induced and induced knockdown cells 
Results are weighted means ± associated error of 3 independent experiments. 
 
 
  
Drug 3 days  6 days 
 - Tet + Tet Fold 
Shift 
 - Tet + Tet Fold 
Shift 
 
Methotrexate 
 
 
14.5 + 
0.4 
 
444 + 17 
 
30.6 
  
8.73 +  0.39 
 
321 + 13 
 
36.8 
 
Raltitrexed 
 
11.2 + 
0.3 
 
368 + 14 
 
32.9 
  
5.83  +  0.20 
 
227 + 10 
 
38.9 
 
Pyrimethami
ne 
 
2,500 + 
100 
 
200 + 11 
 
0.08 
  
2,040 + 165 
 
142 + 10 
 
0.07 
 
Nolatrexed 
 
36,200 + 
1,900 
 
16,700 + 
1,000 
 
0.46 
  
39,900 + 2,500 
 
15,600 + 
900 
 
0.39 
 
Melarsoprol 
 
1.73 + 
0.09 
 
1.70 + 
0.08 
 
0.98 
  
1.26 + 0.60 
 
1.29 + 
0.59 
 
1.02 
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noteworthy ‘hit’ in the RTX screen, supported by only a single RIT-seq fragment 
was FPGS (Tb927.10.7520) (Fig 4.3 D, Table 4.2) implicated in folate 
polyglutamylation. It should be noted that no hits appeared in either MTX or RTX 
screens for the putative pteridine transporter genes (BT1-4), members of the FBT 
family, suggesting that they are not implicated in antifolate drug transport.  
 
4.2 RNAi knockdown of putative folate transporters (FT1-3) 
Findings from the RIT-seq analysis strongly implicated FT1-3 genes in antifolate 
drug resistance. To validate FT1-3, an RNAi knockdown transgenic mutant was 
generated and phenotypic studies were performed.  
 
4.2.1 Evidence of RNAi knockdown of FT1-3 
Figure 4.4 A demonstrates that with knock-down of FT1-3, by induction with 
tetracycline (tet), there was no substantial change in cell growth compared to both 
WT and un-induced cells (Figure 4.4 A). Doubling times were determined to be 6.2 
h, 6.1 h and 5.9 h for WT, un-induced and induced cells respectively. qRT-PCR was 
used to determine a quantitative measure of knockdown. RNA transcription analysis 
of RNAi mutant confirmed a down-regulation of mRNA levels to 32 % relative to 
un-induced cells after 3 days of tet induction (p = 0.02) and to 31 % relative to un-
induced cells after 6 days induction (p = 0.001) (Figure 4.4 B).  MTX potency was 
used to determine phenotypic changes associated with FT1-3 RNAi knockdown. 
There was a substantial reduction in MTX potency after induction for 3 days (31-
fold) and 6 days (37-fold) induction (Figure 4.4 C and EC50 values in Table 4.3). 
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Figure 4.5 Vmax of folate transport in FT RNAi line  
Folate transport kinetics measured at day 3 and day 6 in WT cells and FT RNAi 
strains + or - tet, at day 3 and day 6   
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4.2.2 Potency shifts of DHFR-TS inhibitors with RNAi knockdown of FT1-3 
As FT1-3 knockdown in T. brucei parasites was shown to affect sensitivity to MTX, 
other antifolates were tested to determine whether there is a similar effect.  After 
both 3 days and 6 days induction EC50 studies demonstrated a > 30 fold reduction in 
parasite sensitivity to RTX (Table 4.3). This is indicative of cross resistance between 
classical antifolates MTX and RTX. However, parasites were hypertensive to the 
non-classical DHFR inhibitor PYR with potency increasing by 12-fold and 14-fold 
after 3 days and 6 days induction respectively. Similarly, a hypersensitivity to the 
non-classical TS inhibitor, NTX, was evident; a 2-fold reduction in EC50 after both 3 
days and 6 days induction. This is indicative of increased sensitivity of T. brucei to 
the non-classical antifolates with knockdown of FT1-3. No marked change in 
sensitivity for the control, melarsoprol, was found after 3 or 6 days induction.  
 
4.2.3 Transport of folate with RNAi knockdown of FT1-3 
As shown earlier in this thesis, folate and MTX are competitive substrates for 
transport into cells (section 3.7.5) and FTs were indicated from an RIT-seq screen 
(section 4.1) to be involved in MTX-resistance mechanisms. It seemed prudent 
therefore to determine folate transport in the RNAi knockdown cell line. Indeed, 
Vmax of folate uptake was substantially reduced with RNAi knockdown (Figure 4.5). 
After 3 days, the Vmax of induced cells was reduced by 10-fold and 9-fold compared 
to WT and un-induced cells respectively. Likewise, after 6 days, the Vmax of induced 
cells was reduced by 4-fold compared to both WT and un-induced cells.  No changes 
in folate Km app was detected between induced, un-induced and WT after 3 days (2.56 
+ 0.20 µM, 3.43 + 0.24 µM  and 3.47 + 0.77 µM, respectively) or 6 days (2.77 + 
1.68 µM,  2.68  + 1.68  µM and 2.67 + 0.26  µM, respectively).  
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Figure 4.6 Generation of MTX-resistant trypanosomes and EC50 confirmation 
(A) Stepwise generation of resistance to MTX (B) Representative drug sensitivity 
(EC50) plots. The parental WT line had an EC50 value of 3.90 + 0.10 nM   and the 
resistant clones: line 1A,  1380 + 80 nM; line 1B, 1170 + 180 nM; line 1C,  1280 +  
50 nM; line 2A, 1350 + 90 nM; line 2B 1490 + 70 nM; line 2C, 1320 + 90 nM.  Data 
are the weighted mean of two independent experiments. 
74 
 
4.3 MTX Resistant Cell Line 
 
4.3.1 Generation of MTX resistance 
To investigate the ease in which resistance to MTX could occur in vitro, two 
independent cell lines of BSF T. brucei were cultured in the continuous presence of 
MTX in TBM until they were able to sustain normal growth in 800 nM MTX. This 
process took 72 days to achieve (Figure 4.6 A).  Three clones were selected from 
each independent resistant line (6 in total), and MTX sensitivity was determined. A 
comparable EC50 was found in all six clones (1.17 to 1.49 µM) and the resultant EC50 
shifts were >300-fold compared to the sensitivity of the parental cell line (WT EC50 
= 3.9 nM) (Figure 4.6 B). From each independent cell line the clone displaying the 
greatest resistance to MTX was selected for further studies. For cell line 1 this was 
clone A with EC50 = 1.38 µM (now named MTX R1) and for cell line 2, clone B with 
EC50 = 1.39 µM (named MTX R2). Of note, cumulative growth for MTX R1 and 
MTX R2 was similar to the parental cell line (doubling times of 6.2 h for WT, 6.2 h 
for MTX R1 and 6.4 h for MTX R2). Moreover, after 4 months of continual passage 
in the absence of MTX, resistance in MTX R1 and MTX R2 was retained (EC50 1.0 
µM and 1.1 µM respectively). 
 
4.3.2 Potency shifts of DHFR-TS inhibitors in MTX-resistant trypanosomes 
MTX R1 and MTX R2 demonstrated cross-resistance to the classical antifolates as 
depicted in Table 4.4. For the classical TS inhibitors RTX and PMX there was a 
substantial reduction in sensitivity in both cell lines compared to the parental line (~ 
200-fold and ~ 50-fold respectively). The opposite effect was seen with non-classical 
antifolates, where MTX R1 and MTX R2 parasites became more sensitive to these 
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Figure 4.7 MTX and folate tranport studies in MTX-resistant trypanosomes
Uptake of [3H]-folate and [3H]-MTX was determined at a set concentraion of 
unlabelled subtrate (5 μM folate and 20 μM MTX). Linear rate of uptake was 
determined in triplicate and the weighted mean of the experimental triplicate 
was calculated. p values were calculated using a student’s unpaired t-test.
(A) (B) Data is meighted means + SEM. (A) MTX uptake, measures at 20 μM 
MTX. (B) Folate uptake, measures at 5 μM folate. 
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compounds. Sensitivity to the non-classical DHFR inhibitors, PYR, TMP and MTP, 
increased to a similar extent (between 6 and 13-fold) in MTX R1 and MTX R2 cells, 
apart from TMX where sensitivity increased by ~40-fold.  There was a slight 
increase in sensitivity to the non-classical TS inhibitor NTX in MTXR1 and MTXR2 
(~1.4-fold).  No change in melarsoprol sensitivity was detected compared to the 
parental cell line for either clone.  
 
4.3.3 Transport of MTX and folate in MTX-resistant trypanosomes 
As FTs had been established to be involved in MTX drug resistance mechanisms by 
RIT-Seq, transport of the FTs substrates, MTX and folate, was determined in MTX 
resistant trypanosomes. For this, transport was determined at fixed concentration of 
unlabelled substrate (20 µM MTX and 5 µM folate) instead of at varying 
concentration (Figure 4.7). For MTX and folate, the rate of transport was 
substantially reduced in both clones compared to the parental WT cells. For MTX 
uptake there was a 15-fold reduction in MTX R1 (p = 0.03) and an 8-fold reduction 
in MTX R2 (p = 0.04). For folate uptake there was a 5 fold reduction in MTX R1 (p 
= 0.001) and a 4-fold reduction in MTX R2 (p = 0.01). This data suggests that the 
rate of folate uptake may be affected less than MTX uptake in MTX-resistant 
trypanosomes.  
 
4.3.4 Sequencing of FT1-3 in MTX-resistant trypanosomes 
Results illustrate that there is a substantial transport deficit for folate and MTX in 
both resistant cell lines, thus sequencing of FT genes was undertaken to establish if 
any mutations had arisen that may account for these phenotypes.  Putative FT genes 
(FT1-3) are each 1899 bp in length and share 96% nucleotide identity. They are 
 
 
 
 
Figure 4.8 Schematic of FT1-3 sequencing  
(A) Schematic of 927 FT1-3: Tb927.8.3620, Tb927.8.3630, Tb927.8.3650 (blue 
bars) in tandem interrupted by Tb927.8.3640 (grey bar)  
(B) Primer design for FTs. universal primers in intragenic regions common to the 
FTs depicted in black, unique primers specific for the upstream and downstream 
regions near the ORF of each individual gene depicted in red. 
(C) Sequence coverage of FT1-3 in MTX-resistant trypanosomes. Gene coverage 
represented by blue bars and areas not covered by light blue bars. 
 
Figure 4.9 PCR products of FT1 and FT2 in MTX-resistant trypanosomes 
PCR products separated on an agarose gel.  
Lanes 1-3: PCR reactions using primers FT1 Fw and Un Rv 1. ~900 bp band in lane 
1 (WT); not evident in lane 2 (MTXR1) and lane 3 (MTXR2). 
Lanes: 4-6 PCR reactions using primers FT2 Rv and Un Fw 2 ~1900 bp band in lane 
4 (WT); not evident in lane 5 (MTXR1) and lane 6 (MTXR2)  
 
 
 
 
 
Table 4.5 Amino acid changes in FT1-3 in MTX-resistant cell lines 
 
 
 
Position MTX R1 and R2 WT 927 Reference 
FT1           216 valine leucine leucine 
                 218  threonine valine valine 
FT3           216 leucine valine leucine 
                 218 valine threonine valine 
                 278 glutamate lysine lysine 
                 282 arginine histidine histidine 
                 523 tyrosine serine serine 
                 526 alanine methionine methionine 
                 530 valine leucine leucine 
                 536 histidine asparagine asparagine 
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arranged in tandem on chromosome 8 and interrupted by an unrelated gene 
(Tb927.8.3640, putative JAB1/Mov34/MPN/PAD-1 ubiquitin protease) (Figure 4.8 
A). In order to individually sequence these highly homologous genes, unique primers 
were designed that were specific for the upstream and downstream regions near the 
ORF of each individual gene. To attain full sequencing coverage of the genes, 
primers were also designed in the intragenic regions common to the FTs (Figure 4.8 
B illustrates primer coverage and all primer sequences are given in Table 2.2).  
In the WT parental line sequence coverage was attained for all three FT 
genes (1899 bp of each gene). However, full coverage was not attained for the MTX 
resistant clones with segments missing from FT1 and FT2.  Specifically, coverage 
was not attained for the first 548 bp of FT1 for both MTX-resistant lines (coverage 
549-1899 bp), for the last 1354 bp of FT2 in MTX R1 (coverage 1-545 bp) and for 
the last 1345 bp of FT2 in MTX R2 (coverage 1-546 bp) (Figure 4.8 C). This is due 
failure to obtain PCR products for these regions using the unique primers (see Figure 
4.8 C, Figure 4.9) despite attempts to optimise PCR conditions. Indeed, no PCR 
product was generated for PCR reactions using the FT1 Fw primer for MTX R1 and 
MTX R2 and reactions using the FT2 Rev primer for MTX R1 and MTX R2 (Figure 
4.9 as an example).  The DNA and protein sequences of MTXR1, MTXR2 and WT 
were aligned with T. brucei 927 reference genome sequences using Clustal Omega 
and are shown in the supplementary materials (Figures S1 and S2). Two predicted 
amino acid changes were seen encoded by FT1 for both MTX-resistant lines 
compared to WT and the 927 reference genome (V216L, T218V). For FT3, eight 
amino acid changes were predicted in both MTX-resistant lines (L216V, V218T, 
E278K, R282H, Y523S, A526M, V530L, H536N) (Table 4.5).  Of note, for the first 
two mutations in FT3 (L216V, V218T) although there are mutations in the MTX-
At2g32040         MASRSLFSISISPSQFTVLPSINNERRRLAIAARSHRLSRRKIRKRPPDRDMSSIVSIPE 
Slr0462           ------------------------------------------------------------ 
FT3MTXR2          -----------------------------------MTTSPNACQDQPPQHSAPQA----- 
LinJ.10.0400      ----------------------------------------MSYKEAAPKREKDA------ 
                                                                               
 
At2g32040         LPRRRDSEESLLLDSRISVAEGDTSNTDVEGDRDTTSSIRTQPPPRKGRNLSSSRIKFYG 
Slr0462           ----------MLV------AM----------SMTPIAILFSTPLKRF---L--REKVLLG 
FT3MTXR2          ----HEAEC---TTHKLSAEETM----DARPVHPDARALFRKLP-------CVWSIPVFG 
LinJ.10.0400      ------AGA---AAVPEAAAAGN----DGKYIHPEAASLFARCP-------WVRRVPVFG 
                                                        :                  . * 
 
At2g32040         VELSPDNV-----AVAMVYFVQGVLGLA-RLAVSFYLKDDLHLDPAETAVITGLSSLPWL 
Slr0462           NAPSWELL-----AILSIYFVQGVLGLS-RLAVSFFLKDELGLSPAAMGALIGLGAAPWI 
FT3MTXR2          TAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQRMSSLVTFGYA 
LinJ.10.0400      EAVKGYGLKFIVALGASNLLCKGVADQILYGQTYAMMIDRYGIDVARYQRLSSISTMGWS 
                     .               : :*:            :      .      : .: :  :  
 
At2g32040         VKPLYGFISDSVPLFGYRRRSYLVLSGLLGAFSWSLM---AGFVDSKYSAAFCILLGSLS 
Slr0462           LKPVLGLMSDTVPLFGYRRRSYLWLSGLMGSAGWLLF---AAWVSSGTQAGLVLLFTSLS 
FT3MTXR2          VKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTSFT 
LinJ.10.0400      IKAFTAMLCDGFAFLGYTKRWYMFISCVGGGAFALIYGLLPAKEASANVACAFIFLSSWG 
                  :* . .::.* . ::** :* *: :* : *.    :     .       *   ::. *   
 
At2g32040         VAFSDVVVDSMVVERARGESQSVSGSLQSLCWGSSAFGGIVSSYFSGSLVESYGVRFVFG 
Slr0462           VAIGDVIVDSLVVERAQRESLAQVGSLQSLTWGAAAVGGIITAYASGALLEWFSTRTVFA 
FT3MTXR2          KANLDILTQGHY-SRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAVF 
LinJ.10.0400      KANVDILSQGHY-SRLMRQNPKPGPALVSWMWFCIMIGSLIATVMNGPLADAGKPQISIF 
                   *  *:: :.   .*   .      :* *  * .  .*.::::   * * :    :  .  
 
At2g32040         VTALLPLITS-------------------AVAVLVNEQRVVRPA---------------- 
Slr0462           ITAIFPLLTV-------------------GAAFLISEVSTAEEE---------------- 
FT3MTXR2          ISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREEQLEREADAVRLQGSE-------- 
LinJ.10.0400      VSAALQAITCVFYLFNWYGEKKNRVLRSEDALFILEETRKE-RERLGLEGVNNGTAGAQH 
                  ::* :  :                        .: .*                        
 
At2g32040         ----------------------------SGQKENITLLSP--------------G----- 
Slr0462           ----------------------------E------------------------------- 
FT3MTXR2          -----------------ATSGSL--------------------DNPSDTEEVGEG----G 
LinJ.10.0400      GGAAKGKRSPQRSHSDEDVEGAVRDALNDGQRDNGELVQDVYDDAYDDGEEVAEGEVYYG 
                                                                               
 
At2g32040         ---------FLQTSKQNMIQLWGAIK-------------QPNVFL--------------- 
Slr0462           ----------KPQPKAQIKLVWQAVR-------------QKTILL--------------- 
FT3MTXR2          ARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRLQLLITSVVASFT 
LinJ.10.0400      KPPVPCLFGLFEANTEVISKNWKIFVYSVVMTCAVIAMLCANILADTLGLLVACVVVSTI 
                                   :      .                .::                 
 
At2g32040         ---------------PTLFIFLWQ----ATPHSDSAMFYFTTNKLGFTPE----FLGR-V 
Slr0462           ---------------PTLFIFFWQ----ATPSAESAFFYFTTNELGFEPK----FLGR-V 
FT3MTXR2          LCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGGPNFSYFYYSTVG 
LinJ.10.0400      CCAASFWALPLVIAKANVFAYLDKAVSIRVSGPLNAFYLNTYGCPGNLPNFTYTFYNTVA 
                                  .:* :: :          . .:  *       *:    :      
 
At2g32040         KLVTSIASLLGVGLYNGFLKTVPLRKIFLVTTIFGTGLGMTQVILVSGFNRQLGISDEW- 
Slr0462           RLVTSVAGLIGVGLYQRFLKTLPFRVIMGWSTVISSLLGLTTLILITHANRAMGIDDHW- 
FT3MTXR2          NMIGAMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVERWNRPY-VSDHVV 
LinJ.10.0400      GVINTIVGMITVTLFNFLFAKHGYRLTFIVTTIMQVLAALFDIIIVKRWNLYIGIPDHAM 
                   :: :: .:: * *:. .: .   *  :  :*::    .:  :*::   *    : *.   
 
At2g32040         FAIGDSLILTVLAQASFMPVLVLAARLCPEGMEATLFATLMSISNGGSVLGGLMGAGLTQ 
Slr0462           FSLGDSIILTVTGQIAFMPVLVLAARLCPPGIEATLFALLMSVMNLAGVLSFEVGSLLTH 
FT3MTXR2          FVLGDQIIHQVCYMMHFMPTVMLISRLCPRGYESAVYAVLAGCAHFGRSLSNTLGWLLME 
LinJ.10.0400      YIWGDAVVGEIVYMLGFMPQIVLLSRLCPRGSESVVYALMAGFARLGRTTAASLGAILLE 
                  :  ** ::  :     *** ::* :**** * *:.::* : .  . .   .  :*  * . 
 
At2g32040         AF--------GITRDSFGNLSTLIILCNLSSL-LPLPLLGLL-P-RDSPDTLTKDDADVE 
Slr0462           WL--------GVTETQFDNLALLVIITNLSTL-LPLPFLGLL-P-AGDPQVKDKTEKEDN 
FT3MTXR2          YVWNVQSDI-TVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICDVLDENGKAIT 
LinJ.10.0400      YGLPVFKTQDDGSRCNYDNLPLLLFLCSMCTPLLAIPLSIILLPKARICDDIDIDGKVVR 
                                 .: *:  *:::  : :  : :*:  :* *     :           
 
At2g32040         MKSN*------------------------------------------------ 
Slr0462           PDDPGDRL--VLPPAEVF----EHHTVGSLSDQNFL--PEFFPEKSS--SRP* 
FT3MTXR2          KKAEDVHA----PSNDSP--RRREPTAN*------------------------ 
LinJ.10.0400      QAVDKQVAAAPLPSSDSDAVMNAEPLHGNKADEREAARGEAVQGKRAGASEK*  
Figure 4.10 Protein sequence alignment of FT3 MTX R2 compared to FBTs in 
Leishmania, cyanobacteria and plant. Highlighted in yellow: residues shown to be critical 
to folate transport by mutagenesis studies in Synechocystis, highlighted in purple: residues shown to 
be critical to folate transport by mutagenesis studies in Leishmania, red font: residues found to be 
critical to folate transport by bioinformatics modelling in Synechocystis, highlighted in green: 
mutations present in T. brucei FT3 in MTX R2. 
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resistant cell lines compared to WT (leucine to valine, valine to threonine 
respectively) this is not the case when compared to the 927 reference genome 
(leucine to leucine and valine to valine respectively).  This is an anomaly as one may 
expect WT and 927 reference strain to have the same amino acids and changes 
evident in MTX R1 and MTX R2, as is the case for FT1. With this anomaly in mind, 
the PCR reaction was repeated and also fresh genomic DNA from the MTX-resistant 
lines was isolated and the experiment repeated. The same result was returned.  The 
cause of this discrepancy with FT1 is not known; it could have been due to a mix up 
of the primers, cell lines or genomic DNA. Further work is required to resolve this 
issue. In contrast, there was no ambiguity in the sequence data for FT3. Out of the 
eight mutations in FT3, three of these represent a change in either polarity or size.  
For E278K the side group changes to being negatively charged (E) from positively 
charged (K), for R282H an increase in size from (H) to (R) is evident, and Y523S 
changes to an aromatic side group (Y) from a polar side group (S).  
 
4.3.5 Structure-function analysis of FT1-3 mutations 
To identify if mutations found in MTX resistant-cell lines could be critical to folate 
transport activity, the protein sequence of MTX R2 for T. brucei FT3 was aligned to 
protein sequences of other members of the FBT family in which critical residues 
responsible for folate transport have been identified (Figure 4.10).  
The novel FBT superfamily was identified first in Leishmania (Richard et al., 2002) 
and is present in other kinetoplastids (Ouameur et al., 2008) (including T. brucei), 
malaria (Wang et al., 2007), Toxoplasma (Massimine et al., 2005), plants  and in 
cyanobacteria (Klaus et al., 2005) The Synechocystis slr0642 gene and its closest 
Arabidopsis homolog, At2g32040 gene, have been expressed in E.coli and shown to 
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mediate uptake of folate and MTX (Klaus et al., 2005). Studies of FBT mediated 
folate transport in Synechocystis and Leishmnia have identified key transporter 
residues implicated in folate transport (Dridi et al., 2010b; Eudes et al., 2010). A 
protein sequence alignment of Synechocystis slr0642, Arabidopsis At2g32040 and   
L. infantum LinJ.10.0400 (FT1 in Leishmania) with MTX R2 for T. brucei FT3 is 
shown in Figure 4.10. In this alignment, the group of four mutations found in MTX 
R2 (Y523S, A526M, V530L, H536N) are in very close proximity to critical residues 
shown to mediate folate uptake in FBT genes. Nearby cysteine and glutamic acid 
residues, conserved in all four FBT genes (position 519 and 524 in T. brucei FT3 
respectively) were shown to be critical to folate transport in Synechocystis and 
Leishmnia respectively (Dridi et al., 2010b; Eudes et al., 2010). Also, three residues 
conserved in Synechocystis slr0642 and Arabidopsis At2g32040 that were implicated 
in folate transport by bioinformatics modelling (using the PSIPRED bioinformatics 
tool) (Eudes et al., 2010) aligned closely to this group of four mutations found in 
MTX R2 (phenylalanine, methionine and asparagine aligning to positions 528, 532 
and 536 in T. brucei FT3).  
A topological model of FT1-3 was rendered in order to visualise and identify 
the location of these mutations in the transmembrane transporters.  FT1-3 are 
predicted by the TMHMM server v 2.0 348 to contain 12 transmembrane helices 
(http://www.cbs.dtu.dk/services/TMHMM/) (Krogh et al., 2001). FT1-3 are family 
members of FBT which belongs to the major facilitator superfamily. Transporters in 
this family typically consist of 12 transmembrane helices with both N and C 
terminus located intracellularly (Paulsen, 2003), so the model predicted by TMHMM 
is consistent with this. Topological models of FT1-3 were visualised using the web-
based Protter software.  Using TriTryp DB (http://tritrypdb.org) and the post 
 
Figure 4.11 Topological models of FT1-FT3. A)  Predicted phosphorylation sites in FT3 for parental WT line. (B, C, D) PCR coverage 
and mutations in FT1-3 for MTX-resistant cell lines. Models made using the web-based Protter software.  
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Figure 4.12 RNA and DNA detection of FT1-3 in MTX-resistant trypanosomes 
(A) qRT-PCR shows no change in FT RNA in WT and MTX-resistant cell lines: normalised 
against endogenous control gene TERT.  Data are the mean + SEM of three experimental 
replicates.  p values shown.  
(B) Agarose gel showing overloading of lane 2 (MTX R1). 
(C) Schematic of EcoRI sites and expected Southern blot bands associated with 427 FT1-3, 
ESAG10 genes and trypanothione reductase. i) 427 in reverse compliment FT1-3; 
Tb427.8.3620, Tb427.8.3630, Tb427.8.3650 (blue bars) in tandem interrupted by 
Tb427.8.3640 (grey bar) ii) ESAG10 genes; Tb427.BES15.1, Tb427.BES51.1, 
Tb427.BES56.1, Tb427.BES59.1 and Tb427.BES126.1 (represented by blue bar) that share 
common EcoRI sites. iii) ESAG10 genes; Tb427.BES134.1 and Tb427.BES153.1 
(represented  by blue bar) that share common EcoRI sites iiii) Tb427.10.10390 (blue bar)  
 
(D) Sothern blot, (i) FT1-3 and ESAG10 genes (ii) trypanothione reductase   
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translation model from Urbaniak et al (Urbaniak et al., 2013), eight serine/threonine 
residues conserved in FT1-3 are predicted phosphorylation sites. Applying WT FT3 
as an example, Figure 4.11 A demonstrates the cytoplasmic location of these sites, 
further giving evidence of this topology model. Figure 4.11 B-D demonstrates the 
amino acid mutations found in FTs and the coverage of each transporter attained by 
PCR. Of note the four mutations in FT3 found in close proximity (Y523S, A526M, 
V530L, H536N) are clustered around the cytoplasmic loop close to the 11 
transmembrane α helix and in the α helix itself.  
 
4.3.6 qRT-PCR and Southern blot in MTX-resistant trypanosomes 
To identify if there was any change in transcription and/or copy number of FTs in 
the MTX-resistant cell lines qRT-PCR and Southern blot experiments were 
performed respectively.  qRT-PCR showed no change in transcription of FT1-3 in 
MTX R1 and MTX R2 compared to the parental WT cell lines (Figure 4.12.A). To 
determine if copy number is changed a Southern blot was performed. After digestion 
with EcoRI, DNA from WT, MTX R1 and MTX R2 were separated on an agarose 
gel. There is DNA overloading for MTX R1 (Figure 4.12 B). The MTX-resistant cell 
line was grown in T. brucei S427 and there are 7 ESAG10 genes in this strain that 
share up to 90-94% gene identify with 927 FT1-3 and 91-95% gene identify with 
427 FT1-3. Although these genes may not be expressed (Hertz-Fowler et al., 2008), 
they need to be considered when analysing the Southern blot.  Figure 4.12.C 
illustrates the cutting sites of EcoRI in 427 FT1-3 and the 7 ESAG10 genes. Five 
ESAG10 genes share common EcoRI cutting sites (1.27 kb and 6.6 kb either side) 
and the two others also share common cutting sites (1.27 kb and 3.1 kb either side).  
The Southern blot identified bands associated with FT1-3 and the ESAG10 genes and 
 
 
 
Figure 4.13 Proteomic analysis of MTX-resistant trypanosomes 
(A) Venn diagram showing proteins with a quantifiable expression change between 
resistant lines and WT in order to calculate an H/L SILAC ratio. Blue circle, MTX 
R1; red circle, MTX R2. 
(B,C) Plot of the proteomics data from (B) MTX R1 and (C) MTX R2.  Protein is 
represented by a point plotted as the Log2 of the H/L SILAC ratio against the Log10 
value of the intensities of peptides that belonging to each protein. Proteins plotted in 
blue (B) and red (C) were found to have significant changes in H/L SILAC ratio.  
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there is no substantial change in the banding patterns between WT and MTX-
resistant trypanosomes (Figure 4.12.D). There is a stronger signal with MTX R1 
which can be attributed to gel overloading (Fig 4.12.B). The T. brucei 427 genome is 
only partially assembled and this may account for band 3 not completely 
corresponding with the expected band size of 3.1 kb. Trypanothione reductase 
(Tb427.10.10390) was used as a control with the EcoRI sites illustrated and the 
expected banding pattern found on Southern blot (Figure 4.12 C,D). Again a stronger 
signal was evident for MTX R1 consistent with unequal loading of the gel.  
 
4.3.7 Proteomic analysis of MTX-resistant trypanosomes 
 
Examining folate/MTX transport in the MTX-resistant parasites gave a targeted 
approach to identify resistance mechanisms. A more global perspective using a 
SILAC proteomic approach may facilitate the identification of other candidates 
implicated in MTX resistance. Such SILAC approaches have been successfully 
utilised in identifying the actions of anti-kinetoplastid compounds including 
oxaboroles in T. brucei (Jones et al., 2015) and nitro-drugs in Leishmania (Fairlamb 
group, unpublished). 
MTX-resistant cell lines and the parental WT line were SILAC labelled, 
mixed in a 1:1 ratio and analysed by LC-MS/MS. For MTX R1/WT 721 proteins 
were identified and of these 522 had a quantifiable expression change between MTX 
R1 and WT in order to calculate a H/L SILAC ratio. For MTX R2/WT 702 proteins 
were identified with 545 quantifiable for a SILAC ratio. Between both cell lines only 
744 proteins could be quantified for SILAC ratios, with 293 proteins present in both 
drug-resistant lines (Figure 4.13.A).   
Table 4.6 Proteins found to be significantly over- or under- expressed in MTX-
resistant trypanosomes 
Blue columns, MTX R1; Red Columns, MTX R2  
 
 
Gene  ID Product Log 2 
Res/WT 
Tb927.8.7950 flagellar member 4 (FLAM4) -1.10 
Tb927.10.2560 mitochondrial malate dehydrogenase 
(mMDH) 
-1.04 
Tb927.6.2420 p22 protein precursor -1.27 
Tb927.1.720 phosphoglycerate kinase (PGKA) -0.59 
Tb927.1.3060 unspecified product 0.95 
Tb927.8.6240 STOP axonemal protein 0.81 
Tb927.3.5020 flagellar member 6 (FLAM6) 0.73 
Tb927.5.1400 hypothetical protein 0.70 
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Proteins that are more abundant  in the resistant populations compared to WT 
will have a SILAC ratio greater than 1 (or log2 > 0) whereas less abundant proteins 
will have a SILAC ratio less than 1 (or log2 < 0). Proteins that are not changed will 
have a ratio = 1 (or log2 = 0).  Only one protein related to folate metabolism was 
identified in this SILAC experiment, namely DHFR-TS. No change in DHFR-TS 
was seen in the resistant cell lines compared to WT (log2 = 0.07 for MTXR1 and log2 
= -0.09 for MTX R2). Moreover FTs were not identified in these experiments. Eight 
proteins were identified with significantly altered expression levels in resistant lines 
compared to WT (statistical significance was assessed using significance B) (Figure 
4.13.B, C and Table 4.6). Two proteins were identified in MTX R1 that were 
significantly under-expressed compared to WT, and six proteins were identified in 
MTX R2, two of which were under-expressed and four of which were over-
expressed (Figure 4.13.B,C Table 4.6). There was no striking change in abundance 
of any of the proteins identified with the top hit, p22 protein precursor 
(Tb927.6.2420), only demonstrating ~2.4 fold lower abundance in MTX R2. 
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Chapter 5: 
Discussion 
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5.1 Mechanism of action of antifolates 
5.1.1 Effects of thymidine and folate on antifolate cell potencies 
To fully assess the effects of thymidine and folate on antifolate drug potency a 
medium deficient of folate and thymidine was established. The first attempt to make 
a folate and thymidine depleted medium (named RPMI-BM) was based on ‘FDM’ 
(Sienkiewicz et al., 2008) but the medium was modified to contain no additional 
thymidine. FDM was prepared using RPMI 1640, supplemented with 50x MEM 
amino acid solution, with amino acids and other nutrient concentrations comparable 
to HMI9-T (Table 2.1). Also it contained 0.5% Serum Plus
TM 
and 10% FCS.
 
Unfortunately parasites could only survive in this medium with thymidine 
supplementation; a finding shared with others members of the Fairlamb group and 
the DDU (personal communication).  A second attempt was to create a media based 
on HMI9-T, but without additional folate and thymidine, named TBM. This media 
contained no Serum Plus
TM 
with serum provided by 10% FCS (Table 2.1). Parasites 
survived and grew at a normal rate in this medium, without the need for thymidine 
supplementation. It is interesting that cells did not grow in RPMI-BM despite this 
media having extra serum (provided by 0.5% Serum Plus
TM
) and therefore extra 
folate; as opposed to TBM that did not contain Serum Plus
TM
 where cells survived 
without the need for thymidine supplementation.  Perhaps, some of the amino acids 
provided by MEM in RPMI-BM were insufficient level support growth and 
thymidine served as nutritional rescue in the medium. Thymidine is synthesised de 
novo from aspartate and glutamine to form dUMP and then 5,10-MeTHF provides 
the methyl group to form dTMP. In turn 5,10-MeTHF is formed from THF with the 
methylene moiety derived from either glycine or serine. Comparison of amino acid 
levels in these media (Table 2.1) reveals that amino acid composition is essentially 
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the same.  However, glutamine is supplied as L-alanyl-L-glutamine in TBM and L-
glutamine in FDM. It is well known that glutamine is unstable in solution and 
possibly became limiting in FDM. It would be of value to measure the thymidine and 
folate levels (e.g. by HPLC) in both RPMI-BM and TBM to provide an accurate 
comparison of these media. 
Antifolate drugs were tested in TBM with the addition of thymidine and/or 
folate. MTX has been shown to have picomolar Ki values against TbDHFR enzyme 
and micromolar Ki values against TbTS (Gibson et al., 2016). The addition of folate 
had a greater effect in reducing whole cell potency than the addition of thymidine 
confirming that MTX is selective for TbDHFR over TbTS. Moreover, the absence of 
thymidine improved MTX cell potency confirming that ‘thymineless death’ is part of 
the mode of action (MOA) of MTX. However, excess thymidine did not totally 
nullify MTX toxicity suggesting that MTX has intracellular targets other than 
DHFR-TS. One probable candidate is PTR1, as MTX have been previously shown to 
be active against this enzyme in T. brucei (Ki app 11.1 nM) (Spinks et al., 2011). The 
fact that MTX is structurally similar to folate metabolites means that MTX could 
inhibit other targets in the folate metabolic pathway such as FPGS, MS or C1-THF 
synthase. In mammalian cells, as well as targeting DHFR, MTX is also known to 
inhibit the enzymes MTHFR and MS resulting in diminished intracellular 5-methyl-
THF levels and a reduction in homocysteine remethylation to methionine (Broxson, 
Jr. et al., 1989; Fiskerstrand et al., 1997). 
The addition of thymidine completely abrogated the actions of classical 
antifolates RTX and PMX suggesting that these drugs are TS- specific. This suggests 
that ‘thymineless death’ is their primary MOA and that there are minimal off-target 
effects. The monoglutamate forms of RTX and PMX are more selective for 
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TbDHFR than TbTS in an enzyme assay (Gibson et al., 2016); this has also been 
reported in the monofunctional human enzymes (Jackman et al., 1991; Shih et al., 
1997). However, these drugs contain a terminal glutamyl moiety which enables 
polyglutamylation by FPGS (Synold et al., 1996). In mammalian cells, 
polyglutamylation of RTX and PMX enables better binding to TS with minimal 
effect on binding to DHFR (Jackman et al., 1991; Shih et al., 1997). In T. brucei, 
RTX and PMX display better whole cell potencies than against the TbDHFR and 
TbTS enzyme activities, implying that polyglutamylation of these drugs probably 
happens.  
 
The non-classical antifolates that were tested included the TbDHFR-specific 
inhibitors TMX, PYR and TMP; and also the TbTS-specific inhibitor NTX. TMX 
has picomolar Ki values against TbDHFR (Gibson et al., 2016), but unlike MTX, this 
does not translate into whole cell potency, possibly due to TMX not containing a 
terminal glutamyl moiety for polyglutamylation and subsequent intracellular 
retention (Jackson et al., 1984). Results showed that PYR and TMP have 
intermediate potency against TbDHFR (Gibson et al., 2016) and display a marked 
drop-off in potency from enzyme target to cell when cultured in TBM. The addition 
of thymidine had little effect in reducing whole cell potency compared to the 
addition of folate, where drug potency was reduced, confirming that PYR and TMP 
are DHFR specific in T. brucei as they are in mammalian, bacterial and protozoan 
cells (Benkovic et al., 1988; Chio and Queener, 1993). Although NTX has 
nanomolar Ki values against TbTS (Gibson et al., 2016)  it displayed only moderate 
whole cell potencies with no change in drug potencies with the addition of folate or, 
notably, thymidine. Again, NTX is a non-classical antifolate; non-classical 
antifolates lack a terminal glutamate and therefore are unlikely to enter the cell via 
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folate transporters and cannot be polyglutamylated. Polyglutamylation may facilitate 
compound concentration in a cell.  The drop-off in cell potency may also be due to 
drug efflux, or non-specific binding to proteins in the medium.  
5.1.2 Cell cycle studies 
Previously, DHFR-TS
-/-
 BSF T. brucei parasites have been shown to undergo cell 
cycle arrest in S-phase when grown in the absence of thymidine (Sienkiewicz et al., 
2008). S-phase arrest has been linked to ‘thymineless death’, in both prokaryote and 
eukaryotic systems (Ahmad et al., 1998). Analysis of DHFR-TS inhibitors RTX and 
MTX confirmed cell cycle arrest in S phase. Indeed this phenotype was rescued with 
excess thymidine supplementation, with a greater ‘rescue’ for RTX than MTX 
treated cells, indicating that ‘thymineless death’ is a more prominent MOA for RTX 
(targeting TS) than MTX (targeting DHFR and PTR1). In T. brucei PTR1 is essential 
both in vitro and in vivo (Sienkiewicz et al., 2010) and displays a low activity in 
reducing folate to DHF (Ong et al., 2011). Histograms of parasites treated with MTX 
and RTX were non-canonical with cell cycle distribution unquantifiable. This non-
canonical histogram profile has also been previously found with the TS inhibitor 5-
fluorouracil (5FU) in yeast (Hoose et al., 2012).  Furthermore, the cytotoxic effect 
during the S phase of the cell cycle has also been observed in mammalian cells 
treated with antifolates, including MTX and RTX (Di Gennaro E. et al., 2009; 
Taylor and Tattersall, 1981). Cell cycle arrest in S phase caused by MTX treatment 
has been previously shown to be partially rescued by supplementation with excess 
thymidine.  In these cancer cell line studies complete rescue was seen when both 
thymidine and hypothanxine were added, suggesting that MTX toxicity was 
associated with inhibition of DNA synthesis from suppression of both thymidine and 
purine synthesis (Taylor and Tattersall, 1981). Unlike mammalian cells, 
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trypanosomatids lack de novo purine synthesis (Bellofatto, 2007) and so MTX 
toxicity via suppression of purine synthesis is not applicable to T. brucei. 
 
The TS inhibitor fluorouracil (5FU) modulated by folinic acid (5FU-FA) is 
widely used in the treatment of metastatic colorectal cancer. The 5FU metabolite 
FdUMP forms a stable tertiary complex with TS and methyl donor 5-10-Methylene-
THF which inhibits TS function (Longley et al., 2003). Folinic acid (leucorovin) is 
known to modulate the effects of 5FU. Leucorovin enters the mammalian cell via the 
RFC and is converted to 5-10-Methylene-THF. Polyglutamylation of 5-10-
Methylene-THF, by FPGS, increases its cellular intracellular retention and also 
improves the stabilization of its tertiary complex with FdUMP and TS (Longley et 
al., 2003). 5FU with leucorovin lead to improved clinical response rates in colorectal 
cancer compared to treatment with 5FU only (Thirion et al., 2004). In cell cycle 
studies, it has been found that supplementation with the drug vorinostat increased the 
magnitude of S phase arrest by 5FU-FA in cancer cell lines (Di Gennaro E. et al., 
2009). Vorinostat is a histone deacetylase inhibitor; this action affects multiple 
pathways that cause cell death including the expression of cell cycle regulation, 
differentiation and/or apoptosis (Xu et al., 2007). It has been shown that TS activity 
is reduced by vorinostat and it has a synergistic anti-proliferative effect when 
combined with either 5FU-FA or RTX leading to a reversal of chemo-resistance to 
both these drugs (Di Gennaro E. et al., 2009).  It would be interesting to determine if 
vorinostat, or other histone deacetylase inhibitors, had any supplementary effect on 
cell cycle disruption caused by antifolates in T. brucei and whether a combination 
regime can indeed enhance antifolate parasite toxicity.  Moreover vorinostat could 
block the ability of thymidine to both rescue S phase arrest associated with RTX and 
MTX treatment and reverse its ability to reduce drug potency in vitro. 
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5.1.3 Determining the trypanocidal nature of MTX and RTX 
Compounds that are cytostatic against T. brucei inhibit parasite growth, whilst not 
killing them, are unlikely to clear parasite burden completely. Furthermore, these 
agents are often not effective in animal models of HAT and so should be identified 
and eliminated from drug discovery pipelines as early as possible (De Rycker et al., 
2012). Of the current drugs used in HAT there is a spectrum of cidal activity e.g.  
melarsoprol is rapidly cidal, pentamidine slow-cidal and DFMO is typically 
trypanostatic ((De Rycker et al., 2012; Sykes et al., 2012). MTX and RTX were not 
fully cidal at 48 h, in fact only static activity was shown in this time frame. Cell 
density dropped after 48 hours drug exposure but did not fall to below the starting 
concentration, in contrast to the rapidly cidal melasoprol. However if the assay was 
modified to have a longer duration of drug exposure (> 48 hours) it is possible that 
cidal activity of MTX and RTX might have been seen. Also, if drug washout was 
done at the end of the assay one could determine whether the MTX and RTX effect 
was reversible (static effect) or if cell death had occurred (cidal effect). In DHFR-TS 
-/-
 studies, null mutants died on removal of thymidine from the medium (100% 
inhibition of the target is lethal not static) and this occurred after 72 hours 
(Sienkiewicz et al., 2008). 
 
 72 hours may be the best time frame to determine cidal 
activity of the DHFR-TS inhibitors MTX and RTX. Furthermore, cidal/static activity 
may be dose dependent. 100% inhibition of DHFR-TS may be lethal (as seen in 
DHFR-TS 
-/-
 studies) whereas a lower dose (90% inhibition) may give growth arrest. 
Another assay used in HAT drug discovery determines T. brucei cidal activity by 
measuring parasite numbers after 24, 48 and up to 72 hour exposure to compounds at 
Minimal Inhibitory Concentrations (MIC) (Sykes et al., 2012). In this assay, cidal 
nature is identified by parasite burden being completely cleared and puromycin is 
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used as a positive control for 100% cell death. An assay like this could be adopted 
for determining MTX and RTX cidal activity.  
Work on current antifolates used against infectious diseases has shown some 
interesting results regarding their nature of killing. The DHFR inhibitor PYR is 
known to act in a ‘slow-cidal’ antiparasitic manner against P. falciparum (Le 
Manach C. et al., 2013). PYR was shown to have a stage-specific profile with 
activity against schizont formation and no activity against younger ring stages (Le 
Manach C. et al., 2013). In mammalian cells, parasite DNA synthesis takes place 
during erythrocytic schizogony (approx. 48 hours after infection) and after the 
parasite invades the hepatocytes (White and Kilbey, 1996). Slow–cidal activity of 
PYR could be explained by its activity against schizonts where DNA synthesis takes 
place. Of note, the most widely used antimicrobial antifolate, TMP, is likely to have 
both bacteriostatic (catabolic effects) and bacteriocidal (folic acid effects) actions 
(Quinlivan et al., 2000). This further highlights that categorising drugs into merely 
static or cidal can often be an oversimplification.  
 
5.1.4 MTX and RTX in vitro potencies as precursor for in vivo studies 
As a precursor for in vivo work, MTX and RTX potency was tested in vitro in 
parasites supplemented with thymidine and folate levels comparative to 
physiological levels seen in mice. It was found that supplementation with 
physiological thymidine concentrations did not affect drug potency; however, when 
physiological folate concentrations were increased MTX and RTX potency was 
reduced. However the 1 μM of thymidine used for supplementation is likely to have 
been used up very rapidly by the parasite (Ali et al., 2013b), whereas folate is stored 
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and recycled intracellularly and therefore low concentrations of folate (30-300 nM 
used here) are more likely to reverse antifolate drug effects. The 1 μM of thymidine 
used was not based on a steady state concentration but a pre-treatment concentration 
in Balb/c mice (Clarke et al., 2000b).   
Reversal of antifolate potency due to modulation of intracellular folate levels 
has been demonstrated in a number of studies relating not only to cancer but also 
infectious disease models both in vitro and in vivo (Peters et al., 1999; Schmitz et al., 
1994; van der Wilt et al., 2001; Wang et al., 2010). Studies in P. falciparum have 
shown that the addition of folate, or its derivatives, decreases the activity of 
antifolates (Carter et al., 2005; Ouma et al., 2006). Indeed, while MTX lacked any 
antimalarial activity against the murine infection, this was partially explained by the 
high content of folate in these mice (Irungu et al., 2009).  Also, in humans it has 
been found that there was reduced efficacy of the antimalarial treatment sulfadoxine-
pyrimethamine when used in patients receiving folic acid supplementation for 
anaemia (Carter et al., 2005). There is a balance between high folate levels inhibiting 
the actions of antifolates and antifolate toxicity with low folate levels.  Moreover, 
leucorovin is often given to patients who are receiving MTX, for the treatment of 
cancer or inflammatory diseases, in order to reduce the toxic side effects of MTX 
(Shea et al., 2014; Treon and Chabner, 1996).  For HAT animal model testing of 
antifolates it would be necessary to consider the effect of folate in the diet of mice 
and how this may impact the drug effect, both high folate levels inhibiting drug 
potency and low folate levels contributing to drug toxicity. Moreover, studies in 
cancer murine models have found that thymidine levels modulate RTX potency in 
vivo. Potency could be abrogated by thymidine supplementation (Jackman et al., 
1991), and drug toxicity caused when thymidine levels were lowered by the inhibitor 
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methoxypolyethyleneglycol-conjugated thymidine phosphorylase (MPEG-TPase) 
(Cao et al., 1999). Physiological levels of folate and thymidine in mice are still 
higher than those found in humans, with studies showing four times the folate 
concentrations in mice ((71 nM in low-folate diet (Wang et al., 2010)) compared to 
humans (17.91 nM (Wahlin et al., 2002)) and eight times thymidine concentrations 
in mice (1 μM)  (Clarke et al., 2000b) compared to humans (0.13 μM) (Howell et al., 
1981) indicating that animal models may not give a true representative of antifolate 
drug activity.  
With this information in hand, T. brucei in vivo studies of antifolate drugs 
would be the next step. However, MTX has already been tested in a HAT animal 
model by the Fairlamb group (personal communication). It was found that a standard 
regime of twice daily 5mg/kg MTX did not reduced parasite burden in mice fed a 
standard diet. However, in mice fed a low folate diet the same dose led to low levels 
of parasitemia but the mice had to be terminated due to toxicity. Folate levels were 
not examined in the mice and it could be that these were at a level that negated any 
MTX potency in mice fed a normal diet; moreover toxicity in the mice fed a low 
folate diet could be reflective of the narrow therapeutic index of MTX (Lennard, 
1999). Moreover, thymidine levels were not measured and this may have impacted 
on MTX activity.  Rescue with leucorovin circumvented MTX toxicity but it also 
increased levels of parasitemia, suggesting that the active reduced metabolites of 
leucorovin can be utilized by T. brucei in vivo. Previously, it has been demonstrated 
that after administration of leucorovin the predominant elevated metabolic forms 
after 2 hours were 5,10-methylene-THF and THF in mouse plasma (Bunni et al., 
1994). It is likely that in T. brucei these folate forms could be taken up and utilised. 
Studies show favourable preclinical RTX pharmacology (Clarke et al., 2000a) and 
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RTX appears a credible candidate for HAT animal model studies. However, RTX 
has limitations in the clinical setting including poor oral bioavailability and lack of 
CNS penetration (Clarke et al., 2000a). Also with current anitfolates there is a lack 
of specificity against the parasite DHFR-TS and human enzyme (Gibson et al., 
2016) which may account for toxicity seen in the animal mouse model with MTX. 
Designing new or refining existing antifolates may help reduce toxicity in the animal 
model and be necessary if this drug class are to be used in T. brucei. With this in 
mind a small phenotypic screen of “antifolate” DDU compounds was undertaken.    
 
5.1.5 The “antifolate set” 
In this “antifolate set” compounds with known activity against folate-dependent 
enzymes displayed better in vitro potencies against T. brucei when tested in TBM 
compared to when tested in HMI9-T.  This small-scale compound screen suggests 
that using routine nutrient-rich media in phenotypic drug screening can mask the 
potency of certain compounds.  It has been previously reported that selective 
TbPTR1 inhibitors, 2-aminobenzimidazoles, showed a lack of whole cell T. brucei 
potency despite having nanomolar TbPTR1 enzyme activity (Spinks et al., 2011). 
Indeed, the 2-aminobenzimidazoles in our “antifolate set” showed moderate whole 
cell potencies across media types with EC50 values in the low micromolar range. 
Moreover, when tested in HMI9-T media, the EC50 of compounds 4 and 5 were 
comparable to the EC50 values previously reported (Spinks et al., 2011).  Further 
work is required to explain the lack of cellular activity for selective TbPTR1 
inhibitors, with proposed reasons including lack of cellular penetration , efflux of the 
drug, high non-specific protein binding, and  high lipophilicity of compounds 
(leading to sequestration into lipid compartments which may negate activity against 
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a likely cytosol drug target)   (Gilbert, 2013). In addition, it has been deduced that 
PTR1 inhibitors require very high levels of enzyme inhibition in order to translate to 
respectable whole cell potencies (Ki < 1 nM, based on the physiological levels of 
substrate and the need for >90% enzyme inhibition) (Gilbert, 2013).  This drop off in 
potency from target to cell is a common problem encountered in target-based T. 
brucei drug discovery endeavours; targets such as fructose 1,6-bisphosphate aldolase 
(Dax et al., 2006) and trypanothione synthase (Spinks et al., 2012) are two examples 
of this. Continued medicinal chemistry efforts are required but it may be that cell 
potency cannot be achieved despite potent target activity.  
 
The 2,4-diaminoquinazolines and pyridopyrimidines (Figure 3.4) are TbPTR1  
inhibitors that were also shown to display ‘off target’ TbDHFR activity.  These 
compounds had nanomolar whole cell potencies when tested in TBM and for some 
of these compounds the addition of thymidine and folate moderately reduced drug 
potency. The moderate potency shift with folate supplementation suggests that 
DHFR activity alone does not account for whole cell potencies.  It also suggests that 
these PTR1 inhibitors are not transported into the cell via folate transporters (as 
opposed to MTX where folate supplementation negated drug activity likely due to 
competition for drug uptake into the cell). A previous study has investigated the in 
vitro efficacy of 2,4 diaminoquinazolines in Leishmania, T. cruzi and T. brucei 
moreover compounds were also assayed against recombinant L. major DHFR 
(Khabnadideh et al., 2005). Correlation with inhibition of L. major DHFR and in 
vitro cell potencies for Leishmania, T. cruzi and T. brucei was often not found for 
this compound set, which suggests that compounds may be killing parasites other 
than by DHFR activity.  2,4-diaminopyrimidines also have activity against L. major 
DHFR  with scaffolds based on this core leading to the 5-benzyl-2,4-
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diaminopyrimidines series being explored further  (Gilbert, 2002). This series was 
found to have activity against TbDHFR with promising in vitro potencies; however, 
in vivo these lead compounds showed poor potency and were toxic (Chowdhury et 
al., 2002). The authors postulated that activity against other enzymes involved in 
folate metabolism may account for disappointing in vivo results. The results of this 
thesis suggest that both pyridopyrimidines and 2,4-diaminoquinazolines do indeed 
have targets other than DHFR in trypanosomes (e.g. PTR1). This is not a surprising 
finding as pyridopyrimidines and 2,4-diaminoquinazolines were known to inhibit 
TbPTR1 from an in-house DDU drug discovery programme (personal 
communication). It is likely that the in vitro potency of these compounds is primarily 
due to PTR1 activity with some potency attributed to TbDHFR activity.  
 
In this “antifolate set” compounds 1 and 2 were chosen for potency determination 
because they contain a pABA-Glu moiety. However, these two compounds showed 
disappointing whole cell potencies against T. brucei. Activity against TbPTR1 and 
TbDHFR has not been determined so it may be that these compounds, although 
structurally similar to classical antifolates, do not inhibit enzymes in the folate 
metabolic pathway to any great extent. WR99210 has been previously shown to have 
very good binding affinity to TbDHFR (Ki 0.9 + 0.1 nM); moreover, it had potent 
whole cell in vitro activity (EC50 of 0.09 + 0.02 μM) (Vanichtanankul et al., 2011).  
However, in this assay WR99210 had only moderate whole cell potency with EC50 ~ 
4 - 6 μM across media types. The previous work on WR99210 was carried out on a 
strain of T.b. rhodesiense, whereas T.b. brucei was used in these studies potentially 
explaining the difference. However, T.b. rhodendiense and T.b. brucei are 
morphologically indistinguishable and genetically near equivalent. It has been 
demonstrated than they can differ by as little as the expression of a single gene, 
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serum resistance-associated (SRA) gene, the gene that confers T. b. rhodendiense its 
human infective phenotype (Gibson, 2003: Sistrom et al., 2016). Also,     whole cell 
potencies of WR99210 against T.b rhodesiense were performed in nutrient deplete 
medium (with no thymidine and folate). It would be prudent to test WR99210 
activity against T.b.b DHFR and T.b.b TS to determine if results do represent 
subspecies variation. If enzyme activity is found it would be worth revaluating why a 
lack of potency was observed in these whole cell studies. 
  
5.1.6 Transport Studies 
The folate transport properties of T. brucei BSF, evident in this thesis, are 
comparable to Leishmania. Uptake is rapid and linear for 2 to 3 min in both 
parasites, the rate of folate uptake is concentration dependent indicating carrier-
mediated transport, and transport in both kinetoplastids exhibits Michaelis-Menten 
kinetics (Ellenberger and Beverley, 1987).  The Km for folate uptake in Leishmania 
is in the sub micromolar range for all the species examined:  Km of 0.7 M for L. 
major (Ellenberger and Beverley, 1987), Km of 0.23 M in L. donovani (Kaur et al., 
1988) and Km app of  0.26 M in  L. tarentolae (Kundig et al., 1999).  The Km app of 
folate transport found in T. brucei BSF 427 strain (2.1 M) is comparatively higher 
than that found in Leishmania. Also the Km app for MTX transport in T. brucei (16 
M) is higher than that  found in Leishmania: Km of 1.8 M in  L. major (Ellenberger 
and Beverley, 1987),   0.41 M in  L. donovani (Kaur et al., 1988) and 0.45 M in L. 
tarentolae  (Richard et al., 2002). The promastigote form (insect vector form) of the 
Leishmania parasite was used for these transport experiments. It may be that the 
environment of the insect stage of Leishmania accounts for a higher affinity of folate 
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transport. It would be interesting to determine if affinity for folate transport changes 
in relation to the stage of parasite development. 
Similar to T. brucei, the potency of MTX in Leishmania is dependent on the 
concentration of folate in the culture medium (Nare et al., 1997; Richard et al., 
2002). Studies in L. tarentolae have found that MTX has an EC50 of 25 M in 
SDM79 (high folate media) compared to 0.25 M in M-199 (low folate media) (El 
Fadili et al., 2003). Overexpression of the enzyme FPGS increased MTX potency by 
four fold in M-199 compared to WT, highlighting the role of polyglutamylation in 
increasing intracellular antifolate potency (El Fadili et al., 2003). It is possible that in 
T. brucei although MTX has a moderate Km app of drug transport, polyglutamylation 
by FPGS, as in Leishmania, may be responsible for its potent intracellular activity. 
In these transport studies substrate uptake is measured at pH 7.3, which is 
close to physiological pH. In mammalian cells, folate and MTX transport at 
physiological pH is primarily carrier mediated via the RFC and so a comparison to 
this mode of transport in mammalian cells is most relevant.  Mammalian cells 
display a lower affinity for folate transport via RFC (100-fold less compared to T. 
brucei) but have a high affinity for 5-methyl-THF (the predominant folate form in 
serum) (Sirotnak, 1985).  Indeed, the Km or Ki values for 5-methyl-THF transport via 
RFC (range 1 to 4 M) (Sirotnak and Tolner, 1999) are similar to the Km app for 
folate in T. brucei (2.1 M).  The lower affinity for MTX uptake found in T. brucei 
(Km app 16 M) is comparable to the affinity for RFC mediated MTX transport (range 
2.3 to 26 M) (Sirotnak and Tolner, 1999). 
The substrate competition assay provided further understanding into the 
structural recognition of folate for its uptake in T. brucei. pABA-Glu and 5-methyl-
 
 
 
 
Figure 5.1: Folate carrier model 
Cell entry is defined by affinity to the membrane transporter (s) (Km), a confirmation 
change in the transporter, and then substrate turnover (kcat) into the cell. F = folate. 
M = methotrexate, E = enzyme (transporter (s)) 
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THF inhibited folate and MTX uptake whereas biopterin had no effect on uptake. 
pABA-Glu and 5-methyl-THF have also been shown to competitively inhibit folate 
and MTX uptake in Leishmania (Ellenberger and Beverley, 1987). Results 
demonstrate that compounds containing pABA-Glu (folate, 5-methy-THF) or a 
pABA-Glu-like moiety (classical antifolates) compete for transport in trypanosomes. 
Adding a pABA-Glu moiety to a non-classical antifolate, e.g. PYR, could potentially 
lead to improved drug uptake. In competing with folate for uptake this may lead to 
reduced intracellular folate levels and potentially improve drug potency by 
outcompeting for the target enzyme (DHFR).  
Folate and MTX were found to be competitive substrates for uptake in T. 
brucei, comparable to studies  in Leishmania (Ellenberger and Beverley, 1987). In 
this ‘folate carrier model’ (Figure 5.1) folate and MTX are mutually competing 
substrates for uptake into the cell. Cell entry is defined by binding to the membrane 
transporter(s) (Km), a conformational change in the transporter, and then substrate 
turnover (kcat) into the cell (Figure 5.1).  This is an active transport model. It would 
also be prudent to determine if folate transport is dependent on protomotive forces 
and whether it is ATP-driven. Transport could be measured in the presence of 
ionophores: e.g. valinomycin, K
+
; carbonyl cyanide m-chlorophenyl hydrazine 
(CCCP), H
+
; monensin, Na
+
; gramicidin, Na
+
/K
+
; and nigericin, K
+
/H
+
; and also in 
the presence of ATPase inhibitors e.g. N-ethylmaleimide (NEM), H
+
-ATPase; 
ouabain, Na
+
/K
+
-ATPase; N,N′-dicyclohexyl-carbodiimide (DCCD), H
+
-ATPase. In 
T. brucei BSF purine transport has been shown to be dependent on protomotive 
forces, which was confirmed by a linear relationship between protomotive forces 
(intracellular pH and membrane potential) and rate of hypoxanthine uptake (De 
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Koning and Jarvis, 1997).  Similar studies could be carried out to determine if 
promotive forces act upon folate transport. 
Of interest, growing cells in a higher folate concentration had little or no 
effect on folate uptake in T. brucei. At saturating concentrations (Vmax) there was a 
slight reduction (12%) in the rate of folate transport in cells grown in high folate 
medium. In Leishmania it has been found that there was a 30% decrease in the Vmax 
of folate uptake for cells grown in a high folate medium, which appeared to be 
independent of the intracellular folate concentration (Ellenberger and Beverley, 
1987). These results demonstrate that folate transport does not appear to regulate 
intracellular folate in T. brucei and Leishmania. Indeed, polyglutamylation of folates 
by FPGS has been found to regulate intracellular folate levels in Leishmania (El 
Fadili et al., 2002). Similar studies could be initiated to determine whether FPGS 
plays a pivotal role in folate retention in T. brucei. 
 
5.2 Mechanisms of antifolate resistance  
5.2.1 RIT-seq Studies 
An RNAi library screen implicated FT1-3 in parasite resistance to antifolate drugs 
MTX and RTX.  FT1-3 belong to the FBT family of which T. brucei has seven 
homologues. The T. brucei FBT family consists of three putative folate transporters 
(FT1-3) that share 96 % gene identity and are clustered on chromosome 8 
(Tb927.8.3620, Tb927.8.3630 and Tb927.8.3650); three putative pteridine 
transporters (BT1-3) that share 99% gene identify and are clustered on chromosome 
1 (Tb927.1.2820, Tb927.1.2850 and Tb927.1.2880), and a putative pteridine 
transporter (BT4) on chromosome 10 (Tb927.10.9080) that shares 68% gene identity 
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with BT1-3. In addition, the genome includes a folate transporter orphan fragment 
(Tb11.v5.0766) that shares 97 to 100% gene identity to FT1-3 (position 736 -1899 of 
ORF). This orphan gene is likely to be non-functional. It encodes a protein that does 
not contain the first 245 residues that are predicted to encode the first 4 
transmembrane portions of the transporter (based on topology modelling).  Of note, 
in the T. brucei S427 strain there are 7 ESAG10 genes that share 90-94% gene 
identity with FT1-3.  ESAG10 genes are found in approximately half of the telomeric 
transcription units (Bloodstream Expression Sites, BES) that regulate the expression 
of VSGs (Hertz-Fowler et al., 2008) and only one BES is transcribed at any time. 
The cell lines used in these thesis express VSG221 from BES1 in which ESAG10 is 
not transcribed (Hertz-Fowler et al., 2008). From evidence in this thesis, in BSF 
T. brucei, FT1-3 are likely the only expressed and functional genes for folate 
transport. In Leishmania there are 14 FBT and one of these transporters, BT1, 
primarily mediates the uptake of biopterin but also has a low affinity for folate 
uptake (Kundig et al., 1999). Indeed, in Leishmania folate, but not MTX, can be 
taken up by BT1, providing the folate requirements in cells lacking functional high-
affinity folate transport (Kundig et al., 1999). The putative biopterin transporters in 
T. brucei (BT1-4) have not been characterised and it would be prudent to determine 
if these transporters have any folate transport activity. Also, it would be worth 
determining if FT1-3 are responsible for any biopterin transport in T. brucei.  
RIT-seq experiments, with MTX and RTX, revealed other hits of interest.  
Both drug screens identified the mitochondrial carrier protein 2 (MCP2), 
(Tb927.11.14360) as a hit. MCPs are a group of structurally conserved proteins that 
are known to modulate the transport of metabolic intermediates across the 
mitochondrial membrane. Twenty four MCP homologues have been found in T. 
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brucei (Colasante et al., 2009). TbMCP2 has been described to be on a phylogenetic 
branch with the human mitochondrial folate transporter (MFT) (Colasante et al., 
2009). MFT is known to regulate the transport of THF cofactors from the cytosol to 
the mitochondria (Lawrence et al., 2011). Moreover, TbMCP2 has been l localised to 
the mitochondria by Myc-tagging (Colasante et al., 2009). The subcellular 
localisation of folate metabolic enzymes has not been fully characterised in T. 
brucei; however, some enzymes have localised to the mitochondria, illustrating that 
folates are indeed imported into this organelle. Methionyl-tRNA
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formyltransferase, needed for mitochondrial protein biosynthesis, has been 
mitochondrially localised (Tan et al., 2002).  Also, components of the GCS were 
determined to be mitochondrial by proteomic analysis (Panigrahi et al., 2009).  
RTX specific hits were C1-THF synthase and the ‘minor hit’ FPGS. Reduced 
C1-THF synthase activity could result in accumulation of 5,10-Methylene-THF.   
TS, the target of RTX, utilises 5,10-Methylene-THF to convert dUMP to dTMP. 
Accumulation of 5,10-Methylene-THF could compete with RTX for its activity 
against TS thus providing a mechanism of drug resistance. Polyglutamylation of 
RTX, by FPGS, is known to account for its potency in mammalian cells (Jackman et 
al., 1991; Shih et al., 1997). Moreover, it is probable that polyglutamylation occurs 
in T. brucei. Reduced TbFGPS activity could impair RTX potency and lead to drug 
resistance. Of the hits identified in RIT-seq experiments FT1-3 were validated to 
account for MTX and RTX drug resistance. Further work would be to establish if 
additional hits seen in these screens; MCP2, FPGS and C1-THF synthase are also 
part of drug resistance mechanisms. Although targeting the mitochondrial transporter 
MCP2 for drug discovery would be technically extremely challenging. 
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Using a RIT-seq approach, gene down regulation (loss of function) confers a 
selective advantage to parasites under drug pressure. However, not all drug 
resistance mechanisms are due to loss of function; drug efflux is an example of this. 
Moreover a RIT-seq approach is unlikely to identify essential genes as RNAi of 
these genes may be lethal, even without drug selection. A genome-wide 
overexpression approach, looking at gain-of-function, would complement the current 
RIT-seq loss-of-function approach. Overexpression libraries are currently being 
developed in T. brucei (Begolo et al., 2014) (personal communication, Mechanism 
of Action Team, DDU). Testing antifolate drugs using such overexpression 
approaches may identify intracellular targets of these drugs, e.g. DHFR-TS, PTR1 
and potential drug efflux mechanisms.  
 
Most Leishmania species lack functional RNAi machinery and therefore an 
RNAi based drug screening approach is not viable (Lye et al., 2010). But, an 
overexpression cosmid library approach, “Cos-Seq”, has recently proved 
successfully in identifying resistance mechanism of antileishmanial drugs (Gazanion 
et al., 2016). Resistance to MTX was tested in these studies and DHFR–TS and 
PTR1 were identified as drug resistance determinants; confirming what had been 
previously found in MTX-resistance Leishmania cell lines (Arrebola et al., 1994; 
Callahan and Beverley, 1992; Coderre et al., 1983; Papadopoulou et al., 1992). Also, 
enriched genomic regions of chromosomes 21 and 34 were identified and two 
phosphatase-related genes emerged as candidates (LinJ.34.2310 and LinJ.34.2320). 
Consequently, transfected parasites with these genes showed a reduced susceptibility 
to MTX. Of note, MTX is known to inhibit protein phosphatase 2A in mammalian 
cells (Fernandez-Perez et al., 2013). It would be interesting if future studies in T 
.brucei identified protein phosphatases in antifolate action and resistance. 
102 
 
5.2.2 Folate transport in drug resistance– RNAi knockdown and MTX-resistant 
trypanosomes 
Studies in this thesis have confirmed FT1-3 in parasite resistance to antifolate drugs. 
Folate transport was substantially reduced with FT1-3 RNAi knockdown; also in a 
MTX-resistance cell line, displaying both a deficit in MTX and folate transport, 
amino acid changes in FT1-3 were identified by PCR.  Looking at antifolate drug 
potency, the same phenotype was found with FT1-3 RNAi knockdown and MTX-
resistant lines; there was a reduced potency to classical antifolates and 
hypersensitivity to non-classical antifolates. Results indicate that folate and classical 
antifolates share a common transport system, via FT1-3, which is not the case for 
non-classical antifolates. When FT1-3 function is reduced, folates and classical 
antifolates have diminished cell uptake (causing reduced antifolate potency) whereas 
uptake of non-classical antifolates is not disturbed (less intracellular folate to 
compete with drug target causing increased sensitivity).  
Studies in Leishmania have also identified a deficit of folate and MTX 
transport in MTX-resistant cells lines and found folate transporters to be implicated 
in MTX resistant (Kundig et al., 1999; Richard et al., 2002; Richard et al., 2004). 
MTX-resistant cell lines were generated by transfection with a genomic cosmid 
bank, functional cloning, and genes determined through fragment identification. BT1 
(originally known as ORFG but later termed BT1 (Lemley et al., 1999)) was 
characterised as a high affinity biopterin transporter and a low affinity folate 
transporter, but was not found to transport MTX (Kundig et al., 1999). 
Overexpression of BT1 and a BT1-null mutant showed resistance or hypersensitivity 
to MTX, respectively. An increase in folate transport with no change in MTX 
transport was evident with BT1 overexpression which is likely to account for MTX 
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resistance developing. FT5 was later discovered to be a high affinity/low capacity 
transporter of folate and MTX (Richard et al., 2002). FT5 was expressed in a MTX-
resistance cell line which resulted in increased folate and MTX transport. Moreover 
the FT5 transfectant improved MTX sensitivity in the resistant line. Conversely in a 
FT5 null mutant, folate and MTX transport was reduced. Interestingly the FT5 null 
was hypertensive to MTX.  A third transporter, FT1, was found to improve folate 
and MTX transport and restore MTX sensitivity in MTX-resistant Leishmania 
(Richard et al., 2004).  FT1 was characterised as a high affinity/high capacity 
folate/MTX transporter. In a FT1 null mutant, folate and MTX transport was reduced 
and also MTX sensitivity was diminished. These Leishmania studies included 
localisation experiments of BT1 and FT1 using GFP tagging and fluorescent 
microscopy (Kundig et al., 1999; Richard et al., 2004). Transporters were found to 
localise to the plasma membrane and also there was some localisation to an area 
corresponding to the flagellar pocket. Such localisation studies for FT1-3 in T. 
brucei would be worthwhile.   
It would be beneficial to determine which of the folate transporters FT1-3 are 
responsible for folate transport. A strategy would be to express FT1, FT2 and FT3 
separately in the MTX-resistant cell lines and establish any recovery of folate/MTX 
transport and drug sensitivity. This could be done by using an overexpression vector 
such as pLEW100 (Kelly et al., 2007). However, with such a vector, integration is 
on an ectopic locus and expression levels can be variable. It has also been found that 
protein expression from such loci can be affected by cell density (Ali and Field, 
2013). This does not mean it is not useful as expression in multiple clones can be 
screened by qPCR. Alternatively one could use a vector that enables constitutive 
expression at the genes’ native locus which is more stable (Alsford and Horn, 2008).  
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Moreover such a vector also has an epitope tag (GFP and cMyc) that allows for 
localisation studies (Alsford and Horn, 2008).  Knockout strategies of the individual 
transporters could be attempted however this may prove challenging due to the close 
genetic homology between them. 
The studies in Leishmania did not examine the potency of other antifolate 
drugs in MTX-resistant cell lines and overexpression/knockdown transporter 
constructs (Kundig et al., 1999; Richard et al., 2002; Richard et al., 2004).   It would 
be interesting to determine if such studies would find the juxtapositioning of 
classical and non-classical antifolates that were seen in T. brucei. In cancer cells, it 
was found that in MTX-resistance, through a transport deficit via RFC, there was no 
real change in sensitivity to the classical antifolate PMX because of compensatory 
depletion of intracellular THF-cofactors (Zhao et al., 2000).  Here, EC50 values were 
compared to a cell line deficient in FPGS.  It may be that if potency was assessed 
against a cell line with normal FGPS activity there could actually be hyper resistance 
to PMX, as FPGS is known to polyglutamylate PMX to a greater extent than MTX 
(Zhao et al., 2000). Indeed, it may be that in MTX-resistant T. brucei there is no 
change in FPGS activity. If FPGS activity was reduced, the hyper resistance to RTX 
and PMX may not have been seen. Measuring antifolate polyglutamylation, via 
strategies like High-performance liquid chromatography (El Fadili et al., 2003), may 
help elucidate the activity of FPGS in the MTX-resistant line. FPGS was not 
identified in RIT-seq studies for MTX, but was identified for RTX, which may 
account for the differences in the drugs dependency on polyglutamylation for 
activity. Studies in other MTX-resistance cancer cells, which display a transport 
deficiency, showed hypersensitivity to non-classical DHFR targeted non-classical 
antifolates TMX and MTP, compared to WT (Diddens et al., 1983). In contrast, 
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when MTX-resistance was due to DHFR overexpression cross-resistance to TMX 
and MTP was evident, demonstrating that different mechanisms of resistant may 
reflect different resistance patterns of antifolate drugs (Diddens et al., 1983). Results 
in T. brucei suggest that DHFR activity may not be changed in MTX-resistant 
parasites as a clear hypersensitivity to non-classical antifols was found (including 
TMX and MTP), which is likely explained by a folate transport deficit. 
Experimentally evaluating TbDHFR activity in our MTX-resistant line would be a 
way to test this hypothesis (Gibson et al., 2016; Shanks et al., 2010).  
Of note, biopterin transport was not measured in studies of FT1 and FT5 in 
Leishmania (Richard et al., 2002; Richard et al., 2004) so the co-transport of 
biopterin, folate and MTX has not been fully elucidated in this organism.  From the 
results in this thesis, it can be deduced that in T. brucei folate and MTX share the 
same transporter system, FT1-3 (within this gene cluster), which is not shared by 
biopterin. In our competition assay biopterin did not inhibit MTX or folate transport 
and pteridine transporters were not identified in our RIT-seq studies of MTX and 
RTX.  To fully exclude any co-transport of biopterin with MTX/folate, biopterin 
transport could be measured both in the FT1-3 RNAi knockdown mutants and MTX-
resistant cells lines. Also, one could establish whether biotperin is indeed mediated 
by the other four members of the T. brucei FBT family (BT1-4) in a similar manner 
that FT1-3 was found to mediate folate transport (e.g. through transport studies and 
RNAi knockdown).   
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5.2.3 Identifying molecular mechanisms of transport mediated MTX-resistance 
In MTX-resistant cell lines sequencing of FT1-3 was determined using a PCR 
approach. This revealed two amino acid changes in FT1 and eight amino acid 
changes in FT3 in MTX-resistant trypanosomes. It is surprising that the same 
mutations were found in independent clones. This could occur if a rare variant was 
present in the original “WT” clone and this was selected out during culture rather 
than by mutation. However, WT clone was 99 % identical on the gene level to the 
FT1, FT2 and FT3 927 reference genome. It may be that these MTX-resistant cell 
lines are not true independent lines and cross-contamination cannot be ruled out. 
Also to find eight amino acid changes is unusual indeed in a mutant line. A single 
point mutation of a critical residue may be sufficient to disrupt transporter function. 
Moreover, other drug transporters in T. brucei, e.g. AQP2 and AT1, are not essential 
and therefore a single point mutation could be sufficient to bring about drug 
resistance without a cost to fitness.  Indeed a single-point mutation in AT1 was 
found in a pentamidine-resistant cell line with no fitness cost (Graf et al., 2016). 
Essentiality of FT1-3 would be worth assessing. 
The protein sequence of MTX R2 FT3 was aligned with FBT family 
members in Leishmania, cyanobacteria and plants in which key residues associated 
with folate transport have been identified (Dridi et al., 2010b; Eudes et al., 2010). 
Mutagenesis studies of Synechocystis slr0642 found seven amino acid residues, 
conserved with Arabidopsis At2g32040, that were critical to folate uptake function 
(Eudes et al., 2010). Bioinformatics modelling identified several other conserved 
residues in the central cavity of the transporters also thought to be critical to 
transport. A study in Leishmania aligned thirty seven hypothetical FBT proteins 
across the species mentioned above and targeted the 10 most conserved charged 
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amino acids (Dridi et al., 2010b). These 10 residues were mutated to neutral amino 
acids and were all found to reduce FT1 folate transport activity in Leishmania. A 
group of mutations found in T. brucei FT3: Y523S, R526M, V530L and H536N are 
in close proximity to conserved C519 and E524 residues determined to be critical to 
FBT mediated folate transport in Synechocystis and Leishmania respectively (Dridi 
et al., 2010b; Eudes et al., 2010). Moreover this group of four mutations in T .brucei 
lies close to regions determined to be critical to folate transport by bioinformatics 
modelling in Synechocystis (Eudes et al., 2010). A topological model of FT3 (Figure 
4.11 D) showed that these four mutation are clustered around the cytoplasmic loop 
close to the 11 transmembrane α helix and in the α helix itself. Out of the eight 
mutations in FT3, three of these represent a change in either polarity or amino acid 
structure. Further structural analysis, by computational modelling or even through 
crystal structures, may elucidate how these mutations could affect the integrity of the 
transporter and ultimately substrate binding.  Disabling mutation may not necessarily 
be associated with ligand binding and could cause abnormal transporter function 
through other mechanisms including defective post-translational protein processing 
(e.g. misfolded protein), defective protein regulation (e.g. increased degradation) and 
alternations in RNA processing. Computational modelling and crystallography may 
help elucidate mutations in FT1-3 that may affect ligand binding. 
Such structural analysis has been useful in identifying substrate binding 
motifs in the pentamidine/melasoprol transporters TbAT1 and AQP2.  An ‘amide’ 
motif in TbAT1, enabling the selectivity of aminopurines but not oxopurines (De 
Koning and Jarvis, 1999), was further explored using computational modelling 
(Collar et al., 2009). Computational modelling of AQPs has also enabled the further 
exploration of a key pore-forming residue in AQP2 implicated in substrate binding 
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(Munday et al., 2015). In an AQP2/AQP3 chimera, mutations in this residue led to 
amino acids with bulkier side-chains that protrude into the pore channel, possibly 
accounting for lack of drug transport and resulting in drug resistance.  Moreover, 
mutagenesis studies of this key pore forming residue in AQP2 abolished pentamidine 
binding and resulted in parasites with reduced sensitivity to pentamidine (Song et al., 
2016). In relation to folate transporters, one could do similar computational 
modelling and mutagenesis studies to validate the amino acid changes that were 
evident in MTX-resistant trypanosomes. By introducing one mutation at a time the 
mutations responsible for any drug resistance could be determined. Indeed a change 
in folate/MTX transport and drug sensitivity may be seen in the mutant transfectants.  
It should be noted that full sequence coverage of FT1-3 was not attained for 
the MTX-resistant trypanosomes. This was due to the fact that PCR product could 
not be attained for reactions using the unique FT1 Fw and FT2 Rev primers despite 
varying PCR conditions. This translated into a segment of the first ~550 bp of FT1 
and the last ~1350 bp of FT2 not being covered.  Given the alignment of these genes 
(Figure 4.8) it could be considered that a homologous recombination event had taken 
place between FT1 and FT2 with a chimeric FT1/FT2 locus being formed. This 
mechanism has been seen with AQP mediated melarsoprol/pentamidine cross 
resistance (MPXR), with evidence of homologous recombination between AQP2 and 
AQP3 in laboratory and clinical strains likely due to the high degree of sequence 
identity between the genes (Graf et al., 2016; Munday et al., 2015). It is important to 
note that FT1 and FT2 also share high sequence identify. Further experiments in this 
thesis showed no change in transcription (qPCR) or copy number/banding pattern 
(Southern blot) of FT1-3 between WT and drug-resistant parasites, suggesting that 
gene deletion has not occurred. If gene rearrangement with a chimeric FT1/FT2 
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locus had occurred a change in banding would have been illustrated in the Southern 
blot. The band representing FT1 and FT2 (8.7 bkb) would be smaller by ~ 3.4 kb 
(inclusive of intergenic region) however this was not clearly evident as a band of 8.7 
kb was seen in all three samples (Figure 4.12 D). Indeed there is currently no 
evidence to suggest gene rearrangement with a chimeric locus. The restriction 
enzyme EcoR1 was used as this was the only unique cutter which was able to 
differentiate the location of FT1-2 to FT3; moreover none of the commercially 
available rare cutters had recognitions sites spanning the tandem repeats of FT1-3. 
Of note Southern blot banding also revealed the ESAG10 genes in T. brucei S427 
that share close homology to FT1-3. As the intergenic regions of FT1-3 are highly 
homologous attempts to identify other unique primers within these regions were not 
fruitful. It may also be that point mutations have taken place in FT1 and FT2 in 
regions that could account for an inability of primer binding and thus lack of PCR 
product.  Whole-genome deep sequencing of the MTX-resistant cell lines may be 
worthwhile in identifying and confirming the underlying mutations in FT1-3. 
Moreover this approach could identify, or help exclude, other gene candidates 
implicated in MTX-resistance (e.g. DHFR, PTR1, FPGS). This approach has been 
used to great effect in studying drug-resistance mechanisms in T .brucei; examples 
include the oxaboroles, nitro-compounds and MPXR (Graf et al., 2016; Jones et al., 
2015; Wyllie et al., 2016). With more time and resources whole-gene sequencing 
would be the investigation of choice to help elucidate the molecular mechanisms of 
drug resistance  
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5.2.4 SILAC studies in MTX-resistant trypanosomes 
A very low number of proteins were identified from this SILAC experiment. SILAC 
ratios were determined for 6% of the T. brucei 927 proteome from each MTX-
resistant cell line and combining the two populations this represented 9% proteome 
coverage. This proteome coverage is very low and reasons why this may have 
occurred will be discussed.  Due to time constraints for thesis submission this 
experiment could not be repeated. However future repetition and development of this 
SILAC work would be invaluable to give a better understanding of any protein 
changes associated with MTX-resistant trypanosomes. There are only a handful of 
published studies using the SILAC proteomic method in BSF T. brucei (Jones et al., 
2015; Urbaniak et al., 2013; Zoltner et al., 2015). In Zolter et al the authors had up 
to 22% proteome coverage (Zoltner et al., 2015); Urbaniak et al had up to 39% 
proteome coverage (peptides were separated by strong cation exchange (SCX) and 
an enrichment step was carried out for phosphopeptides) (Urbaniak et al., 2013)); 
and in Jones et al up to 9% proteome coverage was seen (note this was a pull-down 
chemo-proteomics experiment) (Jones et al., 2015). Given the different 
methodologies and aims of each paper, Zoltner et al is the most comparable by 
sample and analytic methods (no enrichment, no pull-down, and protein ran on SDS-
PAGE). It is therefore timely to consider why protein identification was quite low in 
SILAC experiments in this thesis.  
Looking at cell culture and label incorporation it is unlikely that these 
contributed to poor proteome depth. Cells were grown in a SILAC media previously 
shown to be compatible with T. brucei culture (Jones et al., 2015; Urbaniak et al., 
2013; Zoltner et al., 2015). This SILAC medium normally contains a total of 18 μM 
of folate; however, because resistance to antifolates was examined the media was 
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modified to only contain 9 μM of folate (ideally folate levels would be even lower 
than this).   Cells grew at a normal rate in this media with no morphological changes.  
It has been found that 11 −12 cell divisions would provide sufficient label 
incorporation (>95%) which must be attained in such SILAC experiments (Urbaniak 
et al., 2013). Indeed cells were passaged for 16-18 cell divisions and label 
incorporation was 99.3% for R6K4 for and 99.2% for R10K8. Therefore culture 
conditions enabled sufficient label incorporation.  
Around of 200 μg protein (2 x 10
7 
cells) from the harvested trypanosomes 
was used for further protein separation and MS. This is comparable with other BSF 
T. brucei studies (Urbaniak et al., 2013; Zoltner et al., 2015) (cell number not 
recorded in the other study (Jones et al., 2015). It could be that an error in cell 
counting or in loading the NuPAGE gel may have resulted in a lower volume of 
protein than was initially estimated. Enrichment steps may also have been useful to 
increase proteome depth; indeed, mitochondrial enrichment may help identify 
mitochondrial folate-dependent enzyme of lower abundance. Various biological 
mitochondrial enrichment methods have been used in T. brucei procyclic form (PCF) 
(Acestor et al., 2009; Acestor et al., 2011; Schneider et al., 2007). However these 
methods all use ultracentrifugation for subcellular fractionation at some point, which 
ultimately leads to loss of material. Higher cell densities in PCF make it more 
practical compared to low density BSF, however using more starting material 
(protein) may solve the problem of losses due to ultracentrifugation. Also, it may be 
that mitochondrial separation techniques with more moderate centrifugation forces, 
such as those used in plants (Abas and Luschnig, 2010) could be adapted for BSF T. 
brucei.  
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In this SILAC study, although protein was separated by SDS-PAGE, instead 
of individual gel slices being taken the whole gel was pooled for fractionation by 
chromatography. This however was not intentional; SDS-PAGE was performed by 
myself and the gel then given to the Fingerprints Proteomics facility to further 
processing. It was intended that fractionation would be done by taking individual gel 
slices rather than pooling for chromatography. It is likely that miscommunication 
resulted in this different processing, highlighting the importance of clear and careful 
communication between service provider and user. This pooling of the gel may 
cause suppression of the less represented proteins and result in bias towards the more 
dominant ones (Mostovenko et al 2013). Previously, in T. brucei BSF, two 
orthogonal techniques have been used to fractionate SILAC samples; either at the 
protein level (SDS-PAGE) or at the peptide level (SCX) (Jones et al., 2015; 
Urbaniak et al., 2013; Zoltner et al., 2015). In T. brucei PCF the two different 
fractionation approaches have been used for the same sample set (Urbaniak et al., 
2012). It was found that fractionation at the peptide level (SCX), rather than the 
protein level (SDS-PAGE) identified more proteins. However, the authors noted that 
the higher number of peptides identified by SCX fractionation was likely due to 
higher capacity; about 10 times as much material was loaded on the SCX column. In 
this case, it is likely that the method of fractionation (peptide level rather than the 
protein level) did not result in less proteins being identified.  
With the small proteome coverage and lack of organelle enrichment, only one 
protein related to folate-metabolism was identified through this proteomic SILAC 
approach, namely DHFR-TS. Interestingly this was not changed in MTX-resistant 
parasites. This result further highlights that MTX-resistance in these cell lines is 
primarily through a deficit in drug transport. As discussed previously, cell potency 
113 
 
patterns of antifolates in the MTX resistant trypanosomes also suggest DHFR-TS 
activity is not changed. Strategies like whole-gene sequencing, a gain-of function 
overexpression library screen, assessing enzyme activity and measuring transcription 
may be helpful in fully assessing whether DHFR-TS does have a role in drug 
resistance.  This SILAC experiment did not identify FPGS and therefore changes in 
protein abundance could not be assessed. Results in this thesis have shown that 
modulating extracellular folate levels did not affect folate uptake into cells, 
highlighting the likely role of polyglutamylation of folates, by FPGS, in regulating 
folate metabolism through intracellular retention. FPGS was also a ‘hit’ in RIT-Seq 
studies with RTX but not MTX. It would be prudent to examine FPGS further as this 
may be another mechanism of drug resistance, as well as transport mediated 
resistance. In these SILAC studies eight proteins were identified that displayed a 
significant difference in abundance between the resistant parasites and the parental 
WT; three of which may play important roles in parasite biology, mitochondrial 
malate dehydrogenase (mMDH) (Blattner et al., 1998), phosphoglycerate kinase A 
(PGKA) (Anderson et al., 1998) and p22 protein precursor (Hayman et al., 2001; 
Sprehe et al., 2010).  Of note, protein ‘hits’ identified in these SILAC studies were 
only identified in either MTXR1 or MTXR2 and there were no hits present in both 
MTX-resistance cell lines. It is essential to validate any SILAC ‘hits’ e.g. by reverse 
genetics and showing a phenotypic effect (change in drug EC50). Also repeating 
these experiments with the modifications discussed above will help verify the 
significance of the ‘hits’ that were found in these initial results.  
 
5.3 Concluding remarks 
In conclusion, since the 1940s antifolates have been used successfully in the 
treatment of a number of human diseases ranging from cancer to bacterial infections.  
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Expanding the knowledge of the mechanism of action and resistance of antifolate 
drugs in T. brucei has enabled a better assessment of their potential use in HAT 
treatment. Encouragingly, classical antifolates displayed excellent in vitro potency. 
For HAT animal testing, modulation of serum folate and thymidine levels may be 
needed to accurately assess in vivo potency. Oral bioavailability and CNS 
penetration are two properties that are desirable in determining a clinical candidate 
for HAT (http://dndi.org). Although lack of CNS penetration is a concern for some 
antifolate drugs (e.g. RTX, PMX) others have been found to have adequate CNS 
penetration (e.g. MTX, PYR, TMP) (Clarke et al., 2000a; Kumthekar et al., 2013; 
Nau et al., 2010; Treon and Chabner, 1996).  Although MTX is available in an oral 
form, it is high dose MTX, through IV infusion that achieves adequate CNS 
penetration to treat malignancy (Treon and Chabner, 1996). The disadvantages of 
high dose MTX include long dosing schedules, the need for IV infusion, and toxicity 
(Treon and Chabner, 1996), and these are likely to limit its use in a HAT setting. A 
key characteristic in the  target product profile (TPP) for a new HAT medicine is that 
it can be given orally (http://dndi.org). Oral PYR, a crucial part of cerebral 
toxoplasmosis treatment, has good CNS penetration (McLeod et al., 1992; Weiss et 
al., 1988). Although PYR was found to have modest in vitro potency against T. 
brucei, adding a pABA-Glu moiety to PYR could lead to improved potency by 
becoming a substrate for folate transporters. Current clinical antifolates are 
disappointing candidates for HAT and it may be through designing new or refining 
existing antifolates that antifolate based therapeutic agents may be exploited for use. 
Moreover this thesis has explored, and aided in the understanding of, the biological 
processes involved in folate transport and metabolism, with is beneficial to drug 
discovery endeavours in the T .brucei folate pathway.  
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Supplementary Tables  
Table S1: MTX Low-RIT Data 
 
 
  
Band Primer Hit Score Probability Name 
1 Fw No sequence    
1 Rev Tb927.10.1750 580 3 e-154 Hypothetical protein 
2 Fw Poor quality 
sequence 
   
2 Rev No sequence    
3 Fw Tb927.8.3650 345 7 e-94 Putative folate transporter 
  Tb927.8.3630 102 1 e-20 Putative folate transporter 
  Tb927.8.3620 84.2 4  e-15 Putative folate transporter 
  Tb11.v5.0766 37.4 0.47 Orphan  folate transporter 
3 Rev Tb927.8.3650 50 4 e-5 Putative folate transporter 
4 Fw No sequence    
4 Rev Poor quality 
sequence 
   
5 Fw Tb927.8.3620 188 4 e-47 Putative folate transporter 
  Tb927.8.3630 188 4 e-47 Putative folate transporter 
  Tb927.8.3650 179 2 e-44 Putative folate transporter 
5 Rev No sequence    
Table S2. RTX Low-RIT Data 
 Band Primer Hit Score Probability Name 
1 Fw Tb927.10.1740 331 8 e-90 Hypothetical protein  
1 Rev Tb927.10.1750 554 6 e-157 Hypothetical protein 
2 Fw Tb927.10.2430 329 3 e-89  Receptor-type adenylate 
cyclase GRESAG 4, 
putative  
2 Rev No sequence    
3 Fw Tb927.8.3630 210 1 e-53 Putative folate transporter 
  Tb927.8.3620 188 5 e-47 Putative folate transporter 
  Tb927.8.3650 188 5 e-47 Putative folate transporter 
  Tb11.v5.0766 210 1 e-53 orphan  folate transporter 
3 Rev Tb927.8.3630 95.1 8 e-19 Putative folate transporter 
  Tb927.8.3650 95.1 8 e-19 Putative folate transporter 
  Tb927.8.3620 87.8 1 e-16 Putative folate transporter 
  Tb11.v5.0766 95.1 8 e-19 Orphan  folate transporter 
4 Fw Tb927.8.3630 248 2 e-64 Putative folate transporter 
  Tb927.8.3620 241 2 e-62 Putative folate transporter 
  Tb927.8.3650 149 1 e-34 Putative folate transporter 
  Tb11.v5.0766 149 1 e-34 Orphan  folate transporter 
4 Rev Tb927.8.3620 338 6 e-92 Putative folate transporter 
  Tb927.8.3630 324 1 e-87 Putative folate transporter 
  Tb927.8.3650 324 1 e-87 Putative folate transporter 
  Tb11.v5.0766 324 1 e-87 Orphan  folate transporter 
5   Fw No sequence    
5 Rev No sequence    
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Supplementary Figures 
  
Figure S1: A, B + C; DNA alignments of the folate transporters in 
MTX-resistant trypanosomes. 
Highlighted in yellow: Base changes occurring in both MTX R1 and MTX 
R2 different to both WT and 927 reference 
Highlighted in blue: Base changes occurring in both MTXR1 and MTXR2 
different to WT but same as 927 reference. 
Highlighted in green: Base changes in WT, MTXR1 and MTXR2 that are 
different than 927 reference. 
Highlighted in purple:  Base changes occurring in MTXR2 but not MTXR1. 
 
 
 
 
Figure S1.A DNA alignments for FT1, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
FT1927        ATGACCACGTCACCGAACGCATGCCAGGACCAACCACCTCAACATTCCGCACCCCAAGCT 
FT1WT         ATGACCACGTCACCGAACGCATGCCAGGACCAACCGCCTCAACATTCCGCACCCCAAGCT 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                          
 
FT1927        CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT1WT         CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT1WT         GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        CTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
FT1WT         CTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
FT1WT         CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        TACACCTTTGGTGCTGATGCAAAGCTTTACCAACTGATGGGTGGTATGTCGTCGTTGGGT 
FT1WT         TACACCTTTGGTGCTGATGCAAAACTTTACCAACTGATGGGTGGTATGTCGTCGTTGGGT 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        TACGCAGTGAAGCCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT1WT         TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACC 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT1WT         AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCTGGCTTCCTTGTTTTTGTCATTACC 
FT1WT         TCACTGCCTGGAGAGTTGTCGTATGTACCGGTGGCTGGCTTCCTTGTTTTTGTCATTACC 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------                                                                       
 
FT1927        TTCACAGTTGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT1WT         TTCACTGTTGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT1MTXR1      ---------GCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT1MTXR2      ----------CTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
                        ************************************************** 
 
FT1927        GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCCTTTTGGTTGGCTCC 
FT1WT         GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCCTTTTGGTTGGCTCC 
FT1MTXR1      GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCGTTCTAACTGGTTCC 
FT1MTXR2      GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCGTTCTAACTGGTTCC 
              ********************************************* ** *   *** *** 
 
FT1927        CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT1WT         CTTGTTGCGTCCTCCATTGTAGGGCCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT1MTXR1      CTTGTTGCGTCCTCCATTGTAGGGCCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT1MTXR2      CTTGTTGCGTCCTCCATTGTAGGGCCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
              *********************** ************************************ 
 
FT1927        TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT1WT         TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT1MTXR1      TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT1MTXR2      TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
              ************************************************************ 
 
FT1927        GAACGGAAGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGAAGCTG 
FT1WT         GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGCAGCTG 
FT1MTXR1      GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGCAGCTG 
FT1MTXR2      GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGCAGCTG 
              ******* ********************************************** ***** 
 
FT1927        GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT1WT         GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT1MTXR1      GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT1MTXR2      GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
              ************************************************************ 
 
FT1927        AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
FT1WT         AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGCGCACGGATACTACCTTGTTGCTGT 
FT1MTXR1      AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGCGCACGGATACTACCTTGTTGCTGT 
FT1MTXR2      AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGCGCACGGATACTACCTTGTTGCTGT 
              *********************************** ************************ 
 
FT1927        GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT1WT         GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT1MTXR1      GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT1MTXR2      GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
              ************************************************************ 
 
FT1927        ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT1WT         ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT1MTXR1      ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT1MTXR2      ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
              ************************************************************ 
 
FT1927        CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGACTCGGTTTCGTTGCC 
FT1WT         CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
FT1MTXR1      CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
FT1MTXR2      CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
              ******************************************** **************  
 
FT1927        CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCACGTACATC 
FT1WT         CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT1MTXR1      CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT1MTXR2      CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
              *************************************************** ******** 
 
FT1927        CAACTTCGTGGCGCAATGGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT1WT         CAACTTCGTGGCGCAATGGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT1MTXR1      CAACTTCGTGGCGCAATGGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT1MTXR2      CAACTTCGTGGCGCAATGGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
              ************************************************************ 
 
FT1927        CCTAACTTTTCATACTTTTACTACAACACTGTGGGTAACGTGATTGGGACTATGGGTGGT 
FT1WT         CCTAACTTTTCATACTTTTACTACAACACTGTGGGTAACGTGATTGGGACTATGGGTGGT 
FT1MTXR1      CCTAACTTTTCATACTTTTACTACAACACTGTGGGTAACGTGATTGGGACTATGGGTGGT 
FT1MTXR2      CCTAACTTTTCATACTTTTACTACAACACTGTGGGTAACGTGATTGGGACTATGGGTGGT 
              ************************************************************ 
 
FT1927        GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT1WT         GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT1MTXR1      GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT1MTXR2      GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
              ************************************************************ 
 
FT1927        ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT1WT         ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT1MTXR1      ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT1MTXR2      ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
              ************************************************************ 
 
FT1927        TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAG 
FT1WT         TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAG 
FT1MTXR1      TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAG 
FT1MTXR2      TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAG 
              ************************************************************ 
 
FT1927        CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT1WT         CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT1MTXR1      CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT1MTXR2      CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
              ************************************************************ 
 
FT1927        CGTGGGTCTGAAAGTATGGTGTATGCGGTACTTGCAGGATGTGCGCATTTTGGCCGTTCC 
FT1WT         CGTGGGTCTGAAAGTATGGTGTATGCGGTACTTGCAGGATGTGCGCATTTTGGCCGTTCC 
FT1MTXR1      CGTGGGTCTGAAAGTATGGTGTATGCGGTACTTGCAGGATGTGCGCATTTTGGCCGTTCC 
FT1MTXR2      CGTGGGTCTGAAAGTATGGTGTATGCGGTACTTGCAGGATGTGCGCATTTTGGCCGTTCC 
              ************************************************************ 
 
FT1927        GTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT1WT         GTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT1MTXR1      GTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT1MTXR2      GTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
              ************************************************************ 
 
FT1927        ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTACTTCTTGGTCACTTTGGC 
FT1WT         ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
FT1MTXR1      ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
FT1MTXR2      ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
              ***************************************** ****************** 
 
FT1927        ACTCCACTCATCAGCATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAT 
FT1WT         ACTCCACTCATCAGCATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
FT1MTXR1      ACTCCACTCATCAGCATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
FT1MTXR2      ACTCCACTCATCAGCATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
              ***********************************************************  
 
FT1927        GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT1WT         GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT1MTXR1      GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT1MTXR2      GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
              ************************************************************ 
 
FT1927        AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT1WT         AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT1MTXR1      AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT1MTXR2      AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
              *************************************** 
 
 
 
 
 
 
 
Figure S1.B DNA alignments for FT2, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
FT2927          ATGACCACGTCACCGAACGCATGCCAGGACCAACCACCTCAACATTCCGCACCCCAAGCT 
FT2WT           ATGACCACGTCACCGAACGCATGCCAGGACCAACCGCCTCAACATTCCGCACCCCAAGCT 
FT2MTXR1        ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
FT2MTXR2        ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
                ******************************** ** ************************ 
 
FT2927          CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT2WT           CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT2MTXR1        CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT2MTXR2        CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
                ************************************************************ 
 
FT2927          GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT2WT           GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT2MTXR1        GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT2MTXR2        GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
                ************************************************************ 
 
FT2927          TTCGGCACTGCTGTGGAAGCGTTCGGACCGAGATGTGTCCTCGCCCTTGGCCTCTCCGAG 
FT2WT           TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAATGTGTCCTCGCCCTTGGCCTCTCCGAG 
FT2MTXR1        TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAATGTGTCCTAGCCCTTGGCCTCTCCGAG 
FT2MTXR2        TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAATGTGTCCTAGCCCTTGGCCTCTCCGAG 
                ******************************* ********* ****************** 
 
FT2927          CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGAACCACACTTTTTCCAATGTTTACC 
FT2WT           CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGAACCACACTTTTTCCAATGTTTACC 
FT2MTXR1        CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGAACCACACTTTTTCCAATGTTTACC 
FT2MTXR2        CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGAACCACACTTTTTCCAATGTTTACC 
                ************************************************************ 
 
FT2927          TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT2WT           TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT2MTXR1        TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT2MTXR2        TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
                ************************************************************ 
 
FT2927          TACGCAGTGAAGCCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT2WT           TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT2MTXR1        TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT2MTXR2        TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
                *********** ************************************************ 
 
FT2927          AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT2WT           AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT2MTXR1        AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT2MTXR2        AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
                ************************************************************ 
 
FT2927          TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT2WT           TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT2MTXR1        TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT2MTXR2        TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
                ************************************************************ 
 
FT2927          TTTACCAAGGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT2WT           TTTACCAAGGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT2MTXR1        TTTAC------------------------------------------------------- 
FT2MTXR2        TTTACCAAGGCTA----------------------------------------------- 
                *****                                                        
 
FT2927          GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCGTTCTAACTGGTTCC 
FT2WT           GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCGTTCTAACTGGTTCC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT2WT           CTTGTTGCGTCCTCCATTGTAGGGCCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATGCTGAATTGGTATGGT 
FT2WT           TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          GAACGGAAGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGGGAAGAGCAGCTG 
FT2WT           GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGGGAAGAGCAGCTG 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          GAGCGTGAAGCCGACGCCGCGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT2WT           GAGCGTGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
FT2WT           AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGCGCACGGATACTACCTTGTTGCTGT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT2WT           GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT2WT           ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGACTCGGTTTCGTTGCT 
FT2WT           CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT2WT           CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CAACTTCCTGGCGCAATCGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT2WT           CAACTTCCTGGCGCAATCGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTGTGGGTGGT 
FT2WT           CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTATGGGTGGT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT2WT           GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT2WT           ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
FT2WT           TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT2WT           CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CGTGGGTCTGAAAGTATGGTGTATGCATTACTTGCAGGATTCGCTAATTTTGGCCGTTCT 
FT2WT           CGTGGGTCTGAAAGTATGGTGTATGCATTACTTGCAGGATTCGCTAATTTTGGCCGTTCT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT2WT           CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTACTTCTTGGTCACTTTGGC 
FT2WT           ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAT 
FT2WT           ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT2WT           GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT2MTXR1        ------------------------------------------------------------ 
FT2MTXR2        ------------------------------------------------------------ 
                                                                             
 
FT2927          AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT2WT           AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT2MTXR1        --------------------------------------- 
FT2MTXR2        --------------------------------------- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1.C DNA alignments for FT3, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
FT3MTXR1      ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
FT3MTXR2      ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
FT3927        ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
FT3WT         ATGACCACGTCACCGAACGCATGCCAGGACCAGCCGCCTCAACATTCCGCACCCCAAGCT 
              ************************************************************ 
 
FT3MTXR1      CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT3MTXR2      CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT3927        CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
FT3WT         CACGAAGCTGAGTGTACAACTCACAAACTCTCTGCAGAGGAAACAATGGATGCTCGTCCT 
              ************************************************************ 
 
FT3MTXR1      GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT3MTXR2      GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT3927        GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
FT3WT         GTACACCCTGACGCAAGGGCCTTGTTCCGAAAGCTGCCATGCGTGTGGAGCATTCCCGTA 
              ************************************************************ 
 
FT3MTXR1      TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
FT3MTXR2      TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
FT3927        TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
FT3WT         TTCGGCACTGCTGTGGAAGCGTTCGGACCGAAGTTTGTTTTCGCCCTTGGTTTCTGCGAG 
              ************************************************************ 
 
FT3MTXR1      CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
FT3MTXR2      CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
FT3927        CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
FT3WT         CTCTTCGGCAAAGGAATTGCTGACAACATCATTCGATCCTCACTTTTTCCAATGTTTACC 
              ************************************************************ 
 
FT3MTXR1      TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT3MTXR2      TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT3927        TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
FT3WT         TACACCTTTGGTGCTGATGCAAAGCTTTACCAACGAATGAGTAGCTTGGTTACATTTGGT 
              ************************************************************ 
 
FT3MTXR1      TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT3MTXR2      TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACC 
FT3927        TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
FT3WT         TACGCAGTGAAACCGTTTGCAGCTATGTTCAGTGACCTCTTTGCGTTATTTGGGTACACG 
              ***********************************************************  
 
FT3MTXR1      AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT3MTXR2      AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT3927        AGGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
FT3WT         AAGCGATGGTACCTCGCTCTATCCTGTGTGGTGGGTTCCACCCTCGCTATTGTGTACGGT 
              * ********************************************************** 
 
FT3MTXR1      TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT3MTXR2      TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT3927        TCACTGCCTGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
FT3WT         TCACTGCCCGGAGAGTTGTCGTATGTACCGGTGGCCGGAATACTGGTTTTTGTGACGTCG 
              ******** *************************************************** 
 
FT3MTXR1      TTTACCAAGGCTAACCTTGATATCCTCACACAAGGACATTACAGTCGCTTGATTCGCCGC 
FT3MTXR2      TTTACCAAGGCTAACCTTGATATCCTCACACAAGGACATTACAGTCGCTTGATTCGCCGC 
FT3927        TTTACCAAGGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
FT3WT         TTTACCAAGGCTAACCTTGATATCCTCACACAAGGGCATTACAGTCGCTTGATTCGCCGC 
              *********************************** ************************ 
 
FT3MTXR1      GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCCTTTTGGTTGGCTCT 
FT3MTXR2      GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCCTTTTGGTTGGCTCT 
FT3927        GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCCTTTTGGTTGGTTCC 
FT3WT         GTCCCATTGGCGGGCCCATCGCTTGTGAGTTGGGTTTGGTGGTGCGTTCTAACTGGTTCC 
              ********************************************* ** *   *** **  
 
FT3MTXR1      CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT3MTXR2      CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT3927        CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
FT3WT         CTTGTTGCGTCCTCCATTGTAGGACCACTTACCGATAAGAGGTTGCAGCGAGTGGCTGTG 
              ************************************************************ 
 
FT3MTXR1      TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT3MTXR2      TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
FT3927        TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATGCTGAATTGGTATGGT 
FT3WT         TTTATCTCTGCTGGGATGCAGTTGGTGCCGACGATATTCTTCATACTGAATTGGTATGGT 
              ******************************************** *************** 
 
FT3MTXR1      GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGGGAAGAGCAGCTG 
FT3MTXR2      GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGGGAAGAGCAGCTG 
FT3927        GAACGGAAGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGAAGCTG 
FT3WT         GAACGGAGGAACCGAGAGGAACGTGCGTACGACCTGAAGATTATTCGCGAAAAGCAGCTG 
              ******* *************************************** *** ** ***** 
 
FT3MTXR1      GAGCGTGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT3MTXR2      GAGCGTGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT3927        GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
FT3WT         GAGCATGAAGCCGACGCCGTGAGGTTACAGGGGAGCGAAGCAACAAGTGGCTCACTGGAC 
              **** ******************************************************* 
 
FT3MTXR1      AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
FT3MTXR2      AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
FT3927        AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
FT3WT         AATCCATCGGATACCGAGGAAGTGGGTGAGGGCGGAGCACGGATACTACCTTGTTGCTGT 
              ************************************************************ 
 
FT3MTXR1      GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT3MTXR2      GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT3927        GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
FT3WT         GGTGCCTTTGAAGTGAATCGAGAAGTGTTTGCTCGCAACAAGAAGGTTGTGTTTTACTGC 
              ************************************************************ 
 
FT3MTXR1      ATGCTTCTCACACTTGGCGCCATCGGGATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT3MTXR2      ATGCTTCTCACACTTGGCGCCATCGGGATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT3927        ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
FT3WT         ATGCTTCTCACACTTGGCGCCATCGGTATGGTTCTCGTGACAGTCCTTGGCACAAGGTTG 
              ************************** ********************************* 
 
FT3MTXR1      CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
FT3MTXR2      CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
FT3927        CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGACTCGGTTTCGTTGCC 
FT3WT         CAGCTGCTAATAACCAGTGTTGTGGCGTCATTTACACTCTGTGGTCTCGGTTTCGTTGCT 
              ******************************************** **************  
 
FT3MTXR1      CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT3MTXR2      CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT3927        CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
FT3WT         CTTCCACTTGTGATCGCGAAGGCAAATATGTTCACATTCATCTCGAGGGTCGCGTACATC 
              ************************************************************ 
 
FT3MTXR1      CAACTTCCAGGCGCAATTGACAATGTCTTCATGGCAACCCCCGATTGTTTCCCTGGTGGT 
FT3MTXR2      CAACTTCCAGGCGCAATTGACAATGTCTTCATGGCAACCCCCGATTGTTTCCCTGGTGGT 
FT3927        CAACTTCCTGGCGCAATCGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
FT3WT         CAACTTCCTGGCGCAATCGACAATGTCTTCATGGCGACCCCCGATTGTTTCCCTGGTGGT 
              ******** ******** ***************** ************************ 
 
FT3MTXR1      CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTATGGGTGGT 
FT3MTXR2      CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTATGGGTGGT 
FT3927        CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTGTGGGTGGT 
FT3WT         CCTAACTTTTCATACTTTTACTACAGCACTGTGGGTAATATGATTGGAGCTATGGGTGGT 
              *************************************************** ******** 
 
FT3MTXR1      GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT3MTXR2      GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT3927        GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
FT3WT         GTTATTGGTGTGACGTTATTCAGATACGTATTCTCAAAGCGCAGCTATCGCCTAACATTC 
              ************************************************************ 
 
FT3MTXR1      ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT3MTXR2      ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT3927        ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
FT3WT         ATCGTAACAACTTTGATTGAGATAGTTTCGAGTATCTTTGATATAATCATTGTGGAGCGA 
              ************************************************************ 
 
FT3MTXR1      TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
FT3MTXR2      TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
FT3927        TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
FT3WT         TGGAACCGTCCGTATGTTAGCGATCACGTTGTATTCGTTCTTGGTGACCAAATTATACAC 
              ************************************************************ 
 
FT3MTXR1      CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT3MTXR2      CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT3927        CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
FT3WT         CAGGTGTGCTACATGATGCACTTCATGCCAACTGTAATGCTCATTTCGAGGCTCTGTCCC 
              ************************************************************ 
 
FT3MTXR1      CGTGGGTATGAAAGTGCGGTGTATGCGGTACTTGCGGGATGTGCCCATTTTGGCCGTTCT 
FT3MTXR2      CGTGGGTATGAAAGTGCGGTGTATGCGGTACTTGCGGGATGTGCCCATTTTGGCCGTTCT 
FT3927        CGTGGGTCTGAAAGTATGGTGTATGCATTACTTGCAGGATTCGCTAATTTTGGCCGTTCT 
FT3WT         CGTGGGTCTGAAAGTATGGTGTATGCATTACTTGCAGGATGCGCTAATTTTGGCCGTTCT 
              ******* *******  *********  ******* ****  **  ************** 
 
FT3MTXR1      CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT3MTXR2      CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT3927        CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
FT3WT         CTTTCCAACACACTTGGATGGCTTTTGATGGAATACGTATGGAATGTGCAATCAGACATT 
              ************************************************************ 
 
FT3MTXR1      ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
FT3MTXR2      ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
FT3927        ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTACTTCTTGGTCACTTTGGC 
FT3WT         ACGGTGGGTCCATGCGACTTCAGTAATGTGAAGTGGCTTCTGCTTCTTGGTCACTTTGGC 
              ***************************************** ****************** 
 
FT3MTXR1      ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
FT3MTXR2      ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
FT3927        ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAT 
FT3WT         ACTCCACTCATCAACATTCCTCTTGTGTTTTTACTGATACCTGCGGCACGTATATGTGAC 
              ***********************************************************  
 
FT3MTXR1      GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT3MTXR2      GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT3927        GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
FT3WT         GTTCTTGACGAAAACGGCAAAGCTATTACAAAGAAGGCGGAGGATGTTCATGCCCCCTCT 
              ************************************************************ 
 
FT3MTXR1      AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT3MTXR2      AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT3927        AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
FT3WT         AATGATTCTCCCAGACGGCGGGAACCCACAGCCAATTAG 
              *************************************** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures S2: A, B + C; Protein alignments of the folate transporters in 
MTX-resistant trypanosomes. 
Highlighted in yellow: Base changes occurring in both MTXR1 and 
MTXR2 different to both WT and 927 reference 
Highlighted in blue: Base changes occurring in both MTXR1 and MTXR2 
different to WT but same as 927 reference. 
Highlighted in green: Base changes in WT, MTXR1 and MTXR2 that are 
different than 927 reference. 
 
 
Figure S2.A Protein alignments for FT1, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
 
FT1927        MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT1WT         MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        LGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQLMGGMSSLG 
FT1WT         LGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQLMGGMSSLG 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGFLVFVIT 
FT1WT         YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGFLVFVIT 
FT1MTXR1      ------------------------------------------------------------ 
FT1MTXR2      ------------------------------------------------------------ 
                                                                           
 
FT1927        FTVANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAV 
FT1WT         FTVANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAV 
FT1MTXR1      ---ANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCVLTGSLVASSIVGPLTDKRLQRVAV 
FT1MTXR2      ---ANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCVLTGSLVASSIVGPLTDKRLQRVAV 
                 ********************************:*.********************** 
 
FT1927        FISAGMQLVPTIFFILNWYGERKNREERAYDLKIIREKKLEHEADAVRLQGSEATSGSLD 
FT1WT         FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREKQLEHEADAVRLQGSEATSGSLD 
FT1MTXR1      FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREKQLEHEADAVRLQGSEATSGSLD 
FT1MTXR2      FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREKQLEHEADAVRLQGSEATSGSLD 
              **********************:***************:********************* 
 
FT1927        NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT1WT         NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT1MTXR1      NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT1MTXR2      NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
              ************************************************************ 
 
FT1927        QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVTYIQLRGAMDNVFMATPDCFPGG 
FT1WT         QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLRGAMDNVFMATPDCFPGG 
FT1MTXR1      QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLRGAMDNVFMATPDCFPGG 
FT1MTXR2      QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLRGAMDNVFMATPDCFPGG 
              *************************************:********************** 
 
FT1927        PNFSYFYYNTVGNVIGTMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT1WT         PNFSYFYYNTVGNVIGTMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT1MTXR1      PNFSYFYYNTVGNVIGTMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT1MTXR2      PNFSYFYYNTVGNVIGTMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
              ************************************************************ 
 
FT1927        WNRPYVSDHVVFVLGDQIIQQVCYMMHFMPTVMLISRLCPRGSESMVYAVLAGCAHFGRS 
FT1WT         WNRPYVSDHVVFVLGDQIIQQVCYMMHFMPTVMLISRLCPRGSESMVYAVLAGCAHFGRS 
FT1MTXR1      WNRPYVSDHVVFVLGDQIIQQVCYMMHFMPTVMLISRLCPRGSESMVYAVLAGCAHFGRS 
FT1MTXR2      WNRPYVSDHVVFVLGDQIIQQVCYMMHFMPTVMLISRLCPRGSESMVYAVLAGCAHFGRS 
              ************************************************************ 
 
FT1927        VSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLISIPLVFLLIPAARICD 
FT1WT         VSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLISIPLVFLLIPAARICD 
FT1MTXR1      VSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLISIPLVFLLIPAARICD 
FT1MTXR2      VSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLISIPLVFLLIPAARICD 
              ************************************************************ 
 
FT1927        VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT1WT         VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT1MTXR1      VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT1MTXR2      VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
              ********************************* 
 
 
Figure S1.B Protein alignments for FT2, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
FT2927        MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT2WT         MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT2MTXR2      MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT2MTXR1      MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
              ************************************************************ 
 
FT2927        FGTAVEAFGPRCVLALGLSELFGKGIADNIIRTTLFPMFTYTFGADAKLYQRMSSLVTFG 
FT2WT         FGTAVEAFGPKCVLALGLSELFGKGIADNIIRTTLFPMFTYTFGADAKLYQRMSSLVTFG 
FT2MTXR2      FGTAVEAFGPKCVLALGLSELFGKGIADNIIRTTLFPMFTYTFGADAKLYQRMSSLVTFG 
FT2MTXR1      FGTAVEAFGPKCVLALGLSELFGKGIADNIIRTTLFPMFTYTFGADAKLYQRMSSLVTFG 
              **********:************************************************* 
 
FT2927        YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT2WT         YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT2MTXR2      YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT2MTXR1      YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
              ************************************************************ 
 
FT2927        FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCVLTGSLVASSIVGPLTDKRLQRVAV 
FT2WT         FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCVLTGSLVASSIVGPLTDKRLQRVAV 
FT2MTXR2      FTKA*------------------------------------------------------- 
FT2MTXR1      F*---------------------------------------------------------- 
              *                                                            
 
FT2927        FISAGMQLVPTIFFMLNWYGERKNREERAYDLKIIREEQLEREADAARLQGSEATSGSLD 
FT2WT         FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREEQLEREADAVRLQGSEATSGSLD 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------ 
                                                                           
 
FT2927        NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT2WT         NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------ 
                                                                           
 
FT2927        QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
FT2WT         QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------ 
                                                                           
 
FT2927        PNFSYFYYSTVGNMIGAVGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT2WT         PNFSYFYYSTVGNMIGAMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------ 
                                                                           
 
FT2927        WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGSESMVYALLAGFANFGRS 
FT2WT         WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGSESMVYALLAGFANFGRS 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------ 
                                                                           
 
FT2927        LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
FT2WT         LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
FT2MTXR2      ------------------------------------------------------------ 
FT2MTXR1      ------------------------------------------------------------                                                                        
 
FT2927        VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT2WT         VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT2MTXR2      --------------------------------- 
FT2MTXR1      --------------------------------- 
 
Figure S2.C Protein alignments for FT3, comparing MTXR1, MTR2 to 
parental WT and reference T.brucei 927 strain.  
 
FT3MTXR1      MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT3MTXR2      MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT3927        MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
FT3WT         MTTSPNACQDQPPQHSAPQAHEAECTTHKLSAEETMDARPVHPDARALFRKLPCVWSIPV 
              ************************************************************ 
 
FT3MTXR1      FGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQRMSSLVTFG 
FT3MTXR2      FGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQRMSSLVTFG 
FT3927        FGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQRMSSLVTFG 
FT3WT         FGTAVEAFGPKFVFALGFCELFGKGIADNIIRSSLFPMFTYTFGADAKLYQRMSSLVTFG 
              ************************************************************ 
 
FT3MTXR1      YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT3MTXR2      YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT3927        YAVKPFAAMFSDLFALFGYTRRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
FT3WT         YAVKPFAAMFSDLFALFGYTKRWYLALSCVVGSTLAIVYGSLPGELSYVPVAGILVFVTS 
              ********************:*************************************** 
 
FT3MTXR1      FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAV 
FT3MTXR2      FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAV 
FT3927        FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCLLVGSLVASSIVGPLTDKRLQRVAV 
FT3WT         FTKANLDILTQGHYSRLIRRVPLAGPSLVSWVWWCVLTGSLVASSIVGPLTDKRLQRVAV 
              ***********************************:*.********************** 
 
FT3MTXR1      FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREEQLEREADAVRLQGSEATSGSLD 
FT3MTXR2      FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREEQLEREADAVRLQGSEATSGSLD 
FT3927        FISAGMQLVPTIFFMLNWYGERKNREERAYDLKIIREKKLEHEADAVRLQGSEATSGSLD 
FT3WT         FISAGMQLVPTIFFILNWYGERRNREERAYDLKIIREKQLEHEADAVRLQGSEATSGSLD 
              **************:*******:**************::**:****************** 
 
FT3MTXR1      NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT3MTXR2      NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT3927        NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
FT3WT         NPSDTEEVGEGGARILPCCCGAFEVNREVFARNKKVVFYCMLLTLGAIGMVLVTVLGTRL 
              ************************************************************ 
 
FT3MTXR1      QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
FT3MTXR2      QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
FT3927        QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
FT3WT         QLLITSVVASFTLCGLGFVALPLVIAKANMFTFISRVAYIQLPGAIDNVFMATPDCFPGG 
              ************************************************************ 
 
FT3MTXR1      PNFSYFYYSTVGNMIGAMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT3MTXR2      PNFSYFYYSTVGNMIGAMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT3927        PNFSYFYYSTVGNMIGAVGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
FT3WT         PNFSYFYYSTVGNMIGAMGGVIGVTLFRYVFSKRSYRLTFIVTTLIEIVSSIFDIIIVER 
              *****************:****************************************** 
 
FT3MTXR1      WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGYESAVYAVLAGCAHFGRS 
FT3MTXR2      WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGYESAVYAVLAGCAHFGRS 
FT3927        WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGSESMVYALLAGFANFGRS 
FT3WT         WNRPYVSDHVVFVLGDQIIHQVCYMMHFMPTVMLISRLCPRGSESMVYALLAGCANFGRS 
              ****************************************** ** ***:*** *.**** 
 
FT3MTXR1      LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
FT3MTXR2      LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
FT3927        LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
FT3WT         LSNTLGWLLMEYVWNVQSDITVGPCDFSNVKWLLLLGHFGTPLINIPLVFLLIPAARICD 
              ************************************************************ 
 
FT3MTXR1      VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT3MTXR2      VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT3927        VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
FT3WT         VLDENGKAITKKAEDVHAPSNDSPRRREPTAN* 
              ********************************* 
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